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ABSTRACT
The drug-metabolising enzyme cytochrome P450 (CYP) 2C8 is involved in the elimination of
several important drugs. Inhibition of CYP2C8 may therefore cause clinically relevant drug-
drug interactions. Gemfibrozil, a lipid-lowering agent, is a strong CYP2C8 inhibitor, which
has increased the plasma exposure to many CYP2C8 substrates several-fold in clinical
studies. The asthma drug montelukast is also a potent CYP2C8 inhibitor in vitro; however, it
does not affect the pharmacokinetics of CYP2C8 substrates in vivo. In turn, the cancer drug
imatinib is a CYP2C8 and CYP3A4 substrate in vitro, but CYP3A4 inhibitors have little
effect on its concentrations in vivo. This thesis aimed to study the discrepancies between these
in vitro and in vivo findings, and to determine the role of CYP2C8 in the metabolism of
montelukast and imatinib.
The work comprised in vitro experiments, physiologically based pharmacokinetic (PBPK)
simulations, and two clinical studies with a two-phase, randomised, placebo-controlled
crossover design. In microsomal incubations, among ten CYP enzymes tested, CYP2C8
metabolised montelukast most extensively. Its contribution to the in vivo metabolism of
montelukast was estimated to exceed 70%. In accordance with the prediction, gemfibrozil
increased the area under the plasma concentration time-curve (AUC) of montelukast by 4.5-
fold in healthy subjects.
Based on microsomal data, the roles of CYP2C8 and CYP3A4 were estimated at 40 and 57%,
respectively, of the hepatic clearance of imatinib. However, imatinib also inhibited CYP3A4
irreversibly, suggesting that it can inhibit its own CYP3A4-mediated metabolism. In healthy
subjects, gemfibrozil had no effect on imatinib AUC, while it unexpectedly reduced imatinib
absorption. Gemfibrozil also reduced the AUC of the main metabolite of imatinib, N-
desmethylimatinib, by 48%. PBPK simulations suggested that the findings could be explained
by a complex interaction involving simultaneous inhibition of an uptake transporter involved
in imatinib absorption and of CYP2C8 by gemfibrozil. Furthermore, multiple-dose
simulations suggested that because imatinib inhibits CYP3A4, the role of CYP2C8 in
imatinib pharmacokinetics increases with time.
The findings of this work propose that CYP2C8 is the main enzyme involved in the
pharmacokinetics of montelukast, contributing to about 80% of its elimination. Because
montelukast is generally well-tolerated and safe, it could serve as a CYP2C8 marker substrate
drug in interaction studies. The results for imatinib indicate that it is an irreversible CYP3A4
inhibitor, which suggests that concomitant use of imatinib with CYP3A4 substrates may
increase the risk of concentration-dependent adverse drug reactions. In addition, the findings
propose that during long-term treatment, the elimination of imatinib relies more on CYP2C8
than on CYP3A4. Collectively, these studies strengthen the position of CYP2C8 as a pivotal
drug-metabolising enzyme. In addition, they highlight the importance of carefully validated in
vitro experimental conditions and demonstrate the usefulness of PBPK simulations to explain
complex drug-drug interactions.
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YHTEENVETO
Sytokromi P450 (CYP) 2C8 -entsyymi osallistuu monen lääkeaineen metaboliaan, joten sen
esto voi johtaa kliinisesti merkittäviin yhteisvaikutuksiin. Lipidilääke gemfibrotsiili on
voimakas CYP2C8-estäjä. Se moninkertaistaa eräiden CYP2C8-substraattien pitoisuudet
plasmassa. Astmalääke montelukasti on myös vahva CYP2C8-estäjä in vitro, mutta ei vaikuta
CYP2C8-substraattien plasmapitoisuuksiin in vivo. Syöpälääke imatinibi puolestaan on
CYP2C8- ja CYP3A4-substraatti in vitro, mutta CYP3A4-estäjillä on ollut vain vähäinen
vaikutus imatinibin pitoisuuksiin in vivo. Tämän väitöskirjatyön tavoitteena oli selvittää näitä
in vitro- ja in vivo -havaintojen välillä olevia epäjohdonmukaisuuksia, sekä tutkia CYP2C8-
entsyymin merkitystä montelukastin ja imatinibin metaboliassa.
Väitöskirja koostuu in vitro -töistä, fysiologiaan perustuvista farmakokineettisistä (PBPK)
simulaatioista, sekä kahdesta lumekontrolloidusta yhteisvaikutustutkimuksesta. CYP2C8 oli
tärkein kymmenestä CYP-entsyymistä, joiden osuutta montelukastin metaboliaan testattiin
mikrosomi-inkubaatioissa, ja sen osuudeksi montelukastin in vivo -metaboliassa arvioitiin yli
70 %. Gemfibrotsiili nosti koehenkilöillä montelukastin plasmapitoisuus-aika-kuvaajan
alaisen pinta-alan (AUC:n) 4,5-kertaiseksi.
In vitro -tulosten perusteella lasketut CYP2C8:n ja CYP3A4:n osuudet imatinibin
maksapuhdistumassa olivat 40 % ja 57 %. Toisaalta imatinibi oli myös CYP3A4:n
irreversiibeli estäjä in vitro, mikä viittaa siihen, että imatinibi voi estää omaa CYP3A4-
välitteistä metaboliaansa. Yllättäen gemfibrotsiili pienensi imatinibin imeytymistä
koehenkilöillä, mutta ei aiheuttanut muutosta imatinibin AUC:ssa. Lisäksi imatinibin
päämetaboliitin, N-desmetyyli-imatinibin, AUC laski 48 %. PBPK-simulaatioiden mukaan
nämä havainnot ovat selitettävissä monimutkaisella yhteisvaikutuksella, jossa gemfibrotsiili
estää sekä imatinibin imeytymiseen osallistuvaa sisäänottotransportteria että sen metaboliassa
tärkeää CYP2C8:aa. Toistuvan annostelun simulaatioiden mukaan imatinibin aiheuttama
CYP3A4-esto voi johtaa siihen, että CYP2C8:n rooli imatinibin farmakokinetiikassa kasvaa
ajan myötä.
Väitöskirjatutkimuksessa tehtyjen havaintojen perusteella CYP2C8 vastaa noin 80 %
montelukastin eliminaatiosta ja on siten tärkein entsyymi sen metaboliassa. Koska
montelukasti on yleisesti ottaen hyvin siedetty ja turvallinen lääke, se voisi toimia CYP2C8:n
mallisubstraattina yhteisvaikutustutkimuksissa. Imatinibi osoittautui olevan irreversiibeli
CYP3A4-estäjä, joten sen yhtäaikainen käyttö CYP3A4-substraattien kanssa voi lisätä niiden
pitoisuusriippuvaisia haittavaikutuksia. Jatkuvassa käytössä imatinibin eliminaatio vaikuttaa
olevan enemmän riippuvainen CYP2C8:sta kuin CYP3A4:sta. Yhteenvetona voidaan todeta,
että nämä tutkimukset vahvistavat CYP2C8-entsyymin tärkeyttä lääkeaineita metaboloivana
entsyyminä. Ne myös korostavat tarkasti validoitujen in vitro -olosuhteiden merkitystä ja
osoittavat PBPK-simulaatioiden käyttökelpoisuuden monimutkaisten lääkeyhteisvaikutusten
selittämisessä.
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SAMMANFATTNING
Enzymet cytokrom P450 (CYP) 2C8 deltar i nedbrytningen av flertalet läkemedel. Blockering
av detta enzym kan därmed leda till kliniskt relevanta läkemedelsinteraktioner. Det
lipidsänkande läkemedlet gemfibrozil är en stark CYP2C8-hämmare som har orsakat kraftigt
förhöjda plasmakoncentrationer av flera CYP2C8-substrat. Astmaläkemedlet montelukast är
också en potent CYP2C8-hämmare in vitro, men dess effekt på farmakokinetiken hos
CYP2C8-substrat in vivo är obetydlig. Cancerläkemedlet imatinib metaboliseras sin tur av
både CYP2C8 och CYP3A4 in vitro, men CYP3A4-hämmare har påverkat dess
koncentrationer endast i låg grad in vivo. Målet med denna avhandling var att utreda
motsättningarna mellan dessa in vitro- och in vivo-observationer samt att undersöka
betydelsen av CYP2C8 i metabolismen av montelukast och imatinib.
Arbetet genomfördes i form av in vitro-experiment, fysiologiskt baserade farmakokinetiska
(PBPK) simulationer och två placebokontrollerade interaktionsstudier. Av de tio CYP-enzym
som testades i mikrosomala inkubationer, metaboliserades montelukast i störst utsträckning
av CYP2C8 och enzymets andel i montelukasts in vivo-metabolism uppskattades till >70 %. I
enlighet med denna prediktion förhöjde gemfibrozil montelukasts yta under
plasmakoncentration-tid-kurvan (AUC) 4,5-faldigt hos friska försökspersoner.
På basen av in vitro-data uppskattades betydelsen av CYP2C8 och CYP3A4 i imatinibs
hepatiska clearance till 40 respektive 57 %. Imatinib visade sig även vara en irreversibel
CYP3A4-hämmare, vilket tyder på att imatinib kan hämma sin egen CYP3A4-katalyserade
metabolism. I den kliniska studien minskade gemfibrozil oväntat på imatinibs absorption
medan imatinibs AUC förblev opåverkad. Därtill sjönk AUC av imatinibs primära metabolit
N-desmetylimatinib med 48 % vid samtidigt intag av gemfibrozil. Enligt PBPK-simulationer
kan dessa observationer förklaras av en komplex interaktion där gemfibrozil hämmar en
upptagstransportör som deltar i imatinibs absorption samtidigt som den hämmar imatinibs
metabolism via CYP2C8. Enligt resultat från flerdos-simulationer leder imatinibs hämning av
CYP3A4 till att betydelsen av CYP2C8 i imatinibs farmakokinetik ökar med tiden.
Enligt observationerna i denna avhandling svarar CYP2C8 för ungefär 80 % av montelukasts
elimination och är därmed det huvudsakliga enzymet i dess metabolism. Eftersom
montelukast generellt anses vara ett vältolererat och tryggt läkemedel, tyder resultaten på att
montelukast kunde användas som ett markörsubstrat för CYP2C8 i interaktionsstudier.
Iakttagelserna för imatinibs del tyder på att det hämmar CYP3A4 irreversibelt, vilket
indikerar att samtidigt intag av imatinib och CYP3A4-substrat kan öka risken för
koncentrationsberoende biverkningar. Under långtidsbehandling med imatinib verkar
imatinibs elimination vara mera beroende av CYP2C8 än CYP3A4. Observationerna från
studierna i denna avhandling stärker CYP2C8:s roll som ett viktigt
läkemedelsmetaboliserande enzym. Därtill belyser de vikten av noggrant validerade
experimentella in vitro-betingelser samt demonstrerar hur PBPK-simulationer kan användas
till att förklara komplexa läkemedelsinteraktioner.
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INTRODUCTION
Drug-drug interactions occur when one drug causes clinically relevant changes in the plasma
concentrations and/or pharmacological effect of another drug. In most cases, two or more
drugs can be safely and successfully administered together. Occasionally, however, drug-drug
interactions arise that can have serious clinical consequences, including lack of therapeutic
effect, adverse drug reactions, and even fatalities (EMA, 2013). Inhibition of the drug-
metabolising cytochrome P450 (CYP) enzymes is the most important cause of harmful drug-
drug interactions (Pelkonen et al., 2008). Highly expressed in the liver, about ten individual
CYPs play a significant role in the metabolism of drugs. Therefore, when characterising the
interaction potential of a drug that undergoes metabolism, it is important to determine the
CYP enzymes possibly involved. Correspondingly, drugs should also be tested for their
potential to inhibit and induce different CYPs. These risk assessment studies typically include
a combination of in vitro (laboratory), in silico (computational), and in vivo (animal and
human) methods.
The role of CYP2C8 in drug metabolism was long considered to be of little importance.
However, during the last 15 years, it has received increasing attention as more CYP2C8
substrates and inhibitors have been identified, its structure has been elucidated, and genetic
CYP2C8 polymorphisms have been characterised (Schoch et al., 2004, Lai et  al., 2009,
Aquilante et al., 2013b). The significance of CYP2C8 was recognised following a severe
interaction between the strong CYP2C8 inhibitor gemfibrozil and cerivastatin that resulted in
cases of fatal rhabdomyolysis (Backman et al., 2002, Huang et al., 2008). Gemfibrozil has
also increased the concentrations of many other CYP2C8 substrate drugs several-fold (Niemi
et al., 2003a, Niemi et al., 2003b, Jaakkola et al., 2005, Niemi et al., 2006, Tornio et al.,
2007, Tornio et al., 2008, Backman et al., 2009, Honkalammi et al., 2012, Aquilante et al.,
2013a), and is therefore recommended as a CYP2C8 inhibitor drug in clinical interaction
studies (FDA, 2011, EMA, 2013). In addition, gemfibrozil is an inhibitor of the hepatic
uptake transporter organic anion-transporting polypeptide (OATP) 1B1, which likely explains
its interactions with pravastatin and rosuvastatin (Kyrklund et al., 2003, Schneck et al., 2004),
which are not metabolised by CYP2C8.
The leukotriene receptor antagonist montelukast also interacts with CYP2C8. It is a selective,
competitive inhibitor of CYP2C8 in vitro (Walsky et al., 2005b). In a screening study,
montelukast was the most potent CYP2C8 inhibitor among 209 drugs tested (Walsky et al.,
2005a), and crystallographic studies have shown that montelukast fits the active site cavity of
CYP2C8 well (Schoch et al., 2008). However, despite its ability to inhibit CYP2C8 in vitro,
montelukast has not affected the plasma concentrations of the CYP2C8 substrates
pioglitazone, repaglinide, and rosiglitazone in healthy volunteers (Jaakkola et al., 2006b,
Kajosaari et al., 2006, Kim et al., 2007). The lack of in vivo inhibitory effect suggests that the
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concentrations of montelukast at the CYP2C8 enzyme site in hepatocytes are too low for it to
cause inhibition, in line with its very small unbound fraction in plasma (Singulair Clinical
Pharmacology and Biopharmaceutic Review(s), 1998).
In contrast, the tyrosine kinase inhibitor imatinib is a relatively strong CYP3A4 inhibitor in
vivo, but appears to affect CYP3A4 weakly in vitro. Imatinib has increased the plasma
exposure to the CYP3A4 substrate simvastatin almost four-fold in healthy volunteers (O'Brien
et al., 2003), but this interaction cannot be explained based on its reported inhibition potency
of CYP3A4 in vitro (Gleevec Clinical Pharmacology and Biopharmaceutic Review(s), 2001).
In addition, imatinib is mainly metabolised by CYP3A4 (Marull and Rochat, 2006, Rochat et
al., 2008, Gleevec label, 2014). Despite the proposed role of CYP3A4 in its metabolism, the
CYP3A4 inhibitor ketoconazole increased the area under plasma concentration-time curve
(AUC) of imatinib after a single imatinib dose only moderately (by 1.4-fold) (Dutreix et al.,
2004), while the strong CYP3A4 inhibitor ritonavir had no effect on its plasma exposure after
multiple imatinib doses (van Erp et  al., 2007). Furthermore, the elimination of the CYP3A4
substrates erythromycin and midazolam correlated with imatinib elimination in the beginning
of imatinib treatment, but no longer at steady state (Gurney et al., 2007). Thus, imatinib
steady state pharmacokinetics has been suggested to rely on enzymes other than CYP3A4
(van Erp et al., 2007). In 2010, an in vitro study indicated involvement of CYP2C8 in the
main metabolic pathway of imatinib, the formation of the pharmacologically active metabolite
N-desmethylimatinib (Nebot et al., 2010). However, the study did not contain quantitative
extrapolations of the obtained in vitro findings to clinical relevance. In addition, the finding
did not mechanistically explain why imatinib is sensitive to CYP3A4 inhibition in the
beginning of therapy, but no longer at steady state.
The purpose of this work was to investigate the role of CYP2C8 in the metabolism of
montelukast and imatinib to provide explanations to the inconsistencies documented in the
literature. For montelukast, we first conducted an in vitro metabolism study, followed by an
interaction study in humans with gemfibrozil as the CYP2C8 inhibitor drug. In turn, for
imatinib, in order to understand the role of CYP2C8 in its metabolism, we first examined its
inhibitory effects on CYP3A4 in vitro. Then, using an integrated in vitro, in silico, and in vivo
approach, we carried out in vitro metabolism experiments, physiologically based
pharmacokinetic (PBPK) simulations, and an interaction study with gemfibrozil in healthy
subjects, to examine the importance of CYP2C8 in its elimination.
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REVIEW OF THE LITERATURE
1. Drug-metabolising enzymes and drug transporters
Pharmacokinetics describes the passage of a drug through the body. Following oral
administration, a drug usually undergoes several pharmacokinetic processes, including
absorption, distribution, and metabolism, before it is excreted from the body. These processes
define the relationship between the drug dose and its concentration in the body in relation to
time. Because the effect of a drug is usually related to its concentration at the site of action,
the pharmacokinetics of a drug will influence its pharmacological response and toxicity
(Tozer and Rowland, 2006).
The liver and the intestine are the major sites for drug metabolism. About 70% of clinically
used drugs undergo metabolism as their main elimination route (Pelkonen et al., 2008).
Typically, these drugs are relatively lipophilic and need to be metabolised to become more
hydrophilic so that they are easily excreted from the body (Murray, 1997). In contrast,
hydrophilic drugs tend to be excreted unchanged. Drug metabolism is commonly divided into
phase I and phase II reactions (Testa and Kramer, 2006), although these reaction types can be
overlapping or only one can occur. Phase I enzymes, such as aldehyde dehydrogenases,
carboxyl ester hydrolases, CYPs, flavin-containing monooxygenases (FMOs) and numerous
others, perform functionalisation reactions that introduce or expose a functional group in the
drug molecule. In phase II, enzymes including N-acetyltransferases (NATs), glutathione S-
transferases (GSTs), uridine-5'-diphosphate glucuronosyltransferases (UGTs) and many
others, catalyse conjugation reactions that attach highly hydrophilic moieties to the drug or its
phase I metabolite. In addition to its protective detoxification function, metabolism may
occasionally lead to the formation of reactive and toxic metabolites (Murray, 1997).
Currently under intensive study, membrane transporters also play an important role in drug
exposure. These proteins mediate the transport of endogenous compounds, drugs and other
xenobiotics into and out from cells, thus contributing to their distribution and elimination.
Although transporters are present with varying abundance in all body tissues, those that are
important in pharmacokinetics are mainly expressed in the intestine, kidney, and liver (Figure
1) (Giacomini and Sugiyama, 2011). Together, drug-metabolising enzymes and transporters
determine the intracellular and plasma concentrations of numerous drugs, and influence their
systemic and site-specific effects and toxicities.
Figure 1.
(2011)). Drug
Drug transporters important in pharmacokinetics are
They can
triphosphate
1.1.
CYP enzymes
metabolis
throughout nature
In humans
(Pelkonen
Discovery
monoxide inhibited reactions in
Engel, 1957
suspension
resulted in the appearance of a broad
spectra
identified as a h
and Sato, 1962
(Estabrook
enzyme
studies were
Classification
amino acid
subfamily
Localisation of CYP enzymes and drug transport
-metabolising enzymes, including the CYPs, are mainly located in the liver and intestine.
also be found in other organs and tissues, e.g.
-binding cassette
Human
are
m of a wide range of endogenous
;
, about
 et al., 2008
. The CYP enzyme
). Findings demonstrated that
s containing
(Garfinkel, 1958
aemoprotein
). It soon
 et al., 1963
, but in the 1970s
subsequently
. CYP enzymes are
sequence similarities.
members
transporter;
CYP enzymes
a superfamily
in animals, plants,
a dozen
, Zanger and Schwab, 2013
reduced n
, Klingenberg, 1958
, and it was tentatively named “P
became evident that this pigment
, Cooper
it
undertaken to characterise
are >55%
CYP, cytochrome P450; SLC, solute carrier transporter.
of import
insects,
individual
s were discovered in the 1950s when i
adrenal and
icotinamide adenine dinucleotide
absorption peak at 450 nm in
 et al., 1965
was clear that several different CYP enzymes exist.
divided into
Members of a family share >40% amino acid identity, while
identical (
18
primarily
ant haem
and
lower eukaryotes,
CYPs are
).
liver microsomes
 the  addition of carbon monoxide
). This
). Initially, this system was thought to be one
families and subfamilies
Madan et al.
ers (adapted from
 found
in the blood
-containing
foreign compounds
important
(
carbon monoxide
-450“ for “pigment 450”
was
and isolate
, 2002).
Giacom
in the intestine, liver, and kidney
-brain barrier. ABC, adenosine
proteins that
.
and bacteria
in the metabolism
t was noted that carbon
Conney et al.
(NADH
the
-binding pigment was
able to metabolise drugs
the different forms.
Altogether
ini and Sugiyama
mediate
CYPs are found
 (Nelson, 2009
of drugs
, 1957, Ryan and
to microsomal
) or dithionite
ultraviolet visible
Intensive
based upon their
18 families and 44
.
 the
).
(Omura
19
subfamilies of CYP genes have been identified in humans (Nelson, 2009). The CYP1, CYP2,
and CYP3 families metabolise approximately 75% of clinical drugs that undergo metabolism,
while other CYP families are primarily important in the biosynthesis and metabolism of
endogenous compounds, such as bile acids, eicosanoids, fatty acids, steroids, and vitamins
(Nebert and Russell, 2002, Guengerich, 2008). CYP3A4 is the major drug-metabolising CYP
enzyme in the liver and intestine, and is involved in the metabolism of about 50% of clinically
used drugs (Pelkonen et al., 2008). Other important drug-metabolising CYP enzymes in the
liver include CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6,
CYP2E1, and CYP3A5 (Figure 2). In turn, CYP1A1, CYP1B1, and CYP2J2 are mainly
expressed extra-hepatically (Zanger and Schwab, 2013).
Figure 2. Abundance of drug-metabolising CYP isoforms in the liver (Rostami-Hodjegan and Tucker,
2007, Pelkonen et al., 2008, Achour et al., 2014), and examples of their marker substrates, inhibitors,
and inducers (FDA, 2011, EMA, 2013), adapted from Pelkonen et al. (2008). Substrates, inhibitors,
and inducers recommended for in vitro studies are marked with a diamond (¨), and for in vivo studies
in bold font. The importance of a particular CYP isoform in drug metabolism does not necessarily
correspond to its abundance in the liver. DDC, diethyl dithiocarbamate.
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Genes. In the human genome, 57 genes encoding CYP enzymes and 58 pseudogenes
(defective genes) have been identified (Nelson et al., 2004, Ingelman-Sundberg and Sim,
2010). The CYP genes are highly polymorphic (http://www.cypalleles.ki.se). Mutations in
CYP genes may lead to enzyme variants with higher, lower, or no activity, or to the absence
of enzyme. In particular, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and
CYP3A5 have several polymorphisms, which affect their function. Carriers of variant CYP
alleles can generally be divided into three major phenotypes: extensive metabolisers (EMs),
intermediate metabolisers (IMs), and poor metabolisers (PMs). EMs carry at least one
functional allele and exhibit a normal enzyme function. IMs carry one defective allele or two
partially defective alleles, while PMs are homozygous for the defective allele, leading to a
reduced or no enzyme activity, respectively (Ingelman-Sundberg and Sim, 2010). Moreover,
CYP2D6 ultra-rapid metabolisers (UMs) carry multiple functional alleles. In addition to
affecting the metabolism of drugs, genetic variants of CYP enzymes may also be a
determinant for the extent of drug-drug interactions. For instance, individuals with high
activity variants are expected to be more sensitive to CYP inhibition as compared to
individuals with low activity variants (Konig et al., 2013).
Expression. The liver and intestine are the most important sites for CYP-mediated
metabolism (Pelkonen et al., 2008), but CYPs can be found throughout the body, in particular
at interfaces, such as the nasal and lung epithelia, and skin. In the cells, drug-metabolising
CYP enzymes are mainly located in the endoplasmic reticulum with their active sites exposed
at the cytosolic side of the membrane (Edwards et al., 1991, Lin and Lu, 2001, Cribb et al.,
2005). The expression levels of CYP enzymes vary considerably between individuals and
populations (Shimada et al., 1994). Important sources for inter-individual variability in CYP
concentrations and activities include genetic polymorphisms, epigenetics, and other internal
and external factors such as age, disease, environmental chemicals, medication, nutrition, and
sex (Meyer, 1996, Zanger and Schwab, 2013).
Reaction. The CYP enzymes are haem-thiolate proteins, containing well-conserved helices
(A-L) and folds. The I and L helices are associated with the haem (iron protoporphyrin IX)
(Guengerich, 2001). In the resting state of the enzyme, the haem iron is in ferric state (Fe3+)
and bound to water. When reduced to ferrous state (Fe2+), it can bind ligands such as oxygen
and carbon monoxide.
CYPs mainly catalyse oxidative reactions, such as carbon hydroxylation, heteroatom
oxygenation, dealkylation, and epoxidation (Lin and Lu, 1998, Guengerich, 2001). For
example, CYP-mediated hydroxylation plays an important role in the synthesis of cholesterol
and in its further metabolism to steroid hormones and bile salts. CYPs are called mixed
function oxidases or monooxygenases because they incorporate one atom of molecular
oxygen into substrate and the other one is reduced to water (Scheme 1).
ܴܪ + ܱଶ + ܰܣܦܲܪ + ܪା → ܴܱܪ + ܪଶܱ + ܰܣܦܲା (Scheme 1.)
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For their activity, CYPs need to be integrated into a membrane that contains CYP
oxidoreductase (POR) and, for some reactions, cytochrome b5. The CYP catalytic cycle
consists of at least seven steps: 1) binding of substrate to the ferric form of the CYP, 2)
reduction of the haem iron from ferric to ferrous state by an electron donated by nicotinamide
adenine dinucleotide phosphate (NADPH) via POR, 3) binding of oxygen, 4) transfer of a
second electron from POR and/or cytochrome b5, 5) cleavage of the O-O bond, 6) substrate
oxygenation, and 7) product release and return of the enzyme to its resisting state (Lin and Lu,
1998, Guengerich, 2001). If carbon monoxide binds to the ferrous iron, the catalytic cycle is
interrupted. This reaction yields the classic CO difference spectrum with a maximum at 450
nm.
Most CYP oxidation reactions follow traditional Michaelis-Menten kinetics according to
Scheme 2 and Equation 1:
(Scheme 2.)
where E represents the enzyme, S the substrate, EÍS the enzyme-substrate complex, and P is
the product. Under steady state conditions, Equation 1 can describe the reaction (Korzekwa,
2002):
ݒ = ௠ܸ௔௫ × [ܵ]
ܭ௠ + [ܵ] (Equation 1.)
where v represents the reaction velocity, Vmax is the reaction velocity at saturating substrate
concentrations, [S] is the substrate concentration, and Km is the Michaelis-Menten constant.
This constant describes the concentration of substrate giving half maximal velocity, and is a
useful descriptor of the binding affinity of the substrate for the enzyme.
Some CYP reactions, however, show unusual enzyme kinetics, including activation,
autoactivation, partial inhibition, biphasic saturation, and substrate inhibition (Korzekwa,
2002). Although these reactions have been described for most CYPs, they have primarily
been associated with CYP3A4 (Tracy, 2006).
CYP2C subfamily. Members of the human CYP2C subfamily include CYP2C8, CYP2C9,
CYP2C18, and CYP2C19. Together, these enzymes metabolise about 20-30% of clinical
drugs, and account for almost 30% of the total hepatic CYP amount (Totah and Rettie, 2005,
Rostami-Hodjegan and Tucker, 2007, Lai et al., 2009, Zanger and Schwab, 2013, Achour et
al., 2014). The CYP2C genes are located on chromosome 10q24 arranged as centromere-
CYP2C18-CYP2C19-CYP2C9-CYP2C8-telomere (Gray et al., 1995). CYP2C8 (31 kilobases,
nine exons) is the smallest of the human CYP2C genes (Klose et al., 1999). Although the
CYP2C isoforms show high amino acid identity (>77%), they exhibit variation in their protein
E	+	S E	× S E	+	P
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expression and substrate specificities (Klose et al., 1999, Totah and Rettie, 2005, Niwa and
Yamazaki, 2012). CYP2C8, CYP2C9, and CYP2C19 are primarily located in the liver. Even
though it has high messenger ribonucleic acid (mRNA) levels in hepatocytes, CYP2C18 is
poorly translated into protein (Zanger and Schwab, 2013), and is, in contrast to the other
CYP2C isoforms, not inducible (Gerbal-Chaloin et al., 2001, Rae et al., 2001). CYP2C9 is
considered to be the most important isoform of the subfamily due to its high liver expression
and participation in the metabolism of several important drugs such as S-warfarin, phenytoin,
and non-steroidal anti-inflammatory drugs (NSAIDs). Similarly, CYP2C19 metabolises
several drug classes, including antidepressants, benzodiazepine, and proton pump inhibitors.
The substrates of CYP2C9 and CYP2C19 tend to be mildly acidic and mildly basic,
respectively (Totah and Rettie, 2005). CYP2C8 differs from the CYP2C9 and CYP2C19 due
to its substrate specificity and large active site cavity.
1.1.1. CYP2C8
Although CYP2C8 was early known to metabolise arachidonic acid, carbamazepine, retinol,
and retinoic acid (Leo et al., 1989, Kerr et al., 1994, Rifkind et al., 1995), its importance as a
drug-metabolising enzyme was undervalued for some time. Over the last 15 years, CYP2C8
has gradually gained increased attention as clinically relevant CYP2C8 substrates and
inhibitors have been identified, functional CYP2C8 single nucleotide polymorphisms (SNPs)
have been characterised, and its crystal structure has been resolved. Following a
pharmacokinetic interaction between gemfibrozil and cerivastatin that resulted in
rhabdomyolysis cases, the role of CYP2C8 was recognised by drug regulatory authorities
(Backman et al., 2002, Chang et al., 2004, Huang et al., 2008).
Expression and regulation. CYP2C8 is primarily expressed in the liver, where it is
expressed at 22-30 pmol/mg microsomal protein, thus accounting for about 6-7% of the total
hepatic CYP content (Rowland Yeo et al., 2004, Rostami-Hodjegan and Tucker, 2007,
Kawakami et al., 2011, Ohtsuki et al., 2012, Achour et al., 2014). CYP2C8 mRNA has been
detected in several extrahepatic tissues (Zeldin et al., 1995, McFayden et al., 1998, Klose et
al., 1999, Thum and Borlak, 2000, Nishimura et al., 2003), but immunochemistry has
detected extrahepatic CYP2C8 protein only in kidney and adrenal cortical cells, heart,
salivary ducts, intestine, and tonsils (Enayetallah et al., 2004, Delozier et al., 2007). In the
liver, the protein expression of CYP2C8 is correlated with CYP3A4 > CYP2D6 > CYP2C9 >
CYP2C19 (Naraharisetti et al., 2010, Achour et al., 2014). Induction studies suggest that
CYP2C8 is regulated by several nuclear receptors, including the pregnane X receptor (PXR),
the constitutive androstane receptor (CAR), the glucocorticoid receptor (GR), and the vitamin
D receptor (VDR) (Gerbal-Chaloin et al., 2001, Ferguson et al., 2005, Chen and Goldstein,
2009). The in vivo turn-over half-life of hepatic CYP2C8 protein has been estimated to 22 h
(Backman et al., 2009). Following induction or mechanism-based inhibition, the half-life of
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the CYP determines the time required for complete recovery of the enzymatic activity (Yang
et al., 2008). In comparison, CYP1A2, CYP2D6, CYP2E1, and CYP3A4 have estimated in
vivo half-lives of 36-100 h (Obach et al., 2007, Yang et al., 2008, Grimm et al., 2009).
Structure. In 2004, the first paper reporting determination of the structure of CYP2C8 by X-
ray crystallography was published (Schoch et al., 2004). The molecular weight of CYP2C8
approximated to 54 kDa, and one single crystal diffracted to 2.7 Å. CYP2C8 crystallised as a
symmetric dimer, formed by extensive interaction between the F, F’, G, and G’ helices. Later,
it has been shown that CYP2C8 exists as a dimer also in natural membranes (Hu et al., 2010).
As compared to other CYP isoforms, CYP2C8 has a large active site cavity (1438 Å3)
(Schoch et al., 2004), which is consistent with its ability to metabolise large substrates, such
as cerivastatin and paclitaxel (Lai et al., 2009). The topology of the active site is trifurcated,
resembling a T or Y shape (Schoch et al., 2008). In comparison, the active site cavity of
CYP3A4 is more uniformly distributed, but its volume (1386 Å3) is similar to that of CYP2C8
(Yano et al., 2004). These findings likely explain why CYP2C8 and CYP3A4 often have
common substrates but yield different metabolite profiles. In fact, CYP2C8 has more
substrates in common with CYP3A4 than with CYP2C9 (Totah and Rettie, 2005).
Substrates, inhibitors, and inducers. CYP2C8 metabolises about 5-8% of drugs that
undergo metabolism (Zanger et al., 2008, Lai et al., 2009, Zanger and Schwab, 2013). Due to
its large, sinuous active site, CYP2C8 can accommodate substrates of different sizes and
structures. Its substrates do not share any common structures or chemical patterns, but many
of them are large organic anions at physiological pH with oxidation sites located ~13 Å from
the anionic group (Melet et al., 2004). CYP2C8 metabolises drugs from several different
therapeutic classes; typical CYP2C8 substrates include antimalarial agents, glitazone
antidiabetic drugs, NSAIDs, opioids, and statins (Table 1). In addition, CYP2C8 is involved
in the metabolism of several members of the new protein kinase inhibitor drug class, such as
dabrafenib, erlotinib, pazopanib, and ponatinib. Amodiaquine N-deethylation, paclitaxel 6α-
hydroxylation, and rosiglitazone para-hydroxylation are recommended in vitro marker
reactions of CYP2C8 activity, and amodiaquine, repaglinide, and rosiglitazone are suitable in
vivo CYP2C8 probe drugs, according to regulatory authorities (FDA, 2011, EMA, 2013).
Except for metabolism of drugs, CYP2C8 is also involved in the metabolism of endogenous
compounds such as arachidonic acid and retinoids (Zeldin et al., 1995, Nadin and Murray,
1999).
Several reversible and irreversible CYP2C8 inhibitors have been identified in the literature
(Table 2). Montelukast, quercetin, and trimethoprim are recommended as selective CYP2C8
inhibitors for in vitro studies (FDA, 2011, EMA, 2013). Unusually, two phase II glucuronide
metabolites, gemfibrozil 1-O-β glucuronide and clopidogrel acyl 1-β-D-glucuronide, affect
CYP2C8 by strong mechanism-based inhibition (Backman et al., 2002, Ogilvie et al., 2006,
Tornio et al., 2014). Gemfibrozil has increased the plasma exposure to many CYP2C8
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substrates several-fold in vivo (Backman et al., 2002, Niemi et al., 2003a, Niemi et al., 2003b,
Jaakkola et al., 2005, Tornio et al., 2008, Backman et al., 2009, Honkalammi et al., 2012,
Aquilante et  al., 2013a), and is recommended as a CYP2C8 inhibitor drug in clinical drug-
drug interaction studies (FDA, 2011, EMA, 2013).
CYP2C8 is the most inducible member of the CYP2C subfamily (Gerbal-Chaloin et al., 2001,
Feidt et al., 2010). Typical inducers such as dexamethasone, phenobarbital, and rifampicin
have increased its mRNA and protein expression several-fold in hepatocytes (Gerbal-Chaloin
et al., 2001, Rae et al., 2001, Raucy et al., 2002, Madan et al., 2003). In vivo, rifampicin has
reduced the plasma exposure to several CYP2C8 substrates (Niemi et al., 2000, Niemi et al.,
2004, Park et al., 2004, Jaakkola et al., 2006a), and it is the preferred CYP2C8 inducer for use
both in in vitro and clinical studies (FDA, 2011, EMA, 2013).
Table 1. Examples of CYP2C8 substrate drugs (adapted from (Lai et al., 2009)).
Drug Therapeutic use References
Amiodarone Antiarrhythmic (Ohyama et al., 2000)
Amodiaquine Antimalarial (histamine N-methyltransferase
inhibitor)
(Li et al., 2002)
Buprenorphine Analgesic (opioid) (Picard et al., 2005)
Cerivastatin Hypolipidemic (HMG-CoA reductase inhibitor) (Wang et al., 2002)
Chloroquine Antimalarial (histamine N-methyltransferase
inhibitor)
(Kim et al., 2003)
Dabrafenib Anticancer (BRAF inhibitor) (Lawrence et al., 2014)
Enzalutamide Anticancer (androgen receptor antagonist) (Xtandi Clinical Pharmacology
and Biopharmaceutic Review(s),
2012)
R-ibuprofen Analgesic, anti-inflammatory (NSAID) (Hamman et al., 1997)
Loperamide Antidiarrheal (opioid) (Kim et al., 2004)
Paclitaxel Anticancer (mitotic inhibitor) (Rahman et al., 1994)
Pioglitazone Antidiabetic (PPARγ agonist) (Jaakkola et al., 2006c)
Repaglinide Antidiabetic drug (insulin secretagogue) (Bidstrup et al., 2003, Kajosaari et
al., 2005a)
Rosiglitazone Antidiabetic drug (PPARγ agonist) (Baldwin et al., 1999)
Simvastatin
acid
Active metabolite of simvastatin;
hypolipidemic (HMG-CoA reductase inhibitor)
(Prueksaritanont et al., 2003)
Tazarotenic
acid
Active metabolite of tazaratone; antipsoriatic,
antiacne
(Attar et al., 2003)
Troglitazone Antidiabetic drug (PPARγ agonist) (Yamazaki et al., 1999)
Zopiclone Sedative (Becquemont et al., 1999)
HMG-CoA, 3-hydroxy-3-methyl-glutaryl-coenzyme A; NSAID, non-steroidal anti-inflammatory drug;
PPARγ, peroxisome proliferator activated receptor gamma.
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Table 2. Examples of CYP2C8 inhibitor drugs and their effects on CYP2C8 activity in HLM.
Inhibitor Mode of inhibition Effect on CYP2C8* References
Amiodarone Irreversible or quasi-
irreversible (MBI)
KI = 51 µM
kinact = 0.029 1/min
(Polasek et al., 2004)
Clopidogrel acyl
1-β-D-
glucuronide
Irreversible or quasi-
irreversible (MBI)
IC50 = 56.4 µM
IC50 = 12.0 µM**
KI = 9.9 µM
kinact = 0.047 1/min
(Tornio et al., 2014)
Clotrimazole Reversible IC50 = 0.78 µM (Walsky et al., 2005a)
Felodipine Reversible IC50 = 1.2 µM (Walsky et al., 2005a)
Gemfibrozil Reversible
(competitive)
IC50 = 91-120 µM
Ki = 75-76 µM
(Wang et al., 2002, Ogilvie et al.,
2006)
Gemfibrozil 1-O-
β glucuronide
Irreversible (MBI) IC50 = 24 µM
IC50 = 1.8 µM**
KI =20-52 µM
kinact = 0.21 1/min
(Ogilvie et al., 2006)
Ketoconazole Reversible (non-
competitive)
Ki = 11.8 µM (Bun et al., 2003)
Lovastatin Reversible IC50 = 15 µM
Ki = 8.4 µM
(Tornio et al., 2005)
Montelukast Reversible
(competitive)
IC50 = 0.020-2.0 µM
Ki = 0.014-0.15 µM
(Walsky et al., 2005a, Walsky et
al., 2005b)
Nilotinib Reversible
(competitive)
IC50 = 0.4-0.7 µM
Ki = 0.10-0.90 µM
(Kim et al., 2013b, Wang et al.,
2014)
Phenelzine Irreversible or quasi-
irreversible (MBI)
KI = 54 µM
kinact = 0.17 1/min
(Polasek et al., 2004)
Pioglitazone Reversible
(competitive)
IC50 = 9.4 µM
Ki = 1.7 µM
(Sahi et al., 2003)
Quercetin Reversible
(competitive)
IC50 = 3.1-8.4 µM
Ki = 3.1-10.1 µM
(Bun et al., 2003, Walsky and
Obach, 2004)
Rosiglitazone Reversible
(competitive)
IC50 = 9.6 µM
Ki = 5.6 µM
(Sahi et al., 2003)
Trimethoprim Reversible
(competitive)
IC50 = 54 µM
Ki = 32 µM
(Wen et al., 2002)
Troglitazone Reversible
(competitive)
IC50 = 2.3-20 µM
Ki = 2.6 µM
(Yamazaki et al., 2000, Sahi et
al., 2003)
Vilazodone Reversible
(competitive)
IC50 = 1.8 µM
Ki = 0.46 µM
(Viibryd Clinical Pharmacology
and Biopharmaceutics Review(s),
2010)
Zafirlukast Reversible IC50 = 0.39 µM (Walsky et al., 2005a)
 * Inhibitory effect on amodiaquine N-deethylation or paclitaxel 6α-hydroxylation in HLM. ** IC50 after a
30-min pre-incubation of inhibitor with NADPH in HLM. CYP, cytochrome P450; HLM, human liver
microsomes; IC50, inhibitor concentration producing 50% inhibition; Ki, reversible inhibition constant;
KI, inhibitor concentration supporting half of the maximal rate of inactivation; kinact, maximal rate of
inactivation; MBI, mechanism-based inhibitor.
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Polymorphisms. More than 450 CYP2C8 SNPs have been identified (Lai et al., 2009). Some
of these SNPs have been associated with variability in CYP2C8-mediated metabolism and
changed drug response. To date, 16 CYP2C8 alleles have been identified and named
CYP2C8*1A (wild type) to CYP2C8*14 (http://www.cypalleles.ki.se). Due to discrepancies
between in vitro and in vivo data, and substrate-dependent functional effects, however, the
polymorphic CYP2C8 alleles have not been assigned an activity level or phenotype.
Except for rare variants with no (CYP2C8*5, CYP2C8*7, CYP2C8*11), reduced (CYP2C8*8,
CYP2C8*14), unchanged (CYP2C8*6, CYP2C8*9, CYP2C8*10, CYP2C8*13) or unknown
activity (CYP2C8*12), CYP2C8*2, CYP2C8*3, and CYP2C8*4 are common and have
possibly clinical relevance (http://www.cypalleles.ki.se) (Dai et al., 2001, Bahadur et al.,
2002, Aquilante et al., 2013b, Zanger and Schwab, 2013). As compared to CYP2C8*1,
CYP2C8*2 (c.805A>T, rs11572103) has been associated with reduced enzyme activity in
vitro and in vivo (Dai et al., 2001, Parikh et  al., 2007, Gao et al., 2010, Aquilante et al.,
2013c, Yu et al., 2013). The CYP2C8*2 allele is rare in Caucasians and Asians (<3%), but
common in Africans with a frequency of ~20% (Dai et al., 2001, Parikh et al., 2007, Kudzi et
al., 2009, Pechandova et al., 2012, Wu et al., 2013).
The available evidence for the activity of CYP2C8*3 (c.416G>A, rs11572080 and
c.1196A>G, rs10509681) is conflicting (Aquilante et al., 2013b). For instance, as compared
to CYP2C8.1, CYP2C8.3 has exhibited reduced activity for the metabolism of amodiaquine,
arachidonic acid, and paclitaxel, while amiodarone concentrations were not affected by this
polymorphism in vitro (Dai et al., 2001, Soyama et al., 2001, Bahadur et al., 2002, Soyama et
al., 2002, Parikh et al., 2007). For cerivastatin, pioglitazone, and repaglinide, however,
CYP2C8*3 has been associated with an increased in vitro metabolism (Muschler et al., 2009,
Kaspera et al., 2010, Yu et al., 2013). In clinical studies, this allele has been associated with
unchanged and decreased plasma concentrations of paclitaxel, repaglinide, and rosiglitazone
(Niemi et al., 2003c, Henningsson et al., 2005, Niemi et al., 2005b, Bidstrup et al., 2006,
Kirchheiner et al., 2006, Stage et  al., 2013). The CYP2C8*3 allele is relatively common in
Caucasians (frequency of 7-23%), but rare in Africans and Asians (Dai et al., 2001, Bahadur
et al., 2002, Nakajima et al., 2003, Halling et al., 2005, Parikh et al., 2007, Kudzi et al., 2009,
Pedersen et  al., 2010, Pechandova et al., 2012, Wu et al., 2013). There is a strong partial
linkage disequilibrium between CYP2C8*3 and CYP2C9*2, a reduced function allele of
CYP2C9 (Bahadur et al., 2002, Alessandrini et al., 2013, Aquilante et al., 2013b); more than
95% of CYP2C8*3 allele carriers have also been reported to be carriers of CYP2C9*2 (Yasar
et al., 2002).
CYP2C8*4 (c.792C>G, rs1058930) has a frequency of ~7% in Caucasians (Bahadur et al.,
2002, Totah and Rettie, 2005, Daily and Aquilante, 2009, Pechandova et al., 2012) but is
uncommon or absent in Africans and Asians (Kudzi et al., 2009, Wu et al., 2013). It has been
associated with reduced or unchanged in vitro enzyme activity (Bahadur et al., 2002,
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Rodriguez-Antona et al., 2008, Singh et al., 2008, Smith et al., 2008, Gao et al., 2010, Jiang
et al., 2011, Yu et al., 2013). The in vivo effect of CYP2C8.4 is unclear because the number
of subjects carrying this variant in pharmacogenetic studies has been low.
1.1.2. CYP3A4
CYP3A4 is the most important CYP enzyme. Its expression level in the liver is approximately
58-146 pmol/mg microsomal protein (Shimada et al., 1994, Lin et al., 2002, Westlind-
Johnsson et al., 2003, Wolbold et al., 2003, Kawakami et al., 2011, Ohtsuki et al., 2012), and
its population variability is very high (Zanger and Schwab, 2013). A recent estimate of its
liver expression is 93 pmol/mg (Achour et al., 2014), thus suggesting that CYP3A4
constitutes for about 30% of the total hepatic CYP amount. CYP3A4 is also the main CYP
enzyme expressed in the intestine, where it significantly contributes to the first-pass
elimination of orally administered drugs (Pelkonen et al., 2008).
CYP3A4 is involved in the metabolism of about 50% of clinically used drugs (Pelkonen et
al., 2008). Its activate site is large and flexible, allowing it to accommodate many structurally
different substrates. It is also able to bind and metabolise multiple substrates simultaneously
(Williams et al., 2004). Typical CYP3A4 marker substrate drugs include midazolam,
simvastatin, and testosterone, while ketoconazole, itraconazole, and ritonavir are examples of
strong CYP3A4 inhibitors (Figure 2) (FDA, 2011, EMA, 2013). Rifampicin and St John’s
Wort are CYP3A4 inducers recommended for use in interaction studies.
More than 40 CYP3A4 variant alleles have been identified (http://www.cypalleles.ki.se), but
few of them appear to have clinical significance. CYP3A4*22 (15389C>T, rs35599367) has
been associated with reduced CYP3A4 activity. In a clinical study, patients who were carriers
of the T allele required 1.7-five-fold reduced statin doses, as compared to non-T carriers
(Wang et al., 2011). Furthermore, CYP3A4*22 has been associated with decreased 2-OH-
atorvastatin/atorvastatin AUC ratio and with simvastatin lipid-lowering response in other
studies (Elens et al., 2011, Klein et al., 2012). In turn, CYP3A4*18A (20070T>C,
rs28371759) has been suggested to result from a gain-of-function mutation (Kang et al.,
2009), and has been associated with low bone mass.
1.2. Drug transporters
Drugs cross cell membranes via passive diffusion, facilitated diffusion, and active transport
(Giacomini and Sugiyama, 2011). Evidence suggests that involvement of transport proteins in
the transport of drugs across biological barriers may be more the rule than the exception
(Dobson and Kell, 2008). Drug transporters are involved in both pharmacodynamic and
pharmacokinetic processes of drugs. Those important in pharmacokinetics are primarily
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located in the intestinal, renal, and hepatic epithelia, where they selectively mediate drug
absorption and disposition (Figure 1) (Giacomini and Sugiyama, 2011). They work together
with drug-metabolising enzymes to eliminate drugs and their metabolites. Based on their
function, drug transporters can be divided into uptake and efflux transporters (Konig et al.,
2013). All uptake transporters belong to the solute carrier (SLC) superfamily, while most
efflux transporters are members of the adenosine triphosphate (ATP)-binding cassette (ABC)
superfamily (Konig et al., 2013). Except for mediating tissue-specific drug distribution,
transporters may also serve as protective barriers to organs and cells. For example, in the
blood-brain barrier, the efflux transporter P-glycoprotein (P-gp) protects the central nervous
system from a variety of compounds. On the other hand, drug transporters may also play
critical roles in drug resistance, e.g. overexpression of P-gp in tumour cells may result in
resistance due to increased efflux of anticancer drugs (Giacomini and Sugiyama, 2011).
SLC superfamily. SLC transporters mediate either drug entry into or drug efflux out from
cells (Giacomini and Sugiyama, 2011). They transport their substrates across membranes
through numerous mechanisms, including facilitated diffusion, ion coupling, or ion exchange
(Hediger et al., 2004, Giacomini and Sugiyama, 2011). Altogether 55 SLC families with more
than 350 transporter coding genes have been identified in the human genome (Hediger et al.,
2004, He et al., 2009). Examples of SLC transporters include the OATPs, organic anion
transporters (OATs), organic cation transporters (OCTs), multidrug and toxic compound
extrusion transporters (MATE), novel organic cation/carnitine transporters (OCTNs), and
peptide transporters (PEPTs). OATPs primarily mediate the uptake of amphipathic
compounds. Their substrates include endogenous substances such as bile salts, steroid
conjugates, thyroid hormones, and drugs such as statins. OATP1B1, highly expressed on the
sinusoidal membrane of hepatocytes, is known to mediate uptake of statins into the liver
(Niemi et al., 2011), where they exert their pharmacological effect.
ABC superfamily. ABC transporters mediate unidirectional efflux of solutes across
membranes. They limit the entry of drugs into tissues or enhance their removal from tissues.
ABC transporters are primary active transporters that couple with ATP hydrolysis, and often
work against high concentration gradients. The 49 genes that have been identified as ABC
transporters are grouped into seven families (ABCA to ABCG) (Giacomini and Sugiyama,
2011). Important ABC transporters include P-glycoprotein (P-gp, ABCB1, multidrug
resistance protein 1, MDR1), the bile salt export pump (BSEP, ABCB11), the multi-drug
resistance-associated protein family (MRP; ABCC1-ABCC6), and the breast cancer resistance
protein (BCRP, ABCG2). P-gp is the most studied efflux transporter and it has a wide range
of substrates, many of which also are substrates of CYP3A4 (Konig et al., 2013). In the
intestine, P-gp and CYP3A4 reduce the absorption of many drugs and other xenobiotics,
thereby functioning as an initial protective barrier, preventing foreign compounds from
reaching the systemic circulation (Zhang and Benet, 2001).
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Transporter polymorphisms. Similarly, as for CYP enzymes, genetic polymorphisms in
transporter genes may cause marked variability in drug concentrations and response.
Numerous polymorphisms have been identified, but the best characterised functionally
relevant polymorphisms to date are OATP1B1 c.521T>C (rs4149056) and ABCG2 c.421C>A
(rs2231142) (Giacomini et al., 2013). SLCO1B1 c.521T>C causes an amino acid change in
the transport protein (Tirona et al., 2001), resulting in a significantly impaired transport
activity both in vitro and in vivo. Clinically, c.521T>C is associated with increased plasma
exposure to several statins (Pasanen et al., 2006, Niemi et al., 2011). Because myopathy is a
concentration-dependent adverse reaction to statins, this SNP may increase the risk of
simvastatin-induced myopathy (Link et al., 2008). Also ABCG2 c.421C>A is associated with
impaired transport activity in vitro (Furukawa et al., 2009), and it has been linked to increased
plasma concentrations of its substrate drugs, such as gefitinib, rosuvastatin, and sunitinib
(Cusatis et al., 2006, Zhang et al., 2006b, Keskitalo et al., 2009, Mizuno et al., 2010,
Tomlinson et al., 2010).
2. Pharmacokinetic drug interactions
Drug-drug interactions occur when one drug alters the pharmacokinetics and/or
pharmacological effect of another drug. Usually, co-administration of two drugs does not
result in undesired pharmacokinetic or pharmacodynamic alterations. However, if a kinetic
interaction is evident, its clinical relevance depends on whether the variation in the plasma
and/or tissue exposure to the affected drug is large enough to produce a clinically important
change in its effect and/or toxicity (Tozer and Rowland, 2006). Drug-drug interactions can
have serious clinical consequences in terms of lack of therapeutic effect, severe adverse
reactions, and even fatalities (EMA, 2013). Interactions have resulted in early termination of
drug development, refusal of approval, prescribing restrictions, and withdrawals of drugs
from the market (Zhang et al., 2006a).
Pharmacokinetic interactions can originate from any of the pharmacokinetic processes of a
drug; from its absorption, distribution, metabolism, or elimination (Tozer and Rowland,
2006). Metabolism-based interactions are generally due to inhibition or induction of CYP
enzymes. Similarly, inhibition and induction of drug transporters may also result in
interactions. The interaction outcome largely depends on three key factors; the perpetrator
drug (e.g. interaction mechanism, potency, dose), the affected drug (e.g. importance of the
affected enzyme/transporter in its pharmacokinetics, presence of alternative elimination
routes, therapeutic window), and the patient (e.g. age, disease, concomitant medications,
genetics), in addition to the site of interaction.
The therapeutic window of a drug defines the concentration range where the benefit/risk ratio
of a drug is optimal; the effect will be small below this range, while the risk for toxicity
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increases at concentrations above the window. A drug with a narrow therapeutic window is
thus sensitive to changes in its concentrations. The therapeutic window of a drug can be
quantified by the therapeutic index, which is classically defined according to Equation 2:
ܶℎ݁ݎܽ݌݁ݑݐ݅ܿ	݅݊݀݁ݔ = ܶܦହ଴
ܧܦହ଴ (Equation 2.)
where TD50 is the dose that causes a toxic response in 50% of subjects, while ED50 is the dose
that causes a pharmacological response in 50% of subjects (Baca and Golan, 2012). However,
as there may be marked inter-individual variability in drug concentration levels at the same
dose, the therapeutic index (or safety margin) is nowadays primarily based on drug exposure
rather than dose (Muller and Milton, 2012). It is thus regarded as the ratio of the highest
exposure to the drug that causes no toxicity to the exposure that produces the desired
response. Accordingly, a high therapeutic index will represent a large therapeutic window.
2.1. Inhibition of drug-metabolising enzymes
Inhibition of CYP enzymes is the most important cause of harmful drug-drug interactions
(Pelkonen et al., 2008). Pharmacokinetically, CYP inhibition may lead to increased
bioavailability and decreased clearance of drugs that depend on these enzymes for their
elimination. For pro-drugs, CYP inhibition may reduce the formation of their
pharmacologically active species. CYP inhibition may thus result in both an increased and
reduced therapeutic effect as well as increased toxicity. Based on the effect on the inhibited
enzyme, CYP inhibition mechanisms are generally divided into reversible, quasi-irreversible,
and irreversible inhibition.
2.1.1 Reversible inhibition
Direct, reversible inhibition occurs when a parent drug inhibits CYPs without requiring
metabolism (Madan et al., 2002). The binding of direct inhibitors to the enzymes is usually
weak; bonds are formed and broken down easily (Pelkonen et al., 2008). Thus, the onset and
offset of inhibition are rapid, and inhibition does not result in a long-term inactivation of the
enzyme. Direct, reversible inhibition can further be divided into three subtypes: competitive,
non-competitive, and uncompetitive inhibition. Competitive inhibition is the most common
inhibition mechanism and occurs when the substrate and inhibitor compete for binding to the
active site of the enzyme (Korzekwa, 2002, Madan et al., 2002). Thus, a competitive inhibitor
will increase the Km of the substrate (Table 3). In non-competitive inhibition, the inhibitor
binds to another site than the substrate, which causes conformational changes of the enzyme.
The alterations do not affect the binding of the substrate but the enzymatic reaction is
inhibited; hence the Km of the substrate is unaffected, while its Vmax is decreased.
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Uncompetitive inhibitors bind directly to the enzyme-substrate complex, and inhibit it,
leading to a reduction of both Vmax and Km. Thus, competitive and non-competitive CYP
inhibition will result in a decrease in the intrinsic clearance (Vmax/Km) of the substrate, while
uncompetitive inhibitors have minimal effect on the intrinsic clearance at low substrate
concentrations (Lin and Lu, 1998, Obach, 2008). In addition to the above mechanisms, mixed
inhibition is often observed; herein both competitive and non-competitive inhibition occur
(Table 3) (Madan et al., 2002, Pelkonen et al., 2008).
The kinetics and affinity with which a reversible inhibitor binds to the CYP enzyme can be
defined by its inhibition constant Ki. This constant describes the dissociation of the enzyme-
inhibitor complex. Modifications of the Michaelis-Menten equation can be used to calculate
the Ki value and for graphical determination of the inhibition mechanism, according to
Equations 3, 4, 5, and 6 for competitive, non-competitive, uncompetitive, and mixed
inhibition (Table 3), respectively.
Table 3. Direct, reversible inhibition mechanisms (Fowler and Zhang, 2008).
Inhibition
mechanism
Equation Change in substrate
Vmax Km Vmax/Km
Competitive ݒ = ௠ܸ௔௫ × [ܵ]
ܭ௠ × (1 + [ܫ] ܭ௜⁄ ) + [ܵ] (Equation 3.) - # $
Non-
competitive
ݒ = ௠ܸ௔௫ × [ܵ]
ܭ௠ × (1 + [ܫ] ܭ௜⁄ ) + [ܵ] × (1 + [ܫ] ܭ௜⁄ ) (Equation 4.) $ - $
Uncompetitive ݒ = ௠ܸ௔௫ × [ܵ]
ܭ௠ + (1 + [ܫ] ܭ௜⁄ ) × [ܵ] (Equation 5.) $ $ -
Mixed ݒ = ௠ܸ௔௫ × [ܵ]
ܭ௠ × (1 + [ܫ] ܭ௜⁄ ) + [ܵ] × (1 + [ܫ] ܭ௜ᇱ⁄ ) (Equation 6.) $ #$ -$
[I], inhibitor concentration; Ki, reversible inhibition constant; KI, inhibitor concentration supporting half
of the maximal rate of inactivation; Km, Michaelis-Menten constant; [S], substrate concentration; v,
reaction rate; Vmax, maximum velocity.
Other reversible inhibitors include slow- and tight-binding inhibitors. These inhibitors
typically bind to and/or dissociate from the target enzyme slowly (Copeland, 2005), which
leads to a time-dependence for the onset of inhibition. Inhibition by slow- and tight-binding
inhibitors may seem irreversible because the dissociation rate of the enzyme-inhibitor
complex may be too slow to be experimentally measured, but the inhibition is most often
reversible (Silverman, 1995, Copeland, 2005). Slow- and tight-binding CYP inhibitors are
rare but some clinical examples exist, such as clotrimazole, itraconazole, and ketoconazole
(Gibbs et al., 1999, Pearson et al., 2006, Ogilvie et al., 2008, Peng et al., 2012).
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Figure 3. Examples of different inhibition mechanisms. Inhibition of CYPs can be due to inhibition by
the parent inhibitor drug, a metabolic intermediate, or a product (metabolite). Inhibitors causing
irreversible inhibition are marked grey.
2.1.2 Quasi-irreversible and irreversible inhibition
Inhibitors causing quasi-irreversible or irreversible inhibition are commonly referred to as
inactivators. Affinity labelling agents typically contain reactive electrophilic elements that
alkylate or acylate enzyme nucleophiles, forming irreversible, covalent bonds (Silverman,
1995, Copeland, 2005). Due to their reactivity, which may cause toxicity and adverse
reactions, affinity labelling agents are usually not suitable as drugs (Silverman, 1995).
Reactive metabolic intermediates of a drug may also inactivate CYP enzymes (Figure 3). In
quasi-irreversible inhibition, these agents complex with the ferrous haem iron of the CYP,
forming inactivating metabolic intermediate complexes (MICs). MICs exhibit an absorbance
maximum in the Soret region between 448 and 456 nm (Franklin, 1991), and spectral
measurements can thus be used to assess whether the inactivation occurs via formation of
MICs. In vitro, the enzyme activity can be restored by irradiation, addition of potassium
ferricyanide, or incubation with highly lipophilic compounds, which dissociates or displaces
the MIC from the enzyme (Ullrich and Schnabel, 1973, Elcombe et al., 1975, Dickins et al.,
1979, Lin and Lu, 1998). However, inhibition by MICs is generally regarded as quasi-
irreversible, as the in vivo activity of the CYP is expected to be restored only by synthesis of
new enzyme (Lin and Lu, 1998).
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drug
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In turn, irreversible inhibitors inactivate the CYP enzyme through haem alkylation and/or
covalent binding to the protein (Silverman, 1995, Lin and Lu, 1998). In general, modification
of the haem always inactivates the CYP, while changes in the protein cause loss of enzyme
activity only if amino acids essential for substrate binding, electron transfer, and oxygen
activation, are modified. Reactive metabolic intermediates causing irreversible CYP
inhibition are denoted mechanism-based inhibitors (Silverman, 1995, Lin and Lu, 1998).
2.1.2.1 Mechanism-based inhibition
A mechanism-based enzyme inhibitor is an unreactive compound that is metabolised by an
enzyme to an intermediate that, before leaving the active site, inactivates it (Silverman, 1995).
Due to the irreversible nature of the inhibition, synthesis of new enzyme is required to restore
enzyme activity. Therefore, the effects of mechanism-based inhibition can be more serious
and persist longer than those of reversible inhibition (Ghanbari et al., 2006).
Scheme 3 describes the process of mechanism-based inhibition (Silverman, 1995). First, the
unreactive inhibitor drug (I) binds to the active site of the enzyme (E), in a similar manner as
a typical substrate or competitive inhibitor of the enzyme. Next, however, a new complex
(E×I’) is formed in a step (k2) that is usually unidirectional, and responsible for the observed
time-dependence of the inactivation. The formed complex can have several fates: 1) if it is
unreactive but forms a tight complex, the inhibition may be result from a non-covalent tight-
binding complex, 2) the intermediate is reactive and undergoes nucleophilic, electrophilic, or
radical reactions (k4) to form a covalent complex (E×I’’), 3) the species generated could be
released (k3) from the enzyme as a stable end product (P), or, in some instances, as a reactive
intermediate (I’) that can react with cellular constituents (Silverman, 1995, Kalgutkar et al.,
2007). Reactive intermediates that are released into the cytosol are often inactivated by
glutathione, and the resulting conjugates can usually be detected in plasma or urine.
(Scheme 3.)
The efficiency of a mechanism-based inhibitor can be described by its partition ratio (r) k3/k4,
which depicts the ratio of the end product release to enzyme inactivation. Thus, when r is 0,
every turnover of inactivator produces inactivated enzyme (Silverman and Invergo, 1986).
Mechanism-based inactivation can further be described by Equation 7:
E	+	I E	× I E	× I’ E	× I’’
E	+	P
kon
koff
k2 k4
k3
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݇௢௕௦ = ݇௜௡௔௖௧ × [ܫ]ܭூ + [ܫ] (Equation 7.)
where kobs is the observed initial rate of inactivation, kinact is the maximal inactivation rate, KI
is the inactivation constant defined as the inhibitor concentration supporting half of the
maximal rate of inactivation, and [I] is the inhibitor concentration. In vitro, for a drug to be
classified as a mechanism-based inhibitor, it needs to fulfil several criteria, for instance, time-
and NADPH-dependency, saturation, involvement of catalytic step, and irreversibility
(Silverman, 1995, Fontana et al., 2005). Structural elements of a drug may indicate a potential
for mechanism-based inhibition. Numerous structures, such as side chains with unsaturated
carbon-carbon bonds and furan ring systems, alkylamino and methylenedioxy groups have
been associated with this inhibition type (Murray, 1997). However, in vitro experiments are
the best way to determine the mechanism-based inhibition potential of a drug (section 4.2.).
Clinical relevance. Mechanism-based inhibition can be of greater concern than reversible
inhibition as the clinical outcome may be a more profound and long-lasting inhibition than
what could be expected based on the dose or drug exposure (Ghanbari et al., 2006). In fact,
among drugs that cause interactions, mechanism-based inhibitors of CYPs represent several
of those agents causing interactions of the greatest extent (Table 4) (Venkatakrishnan et al.,
2007). For instance, mibefradil, a mechanism-based inhibitor of CYP3A4, was withdrawn
partially because of unmanageable drug-drug interactions. In a clinical study, a low mibefradil
dose of 50 mg once daily for three days increased the plasma exposure to triazolam by nine-
fold (Table 4) (Backman et al., 1999). However, many important drugs that have been
identified as mechanism-based inhibitors of CYPs are used clinically, but often with
contraindications and restrictions to use with such drugs that might be subject to inhibition.
Of the 129 identified CYP inhibitors on the United States market in 2009, 24 (19%) were
mechanism-based inhibitors (Isoherranen et al., 2009). Eight of these drugs have caused
strong interactions in vivo (defined as a ≥five-fold increase in AUC of the victim drug),
including clarithromycin (CYP3A4), nefazodone (CYP3A4), nelfinavir (CYP3A4),
paroxetine (CYP2D6), ritonavir (CYP3A4), saquinavir (CYP3A4), ticlopidine (CYP2C19),
and troleandomycin (CYP3A4). Since 2009, several other drugs have been identified as
mechanism-based inhibitors. For instance, many protein kinase inhibitors are mechanism-
based inhibitors of CYP3A4 in vitro (Kenny et al., 2012, Filppula et al., 2014). Compounds
other than drugs may also affect CYPs by mechanism-based inhibition, such as components in
grapefruit juice and liquorice root.
Apart from the risk of long-lasting drug-drug interactions, mechanism-based inhibitors that
bind covalently to CYP enzymes and other cellular proteins are of additional concern due to
the risk of idiosyncratic drug reactions (Ghanbari et al., 2006). Tienilic acid, a mechanism-
based inhibitor of CYP2C9 (Lecoeur et al., 1994), was withdrawn because of hepatotoxicity
mediated by an auto-immune response.
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Table 4. Examples of drug-drug interactions due to mechanism-based inhibition of CYP enzymes.
* The glucuronide metabolite of clopidogrel is a mechanism-based inhibitor of CYP2C8. AUC, area
under concentration-time curve; Cmax, peak concentration; CYP, cytochrome P450; MBI, mechanism-
based inhibitor; t½, elimination half-life.
2.1.3 Inhibition by metabolites
Except for reactive metabolic intermediates, other drug metabolites may also inhibit CYP
enzymes and contribute to drug-drug interactions. Not taking circulating inhibitory
metabolites into account when predicting the inhibitory potential of a drug may cause
significant underpredictions of its possible interactions (Yeung et al., 2011). For instance,
inhibitory metabolites of the CYP3A4 inhibitor itraconazole have been estimated to account
for about 50% of its total inhibitory effect on CYP3A4 in vivo (Templeton et al., 2008,
Templeton et al., 2010). Other examples of drugs with metabolites causing reversible or
irreversible CYP inhibition include bupropion, clopidogrel (Table 4), fluoxetine, and
gemfibrozil (Stevens and Wrighton, 1993, Ogilvie et al., 2006, Reese et al., 2008, Sager et
al., 2014, Tornio et al., 2014). Product inhibition (“feedback inhibition”) occurs when a
metabolite (product) inhibits an enzyme involved in the metabolism of the parent drug (Figure
3).
2.2. Induction of drug-metabolising enzymes
In comparison to direct inhibition of CYPs, enzyme induction is a slow process. Induction of
drug-metabolising enzymes usually increases the elimination of the victim drug, which may
result in reduced plasma concentrations and therapeutic failure. In turn, if the drug is a pro-
drug, induction may lead to an increased formation of the active agent.
Enzyme induction leads in general to increased protein synthesis or reduced enzyme turnover
due to increased gene transcription, or mRNA or enzyme stabilisation, respectively (Brown et
al., 1954, Conney, 1967, Gonzalez, 2007). CYPs are typically induced by transcriptional gene
activation (Sinz et al., 2008). In general, the CYP1A subfamily is induced by aryl
MBI Victim drug Inhibited
enzyme
Change in
Cmax AUC t½
References
Clopidogrel* repaglinide CYP2C8 # 2.5-fold # 5.1-fold # 1.4-fold (Tornio et al.,
2014)
Paroxetine S-metoprolol CYP2D6 # 2.0-fold # 5.1-fold # 2.1-fold (Hemeryck et
al., 2000)
Mibefradil triazolam CYP3A4 # 1.8-fold # 9.0-fold # 4.9-fold (Backman et al.,
1999)
Ticlopidine omeprazole CYP2C19 # 3.0-fold # 6.2-fold # 2.6-fold (Ieiri et al.,
2005)
36
hydrocarbon receptor ligands, while PXR and CAR mediate induction of the CYP2 and CYP3
families. Many other drug-metabolising enzymes and drug transporters are also induced by
these nuclear receptors. The receptors are activated by ligand (inducer) binding, which causes
conformational changes, leading to release of co-repessors and recruitment of co-activators
and dimerisation partners. In turn, these processes result in chromatin remodelling and
transcriptional activation. Transcription regulation is achieved through binding of the receptor
to deoxyribonucleic acid (DNA) response elements present in the promoter region of target
genes (Wang and LeCluyse, 2003).
Clinical relevance. The induced increase in enzyme protein levels causes an increased
enzyme activity. In vitro, an increase in the Vmax of the victim drug is observed, while its Km
is unaffected, thus leading to an increased intrinsic metabolic clearance (Vmax/Km). Clinically,
the resulting increase in hepatic clearance may cause reduced plasma exposure to the victim
drug (Table 5) (Sinz et al., 2008), and loss of drug response. For instance, reduced efficacy
has been observed in cases where CYP3A4 induction has led to reduced ethinyloestradiol
levels from oral contraceptives or lowered cyclosporine concentrations in transplant patients,
resulting in unwanted pregnancies or organ rejection, respectively (Sinz et al., 2008). Other
possible outcomes of CYP induction include an increased formation of active or toxic
metabolites, enhanced activation of pro-drugs, and hypertrophy of hepatocytes. Autoinduction
occurs when the inducer compound induces its own metabolism, for instance, artemisinin and
carbamazepine are both substrates and inducers of CYP2B6 and CYP3A4, respectively
(Bertilsson et al., 1980, Simonsson et al., 2003). Well-known CYP inducers include
carbamazepine, phenobarbital, phenytoin, rifampicin (Table 5), and St John’s Wort (Pelkonen
et al., 2008). Similarly as for CYP inhibition, compounds other than drugs may also cause
CYP induction. For instance, ethanol induces CYP2E1, while tobacco smoking causes an up-
regulation of CYP1A2 (Figure 2).
Table 5. Examples of drug-drug interactions mainly due to CYP induction by rifampicin.
AUC, area under concentration-time curve; Cmax, peak concentration; CYP, cytochrome P450; t½,
elimination half-life.
Victim drug Induced enzyme(s) Change
in Cmax AUC t½
References
Midazolam CYP3A4 $ 95% $ 98% $ 63% (Backman et al., 1998)
Pioglitazone CYP2C8 ↔ $ 54% $ 53% (Jaakkola et al., 2006a)
Repaglinide CYP2C8, CYP3A4 $ 79% $ 80% ↔ (Bidstrup et al., 2004)
Rosiglitazone CYP2C8, CYP2C9 $ 31% $ 66% $ 62% (Park et al., 2004)
Simvastatin acid CYP3A4, CYP2C8 $ 90% $ 93% ↔ (Kyrklund et al., 2000)
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2.3. Transporter interactions
Inhibition or induction of drug transporters may also result in altered tissue distribution and
plasma concentrations of their substrate drugs. The outcome depends on the importance of the
transporter in the pharmacokinetics of the drug, but also on the type (uptake/efflux) and
localisation of the transporter affected (Endres et al., 2006, Giacomini and Sugiyama, 2011).
For instance, inhibition of an uptake transporter located in the intestine may result in reduced
absorption of its substrates, while inhibition of an intestinal efflux transporter may lead to an
increased drug exposure (EMA, 2013). Inhibition of transporters is complex and may involve
several mechanisms, including traditional competitive, non-competitive and uncompetitive
inhibition of the transporter, or interaction with the ATP hydrolysis of ABC transporters (Lin,
2003, Giacomini and Sugiyama, 2011). However, evaluation of the role of a single transporter
in a drug-drug interaction may be challenging. Many transporters and CYPs show
overlapping substrate specificities, and several membrane transporters are regulated by the
same nuclear receptors as CYPs, such as CAR and PXR (Tirona, 2011, Yoshida et al., 2012).
Clinical relevance. Today it is evident that transporter inhibition or induction may cause
clinical significant drug-drug interactions (Table 6). As compared to interactions due to
transporter inhibition, however, the number of documented interactions resulting from
transporter induction is small (Konig et al., 2013). Some interactions affecting transporters
change the concentrations of a drug within a particular tissue, without altering its
concentrations in plasma (Endres et al., 2006). This is possible because the amount of drug
distributing into a specific tissue is only a small fraction of the total drug amount in the body,
or its clearance may be mainly due to processes other than transport, such as metabolism. For
instance, the P-gp inhibitor verapamil increases the concentration of cyclosporine in the brain,
but not in plasma (Sasongko et al., 2005).
Table 6. Examples of drug-drug interactions due to transporter inhibition or induction.
* CYP3A4 inhibition also involved. ** Other transporters may also be involved. ***Inducer. AUC, area
under concentration-time curve; Cmax, peak concentration; OATP, organic anion transporting
polypeptide; P-gp, P-glycoprotein; t½, elimination half-life.
Perpetrator
drug
Victim drug Affected
transporter
Change in
Cmax AUC t½
References
Cyclosporine repaglinide OATP1B1*
(liver)
# 1.8-fold # 2.4-fold ↔ (Kajosaari et
al., 2005b)
Cyclosporine rosuvastatin OATP1B3**
(liver)
# 10.6-fold # 5.0-fold $ 53% (Simonson et
al., 2004)
Grapefruit
juice
aliskiren OATP2B1**
(intestine)
$ 81% $ 61% $ 10% (Tapaninen et
al., 2010)
Itraconazole digoxin P-gp
(kidney)
↔ # 1.7-fold ↔ (Jalava et al.,
1997)
Rifampicin*** digoxin P-gp
(intestine)
$ 58% $ 30% ↔ (Greiner et al.,
1999)
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3. Guidelines on the investigation of drug-drug interactions
in drug development
Drug-drug interaction studies aim to determine whether there is a potential for clinically
relevant interactions between the study drug and other drugs. In drug development, these
studies should be conducted early as part of the assessment of the safety and effectiveness of
the drug, but also during its clinical use after approval (FDA, 2012, EMA, 2013). The most
recent guidelines on the investigation of pharmacokinetic drug-drug interactions in drug
development from European and United States drug regulatory authorities include the
Guideline on the Investigation of Drug Interactions of the European Medicines Agency
(EMA) published in 2013, and the corresponding draft guidance from the United States Food
and Drug Administration (FDA), issued in February 2012 (FDA, 2012, EMA, 2013).
Figure 4. Decision tree for investigation of metabolism-based drug-drug interactions (modified from
FDA (2012) and EMA (2013)). * Specific for FDA. ** Specific for EMA. CYP, cytochrome P450;
UGT, uridine-5’-diphosphate glucuronosyltransferase.
The interaction potential of a drug can be assessed using in vitro (laboratory), in silico
(computational), and in vivo (animal and human) methods. If the investigations indicate that
the drug is likely to cause (i.e. act as a perpetrator) or be subject (victim) to drug-drug
Conduct in vitro metabolism and drug-drug interaction studies in human tissues
- Phase I enzymes: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A, other
- Phase II enzymes: UGT enzymes
An enzyme catalyses a
main metabolic
pathway, which based
on in vivo data appears
to contribute to the
overall elimination of the
drug by ≥25%.
One or more active
metabolites are
formed. An enzyme
catalyses the formation
or elimination of an
active metabolite.**
The drug or a major
metabolite is an
inhibitor or inducer of
an enzyme. Basic,
mechanistic static
and dynamic models
do not exclude an
interaction.
Observation:
interaction
Conduct in vivo studies with strong inhibitors/
inducers of the enzyme or compare
pharmacokinetics in different genotypes
Study other
substrate drugs
based on likely co-
administration and/or
with narrow
therapeutic window,
or apply mechanistic
modelling.
Observation: interactionObservation:
no interaction
Re-evaluate
enzyme
involvement.
Consider dosage adjustment.
Study other inhibitors/
inducers based on potency and
likely co-administration in vivo, or
apply mechanistic modelling.
The drug is a
substrate of
multiple
enzymes,
together
responsible
for ≥25% of
its systemic
clearance in
vivo.*
Evaluate the
risk of
complex
drug-drug
interactions.
Basic, mechanistic static and/or dynamic models do
not exclude an interaction.
Conduct in vivo
studies with
sensitive/ specific
substrates.
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interactions, actions should be determined to reduce the risk for harmful consequences. These
could include dosage adjustments, therapeutic monitoring, contraindication to simultaneous
use with certain drugs, and other treatment recommendations (FDA, 2012, EMA, 2013). The
potential for drug-drug interactions should be evaluated for small molecule drugs and also for
certain classes of therapeutic proteins (FDA, 2012). Here, a brief overview of the current
regulatory guidelines for interactions affecting drug-metabolising enzymes and drug
transporters by small molecule drugs is presented.
In vitro studies. Drug-drug interaction studies usually start with in vitro experiments to
determine if the study drug is a substrate, inhibitor, and/or inducer of metabolising enzymes
and transporters (Figure 4). The interaction potential of metabolites present at ≥25% of the
parent drug AUC and 10% of the AUC of total drug-related material should also be tested
(FDA, 2012, EMA, 2013). If an enzyme contributes to a metabolic pathway estimated to
account for more than 25% of the total drug elimination, clinical interaction studies are
warranted to study its role in vivo (see in vivo guidelines section) (FDA, 2012, EMA, 2013).
EMA also recommends in vivo studies to evaluate the role of enzymes forming active
metabolites estimated to contribute to more than 50% of the total therapeutic effect in vivo. In
some cases, minor elimination pathways (contributing to ≤25% of drug elimination) should
also be elucidated, e.g. when the study drug is metabolised by a polymorphic enzyme (FDA,
2012, EMA, 2013). Similarly, the effects on enzymes by the parent drug and its major
metabolites should be studied. Drug candidates that do not undergo metabolism should also
be tested for inhibition and induction of metabolising enzymes (FDA, 2012).
FDA recommends that all new drugs should be evaluated in vitro to determine if they are
substrates of P-gp and BCRP. EMA primarily focuses on P-gp, but advises that other
transporters involved in drug absorption should be tested when physiochemical properties of
the drug or other knowledge indicate that additional transporters could be involved. Both
authorities recommend in vitro studies of transporters mediating drug disposition when in vivo
data indicates that the study drug is significantly eliminated by active renal, biliary or gut wall
secretion. Studies of the in vitro roles of OATPs, such as OATP1B1 and OATP1B3, are
recommended when hepatic elimination is ≥25% of the total drug clearance. Furthermore,
FDA suggests that drugs that undergo renal elimination through active secretion by ≥25%,
should be tested for transport by OAT1, OAT3, and OCT2 (FDA, 2012). Drug candidates and
their major metabolites should also be evaluated as possible inhibitors of these transporters
mentioned above (FDA, 2012, EMA, 2013). Because validated in vitro systems to study
transporter induction are lacking, these studies can be carried out using in vivo methods
(FDA, 2012). Both EMA and FDA acknowledge that the drug transport field is evolving
rapidly, so transporters other than those mentioned should be tested when appropriate.
Prediction and modelling guidelines. Together with pharmacokinetic and mass balance data
on main elimination routes and knowledge on enzymes and transporters involved in the
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disposition of the drug, in vitro-in vivo extrapolations are used to predict the clinical
interaction risk based on in vitro data. Basic static models are suitable as a first screening
method to evaluate the need for a clinical study (EMA, 2013). A positive interaction signal
from a basic static model may be further examined by use of mechanistic static models and
more dynamic models (section 5.2.). The criteria used for assessing bioequivalence (predicted
AUC ratio of 0.8-1.25) can be used as a cut-off to determine if in vivo studies are needed
(FDA, 2012, EMA, 2013). Physiologically based pharmacokinetic (PBPK) modelling is
recommended as a useful tool to improve the design of clinical studies (section 5.3.). These
models may be used at different stages in drug development to estimate the interaction
potential qualitatively and to predict the interaction outcome quantitatively (EMA, 2013). In
some cases, PBPK modelling can be used as an alternative to clinical studies, for instance
when determining the likelihood of interactions in special populations, such as paediatric or
geriatric populations (FDA, 2012). Modelling approaches can also be useful in complex drug-
drug interactions involving several mechanisms, for instance, concurrent inhibition and
induction of an enzyme or simultaneous enzyme and transporter inhibition. If conventional
interaction studies cannot be performed, the interaction potential can also be investigated
using population pharmacokinetic analyses (FDA, 2012).
In vivo guidelines. Due to marked species differences, pharmacokinetic interaction studies
should generally be conducted in humans (EMA, 2013). In vivo drug-drug interaction studies
are typically designed to compare drug concentrations with and without a perpetrator drug.
Because a specific study can address a number of questions and clinical objectives, many
study designs for investigating drug-drug interactions can be considered (section 6.). If a
specific enzyme or transporter is involved in the main elimination pathway of a drug,
interaction studies generally start by testing the effect of strong inhibitors and inducers on its
metabolism. A strong inhibitor is defined as an inhibitor causing an ≥five-fold increase in the
AUC of the victim drug, while a strong inducer reduces the victim drug AUC by ≥80% (FDA,
2012, EMA, 2013). If an interaction is observed, studies with less strong inhibitors and
inducers can be evaluated (Figure 4). When testing the perpetrator potential of a drug, in vivo
studies start by testing its effect on sensitive probe drugs. A sensitive substrate is defined as a
drug, whose AUC is increased ≥five-fold when taken together with a known CYP inhibitor
(FDA, 2012). As an alternative or complement to interaction studies, clinical studies in
different polymorphic populations may be carried out (EMA 2013).
4. In vitro methods for study of CYP-mediated drug
interactions
The in vitro characterisation of drug metabolism and interactions must be performed with
high quality and consistency, in particular when they influence the design of clinical trials.
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This section describes some common methods for studying CYP-mediated drug metabolism
and inhibition in vitro, while induction will not be discussed.
4.1. Phenotyping of CYP-mediated reactions
In drug metabolism, reaction phenotyping is defined as the process of identifying the enzyme
that is responsible for metabolising a drug (Ogilvie et al., 2008). Reaction phenotyping allows
an estimation of the victim potential of a drug. Before conducting such studies, however, it is
important to first determine the main elimination pathways of the drug, and the most
appropriate test systems in which to study the reactions. CYP reaction phenotyping data will
be of clinical interest only if oxidative metabolism reactions are estimated to play a significant
role in the overall elimination of a drug (Bjornsson et al., 2003).
Table 7. Human enzyme sources used in in vitro metabolism and interaction studies (modified from
Madan et al. (2002) and Pelkonen and Turpeinen (2007)).
Enzyme source Advantages Disadvantages
Liver slices Contain all hepatic enzymes and drug
transporters, induction can be studied.
Limited availability, as fresh tissue is
needed. Require specific techniques
and procedures. Have a barrier to the
diffusion of drugs to cells. Limited
viability.
Liver
homogenates
Contain nearly all hepatic enzymes. Liver architecture lost.
Primary and
cultured
hepatocytes
Contain all hepatic enzymes and
several transporters cellularly
integrated. Induction can be studied.
Requires specific techniques and
procedures. Quality and stability may
vary. Interpretation of findings may be
challenging. For primary hepatocytes,
limited availability and relatively
healthy tissue needed.
S9 fractions Contain many enzymes, including
CYP, FMO, and UGT enzymes.
Lower enzyme activity than in
microsomes and expressed enzymes.
HLM Contain the most important drug-
metabolising enzymes, low in cost and
easy to store. Commercially available
from several sources.
Contain only phase I and UGT
enzymes. Enzyme levels can vary.
Contain lipids and proteins that can
reduce unbound drug concentrations.
Expressed
individual CYPs
Useful for high throughput screening.
The importance of an individual
enzyme and its variants can easily be
studied. No need for CYP-specific
substrates. Commercially available
from several sources.
Only one enzyme can be studied at a
time, and the metabolic contribution of
other enzymes is not represented.
Cytochrome b5 and POR levels may
vary.
CYP, cytochrome P450; FMO, flavin-containing monooxygenase; HLM, human liver microsomes;
POR, cytochrome P450 oxidoreductase; UGT, uridine-5’-diphosphate glucuronosyltransferase.
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Test systems. The in vitro metabolism of a drug is studied by measuring the reduction in its
concentrations and/or the increase in metabolite concentrations with time (Pelkonen and
Turpeinen, 2007). Various enzyme preparations are available for these studies (Table 7).
Because all systems have advantages and disadvantages, selection of a given system should
be based on the desired endpoint. When preliminary information on the metabolism of the
drug is scarce, more advanced test systems such as hepatocytes, liver homogenates and slices
can be useful to identify different metabolic pathways. Otherwise, human liver microsomes
(HLM) and recombinant enzymes are recommended for phenotyping of CYP-mediated
reactions because of their accessibility, and due to the fact that measurements in these reduced
systems are not confounded by other metabolic processes or cellular uptake (Bjornsson et al.,
2003).
Incubation and reaction conditions. In vitro incubation conditions attempt to mimic the
chemical environment of the hepatic cytosol. Common reaction conditions for HLM and
recombinant enzyme experiments include 100 mM buffer, pH 7.4, 37°C, and possibly a co-
factor such as MgCl2 (Madan et al., 2002, Venkatakrishnan et al., 2003). Addition of NADPH
initiates the reactions, while protein precipitation by organic solvents or an acid are used to
stop them. In the incubations, the lowest microsomal protein concentration possible should be
used in order to minimise non-specific binding of the test compounds. Experiments where
reaction rates are measured are generally conducted under initial-rate conditions. Here, the
formation of the metabolite should be directly proportional to the incubation time and enzyme
concentration, to ensure that the enzyme activity remains stable. Furthermore, in order to
ensure that accurate substrate concentration information is available and reduce the risk of
product inhibition, the consumption of substrate should be held at a minimum (<20%) (Madan
et al., 2002).
In contrast, when reduction in substrate concentration with time is monitored (substrate
depletion approach), substrate consumption usually exceeds 20%. The substrate concentration
should correspond to its clinically relevant unbound concentrations in plasma because
Figure 5. Determination
of intrinsic clearance.
A, Enzyme kinetic plot.
B, Substrate depletion.
kdep, depletion rate
constant; Km, Michaelis-
Menten constant; [S],
substrate concentration; v,
reaction velocity; Vmax,
maximum velocity.[S]
v
Time
Km
Vmax
Vmax / 2
A
Slope = -kdepL
n
[S
]
B
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inappropriate concentrations may yield results that are not reflective of the in vivo situation.
Furthermore, concentrations of organic solvents should be kept low (≤1%) in the incubations,
as solvents may inhibit CYPs (Ogilvie et al., 2008).
Experiments. To identify which CYP isoforms contribute to the oxidative metabolism of
drugs in vitro, three main approaches are generally used, including: 1) use of selective CYP
inhibitors (Figure 2) or inhibitory antibodies in HLM, 2) metabolism in recombinant enzymes,
and 3) metabolic correlation of the reaction activity with CYP-selective isoform markers
reactions in HLM (Lin and Lu, 1998, Bjornsson et al., 2003). Use of at least two approaches
is generally recommended. The enzyme kinetics of a specific reaction is determined using
initial rate conditions and substrate concentrations ranging from 0.1 Km to  10 Km.  Vmax and
Km are determined by non-linear regression of a plot of enzyme activity versus substrate
concentration (Figure 5) (Bjornsson et al., 2003). The intrinsic clearance (CLint) of the
reaction can be calculated based on these constants (Equation 8), usually assuming that the
substrate concentration is much lower than its Km value and therefore does not need to be
considered in the equation. In the substrate depletion approach, the total intrinsic clearance of
a substrate in a specific test system can be estimated according to Equation 9 (Obach et al.,
1997, Obach, 1999).
ܥܮ௜௡௧,௜௡	௩௜௧௥௢ = ௠ܸ௔௫ܭ௠ + [ܵ] → ௠ܸ௔௫ܭ௠ (Equation 8.)
ܥܮ௜௡௧,௜௡	௩௜௧௥௢ = ln	(2)ݐ½ × [ܯ] = ݇ௗ௘௣[ܯ] (Equation 9.)
where t½ is the half-life of the substrate, [M] is the HLM concentration or CYP concentration
in the incubation, and kdep is the first-order depletion rate constant.
4.2. Evaluation of drugs as inhibitors of CYP enzymes
The primary purpose of testing drugs as CYP inhibitors in vitro is to estimate their interaction
potential and evaluate the need for clinical interaction studies. Well-designed inhibition
experiments can be an important predictor of the clinical outcome. Inhibition of CYP activity
is commonly examined using HLM (Bjornsson et al., 2003). Generally, the incubation and
reaction conditions described in section 4.1. can be adopted.
IC50 and Ki experiments. To determine if a drug inhibits a particular CYP isoform, changes
in the metabolism of a CYP-specific marker substrate (Figure 2) in HLM or recombinant
enzymes are monitored. The potency of the inhibitor is assessed by determination of Ki or
IC50 values (Bjornsson et al., 2003). IC50 is an extrinsic constant, defined as the inhibitor
44
concentration required to cause 50% inhibition under a given set of experimental conditions
(substrate type and concentration, protein concentration, etc.) (Madan et al., 2002). Because
Ki values are intrinsic constants, which in theory should be reproducible from one laboratory
to another, it is preferable to determine Ki rather than IC50 values. Appropriate Ki experiments
require multiple inhibitor concentrations covering several orders of magnitude, as well as
multiple substrate concentrations that embrace the Km of the substrate (Figure 6). The data
obtained are used to determine the Ki value and the inhibition mechanism (competitive, non-
competitive, uncompetitive, or mixed) (section 2.1.).
Figure 6. Different types of inhibition plots. A, IC50-shift experiment. A ≥1.5-fold lower IC50 value
following pre-incubation of the inhibitor with NADPH, as compared to no pre-incubation, indicates
time- and NADPH-dependent inhibition. B, Ki-experiment. In the direct plot, the Vmax of the substrate
does not increase, while its Km value decreases, thus suggesting a competitive inhibition mechanism.
C, Lineweaver-Burk plot. The arrangement of lines based on data of the Ki-experiment also suggests
competitive inhibition. D, Mechanism-based inhibition experiment. The inhibition increases with
increasing pre-incubation time and inhibitor concentration. kobs values of each inhibitor concentration
are calculated on the basis of initial rates of inactivation of the enzyme (slope). E, Saturation curve.
kinact and  KI can be obtained from a saturation curve where kobs is plotted against inhibitor
concentration. F, Kitz-Wilson plot. The inactivation constants can also be derived from a reciprocal
plot of kobs and inhibitor concentration. [I], inhibitor concentration; IC50, inhibitor concentration
producing 50% inhibition; KI, inhibitor concentration supporting half of the maximal rate of
inactivation; kinact, maximal rate of inactivation; kobs, inactivation rate constant for a particular inhibitor
concentration; NADPH, nicotinamide adenine dinucleotide phosphate; preinc, pre-incubation; [S],
substrate concentration.
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However, IC50 experiments are less laborious than Ki experiments, and IC50 data can be useful
to guide the design of Ki and other inhibition experiments (Figure 6). In contrast to Ki
experiments, IC50 experiments only require a single substrate concentration (at ≤Km), while
the inhibitor concentrations vary. The rate of the marker reaction is measured in the presence
of various inhibitor concentrations, and the percentage remaining activity with respect to
inhibitor concentrations are plotted to derive an IC50 value (Figure 6). In IC50-shift
experiments, the inhibitor is also tested for NADPH- and time-dependent inhibition. If the
IC50 value is ≥1.5-fold lower following a 30 min pre-incubation with NADPH as compared to
no pre-incubation, the inhibitor should be tested for mechanism-based inhibition (Figure 7)
(Grimm et al., 2009).
Figure 7. Decision tree for inhibition studies when inhibition is observed (adapted from Grimm et al.
(2009), Xenotech (2011)). HLM, human liver microsomes; [I], inhibitor concentration; IC50, inhibitor
concentration producing 50% inhibition; Ki, reversible inhibition constant; KI, inhibitor concentration
supporting half of the maximal rate of inactivation; kinact, maximal rate of inactivation; Km, Michaelis-
Menten constant; NADPH, nicotinamide adenine dinucleotide phosphate; [S], substrate concentration.
B) As compared to no preincubation,
shift to a ≥1.5-fold  lower IC50 value
following a 30-min preincubation in
the presence of NADPH.
C) Shift to lower IC50
value following a 30-min
preincubation in the
absence of NADPH.
Determination of KI and kinact
Preincubation of multiple [I] with
HLM and NADPH, then dilution with
a high [S] and buffer.
Follow-up studies
Determination of reversibility
IC50 determination
HLM, multiple [I] and a single marker [S] at its Km.
A) No pre-incubation to assess direct inhibition. B) 30-min preincubation + NADPH to assess
metabolism-dependent inhibition. C) 30-min preincubation - NADPH to assess slow-binding
inhibition.
Follow-up study
Evaluate slow-binding
inhibition, non-
enzymatic degradation
and metabolism by non-
NADPH enzymes to
inhibitory metabolites or
degradation products.
Determination of partition
ratio
Substrate depletion, titration of
enzyme with test compound.
A) Reversible vs quasi-irreversible and irreversible
- Dialysis or microsomal washing
- Substrate protection experiment
B) Quasi-irreversible vs irreversible
- Ferricyanide treatment, irradiation, incubation with
lipophilic compounds
In vitro – in vivo
extrapolation
Prediction of
interaction potential.
Determination of
direct Ki and inhibition
mechanism
HLM, multiple [I] and
multiple [S], no pre-
incubation.
A) Low IC50 value
following direct inhibition.
Increasing inhibition with pre-
incubation time and increasing [I].
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Mechanism-based inhibition. In mechanism-based inhibition experiments, multiple inhibitor
concentrations are first pre-incubated with high HLM concentrations and NADPH (Grimm et
al., 2009). At determined time points, aliquots are removed and diluted by a factor of 10 or
more with buffer and the marker substrate to determine the residual CYP activity. Dilution
and a high substrate concentration are used to minimise reversible inhibition by the inhibitor.
kobs of each inhibitor concentration are estimated graphically from the initial slope of a graph
where the natural log of the remaining enzyme activity is plotted against pre-incubation time
(Figure 6). Then, kinact and KI are estimated using non-linear regression and Equation 7. These
values can also be determined from linear regression of a double-reciprocal plot of the kobs
versus inhibitor concentrations (Figure 6). Possible follow-up experiments include evaluation
of the reversibility and efficacy of the inactivation (determination of partition ratio) (Figure 7)
(Grimm et al., 2009).
5. In vitro-in vivo extrapolation
Although determination of in vitro metabolism and metabolic interactions may be relatively
straightforward, a proper interpretation and extrapolation of in vitro data to the clinical
situation requires a good understanding of pharmacokinetic principles. In vitro-in vivo
extrapolations are used to interpret the obtained in vitro data and translate it to clinical
relevance. However, even if a drug is predicted to cause or be subject to interactions, it does
not necessary imply that they will be clinically relevant. As described in section 2., several
factors need to be considered to estimate the clinical significance of an interaction.
5.1. Prediction of drug clearance
Intrinsic clearance values obtained from in vitro experiments (CLint, in vitro) can be scaled to
hepatic clearance (CLH) (Figure 8). Although simplifications and several assumptions must be
done, extrapolation of intrinsic clearance obtained from HLM experiments is fairly
uncomplicated, while that of data from recombinant enzyme incubations is more complex and
several approaches can be used. However, before conducting predictions, it is important that
intrinsic clearance values, enzyme kinetic constants, and inhibition constants are corrected for
non-specific binding to protein in microsomal incubations (Obach, 1996, Bachmann, 2006).
HLM. Predictions of hepatic clearance from in vitro intrinsic clearance obtained from HLM
incubations require scaling factors. These include the amount of microsomal protein per gram
liver (MPPGL), and the amount liver per kg body weight (Equation 10). Values of 40-50 mg
protein/g liver and ~30 g liver/body weight are generally used (Davies and Morris, 1993,
Venkatakrishnan et al., 2003, Houston and Galetin, 2008). The most used model in the
prediction of hepatic clearance is the well-stirred model (Equation 11):
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Table 8. Scaling approaches to predict drug clearance from in vitro data from recombinant CYP
enzyme incubations.
Method Definition Unit Adjusted CLint, in vitro
RA CYPi abundance per microsomal
protein
pmol CYP/mg protein CLint, in vitro Í RA
RAF ܥܮ௜௡௧,ு௅ெ(݉ܽݎ݇݁ݎ	ݎ݁ܽܿݐ݅݋݊)
ܥܮ௜௡௧,஼௒௉,௜	(݉ܽݎ݇݁ݎ	ݎ݁ܽܿݐ݅݋݊) pmol CYP/mgprotein* CLint, in vitro Í RAF
ISEF ܥܮ௜௡௧,ு௅ெ(݉ܽݎ݇݁ݎ	ݎ݁ܽܿݐ݅݋݊)
ܥܮ௜௡௧,஼௒௉,௜	(݉ܽݎ݇݁ݎ	ݎ݁ܽܿݐ݅݋݊)× 1
ܥܻ ௜ܲ	ܾܽݑ݊݀ܽ݊ܿ݁	݅݊	ܪܮܯ
- CLint, in vitro Í ISEF Í CYPi
abundance per microsomal
protein
*  If  the  CLint values of the marker reactions are expressed in the same units, then RAF will be
dimensionless. CLint, intrinsic clearance; CYP, cytochrome P450; HLM, human liver microsomes; i,
specific isoform; ISEF, intersystem extrapolation factor; RA, relative abundance; RAF, relative activity
factor.
5.2. Evaluation of enzyme inhibition
Prediction of drug-drug interaction studies based on in vitro inhibition (and induction)
findings may be done using basic static models, mechanistic static models, and dynamic
models. Static models compare the measured inhibition constants with a single, clinically
relevant inhibitor concentration. Basic static models consider only one interaction mechanism
at a time but can be combined to more mechanistic models. Assuming that the clinically
observed substrate concentration is far below its Km value, the degree of inhibition (measured
as its ratio of intrinsic clearance in presence and absence of inhibitor, CLint, i/CLint) can be
described by Equations 12 and 13 for direct and mechanism-based inhibition, respectively
(Mayhew et al., 2000, Ito et al., 2005).
where kdeg is the degradation rate constant of the affected enzyme in the absence of inhibitor.
Depending on whether inhibition in the liver or intestine is evaluated, enzyme degradation
rates and inhibitors concentrations specific for these organs are used. Because of the inverse
relationship between AUC and CLint, the change in AUC of the substrate (defined as its ratio
of AUC in presence and absence of inhibitor, AUCi/AUC) can be calculated according to
Equation 14 (Mayhew et al., 2000, Wang et al., 2004, Zhang et al., 2007), assuming that the
liver is the only organ for clearance.
ܥܮ௜௡௧,௜
ܥܮ௜௡௧
= 11 + [ܫ]ܭ௜ (Equation 12.)
ܥܮ௜௡௧,௜
ܥܮ௜௡௧
= ݇ௗ௘௚
݇ௗ௘௚ + ݇௢௕௦ = ݇ௗ௘௚݇ௗ௘௚ + ݇௜௡௔௖௧ × [ܫ]ܭூ + [ܫ] (Equation 13.)
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ܣܷܥ௜
ܣܷܥ
= 1
௠݂
ܥܮ௜௡௧ ܥܮ௜௡௧,௜⁄ + (1 − ௠݂) (Equation 14.)
where fm is the fraction of the drug metabolised by the affected enzyme. Mechanistic static
models combine several interaction processes. For instance, in Equation 15 direct and
mechanism-based inhibition (denoted as A and B for Equations 12 and 13, respectively) are
combined together with an induction parameter C, in different organs, to estimate the net
interaction effect (Fahmi et al., 2008, Fahmi et al., 2009):
ܣܷܥ௜
ܣܷܥ
= ൬ 1(ܣு × ܤு × ܥு) × ௠݂ + (1 − ௠݂)൰ × ൬ 1(ܣீ × ܤீ × ܥீ) × (1 − ீܨ ) + ீܨ ൰ (Equation 15.)
where H and G denote the liver and intestine (gut), respectively, and FG is the fraction available
after intestinal metabolism in the absence of inhibitor. In most cases, the inhibitor
concentration at the enzyme site is unknown. Based on the hypothesis that only unbound drug
diffuses into the hepatocyte, unbound plasma concentrations of the inhibitor are often used in
these predictions (Pelkonen et al., 2008). However, the unbound inhibitor concentration in
plasma does not always equal the intracellular concentration in the hepatocyte; in particular
very lipophilic drugs may accumulate in hepatocytes (von Moltke et al., 1998). Obviously,
selection of the inhibitor concentration will greatly affect the outcome of the prediction, and
the available literature has not reached a consensus of which inhibitor concentrations to use in
predictions. Various alternatives are available, including total and unbound steady state peak
plasma concentrations of the inhibitor, average steady-state plasma concentrations, inhibitor
concentrations in the portal vein, and estimated inhibitor concentrations in hepatocytes
(Yamano et al., 1999, Kanamitsu et al., 2000, Ito et al., 2004, Bachmann, 2006). For
prediction of the interaction magnitude at the level of the intestine, the inhibitor concentration
in the enterocytes can either be calculated (Rostami-Hodjegan and Tucker, 2004), or
estimated by dividing the dose by 250 ml (Zhang et al., 2008, FDA, 2012).
FDA proposes that the likelihood for an interaction should be based on the ratio of intrinsic
clearance by the metabolising enzyme in the absence and presence of the inhibitor, labelled as
the R value (FDA, 2012). The R values are obtained by inversion of Equations 12 and 13, for
reversible and mechanism-based inhibition, respectively. When a basic model generates an R
value of >1.1, when using total Cmax of the inhibitor, a clinical evaluation of the interaction is
recommended. EMA recommends clinical studies when [I]/Ki for reversible inhibitors is
≥0.02, and for mechanism-based inhibitors when the R value is ≥1.25, when using the
unbound mean Cmax of the inhibitor (EMA, 2013). For mechanistic and dynamic models, a
predicted change in the AUC ratio of the victim substrate of ≥1.25 (or ≤0.8 in case of
induction) warrants a clinical study (FDA, 2012, EMA, 2013).
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5.3. Physiologically based pharmacokinetic modelling
In silico modelling and simulations are becoming increasingly common in drug development
(Rowland et al., 2011). PBPK modelling is an instrument that can be used to predict the in
vivo pharmacokinetics of drugs, and evaluate the effects of diverse intrinsic and extrinsic
factors (such as other drugs) on their concentrations (FDA, 2012). As compared to static
models, PBPK models are dynamic, thus simulating changes in drug concentrations over
time.
A PBPK model consists of a system-dependent component and a drug-dependent component
(Figure 9). The system-dependent module integrates physiological data on body fluid
dynamics, tissue composition and sizes, abundance of drug receptors, drug-metabolising
enzymes and membrane transporters in different tissues and organs (Zhao et al., 2011). Thus,
it forms a ‘virtual human’, which may range from simplified, truncated models containing
only a few tissue/organ compartments to very complex systems comprising multiple
compartments. ‘Population-based’ PBPK models generate different populations of these
’virtual humans’, and can provide information related to variability and uncertainty of the
pharmacokinetic profiles in different patient and ethnic subgroups (Rowland et al., 2011,
Zhao et al., 2011).
The drug-dependent component contains in vitro and in vivo data of the drug of interest
(Figure 9). Physicochemical parameters of the drug can be used to estimate its tissue partition
characteristics, microsomal protein binding, and permeability (unless they have been
experimentally determined) (Zhao et al., 2011). Metabolism, transport and interaction data
from in vitro studies are incorporated to the model. When comprehensive drug-dependent in
vivo parameters are not available, the construction of a PBPK model relies mainly on in vitro
and in silico data. As in vivo data is obtained, it is integrated into the model to refine it. Thus,
the model is constantly evolving as more information is acquired. Model validation is crucial
when developing a PBPK model, and is done by comparing simulated pharmacokinetic
profiles with those from available clinical studies (Rowland et al., 2011, Zhao et al., 2011).
Incorporation of in vitro data on the intrinsic clearance and identities of the enzymes and
transporters involved in the pharmacokinetics of a drug can be used to predict its elimination
and liability to drug-drug interactions. Interaction simulations link two or more drug-
dependent components (drugs) to the system-dependent component. PBPK simulations can be
especially useful for simulating time-dependent events such as mechanism-based inhibition
and induction. Except for standard pharmacokinetic and interaction simulations, well-
designed PBPK models incorporating inter-individual variability can also be used to optimise
clinical study designs, and project pharmacokinetics profiles under different scenarios and in
different patient populations (Zhao et al., 2011).
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victim drug + perpetrator drug followed by victim drug), one-sequence cross-over (victim
drug followed by victim drug + perpetrator drug), or parallel (victim drug in one group of
subjects and substrate + perpetrator drug in another group) schemes (FDA, 2012, EMA,
2013). The selection of design depends on several factors, including dosing, interaction
mechanism, safety considerations etc. Due to the risk of confounding inter-individual
variability, a parallel group design is usually not preferred. However, it can be useful in cases
where it is not possible to perform cross-over or one-sequence studies. Unless
pharmacodynamics endpoints are critical to the assessment of the interaction, clinical
interaction studies can usually be performed as open studies (FDA, 2012, EMA, 2013).
Substrate and perpetrator drugs. A probe substrate should be used when testing whether
the drug candidate inhibits or induces a specific enzyme or transporter. In order to see the
largest impact of the interaction potential of the drug candidate, the selected probe should be
one whose pharmacokinetics is markedly altered by co-administration of known specific
inhibitors/inducers of the affected pathway. Cocktail approaches may be used to investigate
the effect on several enzymes and transporters simultaneously. When testing the drug
candidate for the possibility that its metabolism is inhibited or induced, known
inhibitors/inducers of the pathway studied should be selected. Comparison of drug
pharmacokinetics in poor and extensive metabolisers may replace interaction studies for a
particular pathway when the drug is metabolised by a polymorphic enzyme (FDA, 2012,
EMA, 2013).
Dose. Several dosing regimens of the interacting drugs can be used, including both single and
multiple doses of the victim and perpetrator (FDA, 2012, EMA, 2013). When possible, the
perpetrator and victim drugs should be dosed so that the exposures of both drugs are relevant
to their clinical use, including the highest doses (steady state) likely to be used in clinical
practice. For a drug under investigation, the administration route should be the one planned
for clinical use, but lower doses can be used if there are safety concerns.
Timing of administration. Additional factors include consideration of the sequence of
administration and the time interval between dosing of victim drug and perpetrator (FDA,
2012). A rapid reversible inhibitor may be administered either just before or simultaneously
with the substrate to ensure maximum exposure to the two drugs together. An inducer or
mechanism-based inhibitor, however, should be administered before the victim drug to
maximise the effect. The maximum effect is expected to occur when the affected enzyme has
reached a new steady state level. Timing of administration is particularly critical in complex
interaction situations, such as concurrent inhibition and induction. Furthermore, it is important
to evaluate the duration of the interaction effect after the perpetrator drug has been eliminated
(FDA, 2012, EMA, 2013).
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Subjects. Pharmacokinetic interaction studies are usually performed in healthy volunteers
unless safety considerations preclude their participation (FDA, 2012, EMA, 2013). In some
cases, the use of patients offers advantages, such as the opportunity to study
pharmacodynamic markers not present in or relevant to healthy subjects. The subject number
should be based on considerations taking into account intra-subject variability and the
magnitude of the effect considered relevant to detect. Because the extent of drug interactions
may vary depending on the genotype for the enzyme or transporter being evaluated,
genotyping can be carried out when appropriate. Studies in polymorphic subpopulations are
recommended when possible (FDA, 2012).
Endpoints. Changes in pharmacokinetic parameters are generally used to assess the clinical
importance of drug-drug interactions (FDA, 2012, EMA, 2013). Pharmacokinetic exposure of
the victim drug such as AUC, peak concentration (Cmax), time to Cmax (tmax), and others as
appropriate should always be obtained. In some cases, obtaining the pharmacokinetics of the
perpetrator drug may also be of interest, in particular when the study intends to assess
possible changes in the disposition of both drugs. In addition, in some cases, measurement of
pharmacodynamic endpoints in addition to pharmacokinetic parameters may be useful. The
sampling frequency should be adequate to allow accurate determination of the relevant
measures and/or parameters for the victim drug and its metabolites (FDA, 2012, EMA, 2013).
7. Drugs studied
7.1. Montelukast
Montelukast (orig. Singulair, MK-0476; Merck), a potent and selective leukotriene receptor
antagonist, is widely used in treatment of asthma. It is also indicated for exercise-induced
bronchoconstriction and allergic rhinitis (Singulair Label, 2013). Montelukast was approved
in 1997 (Young, 2012). Before the patent expiration in 2012, Singulair was among the top ten
most prescribed drugs in the United States (Bartholow, 2012). For adults, the recommended
dosing of montelukast is 10 mg once daily (Singulair Label, 2013).
The success of montelukast has been attributed to its efficacy and safety (Paggiaro and Bacci,
2011). In clinical studies, montelukast has been administrated at doses up to 200 mg once
daily to patients for 22 weeks and up to 900 mg once daily for one week, without clinically
important adverse effects (Singulair Label, 2013). The most common adverse reactions
reported in trials (with an incidence exceeding 5% and greater than placebo) include upper
respiratory infection, fever, headache, pharyngitis, cough, gastrointestinal disorders, otitis
media, influenza, rhinorrhoea, sinusitis and otitis (Singulair Label, 2013). However, during
post-approval use, several other adverse reactions have been associated with montelukast use,
54
including hypersensitivity reactions, psychiatric symptoms, and hepatobiliary disorders
(Singulair Label, 2013, Calapai et al., 2014).
Pharmacological mechanism. In human airways, montelukast binds to cysteinyl leukotrienes
(CysLT) type-1 receptors located in smooth muscle cells and other pro-inflammatory cells
such as eosinophils and certain myeloid stem cells (Singulair Label, 2013). Thus, it prevents
the effects of cysteinyl leukotrienes, such as airway oedema, smooth muscle contraction and
other respiratory inflammation. Montelukast may also inhibit symptoms of allergic rhinitis by
binding to receptors in the nasal mucosa.
Montelukast pharmacokinetics. Montelukast has a high molecular weight (586.2 g/mol) and
is strongly lipophilic (logarithm of octanol/water partition coefficient of 9.0-9.5) (HSDB,
2008, Mougey et al., 2009). Following oral administration, it is absorbed rapidly, has a
bioavailability of 60-70%, is highly bound to plasma proteins, and has an elimination half-life
of about 3-7 h (Table 9). In the liver, montelukast is extensively metabolised to one major and
several minor metabolites (Figure 10), which are excreted in bile (Balani et al., 1997).
Following an oral dose of radiolabelled montelukast, 86% of the radioactivity was recovered
in faeces and <1% in urine, within five days (Balani et al., 1997). 36-hydroxy montelukast
(diastereomeric; M6a and M6b) is the major metabolite in plasma. M6 binds to the CysLT1
receptor with almost the same potency as montelukast in vitro (Singulair Clinical
Pharmacology and Biopharmaceutic Review(s), 1998), but its in vivo relevance to the
therapeutic effect of montelukast is unknown. Other primary metabolites of montelukast
include a phenol (M3) and diastereomeric 21-hydroxylated metabolites (M5a and M5b). A
diastereomeric dicarboxylic acid (M4), generated from the further metabolism of M6, is the
main metabolite found in bile, followed by M3, M6, and M5 (Balani et al., 1997). In addition,
small amounts of an acyl glucuronide (M1) and sulfoxides (diastereomeric; M2a and M2b)
are found in bile.
Before 2010, CYP2C9 and CYP3A4 were considered to be the most important enzymes
involved in the metabolism of montelukast (Figure 10). Early in vitro studies concluded that
M6 is formed by CYP2C9, while the formation of M5 and M2 was mediated by CYP3A4
(Chiba et al., 1997). CYP2A6 also catalysed M2 formation. However, in this previous study,
high montelukast concentrations (100-500 µM) were used, corresponding to more than
20,000-fold its unbound clinically relevant concentrations in plasma. In addition, CYP2C8
and CYP3A5 were not included in the CYP screening, and the enzymes forming M3, M4 and
the M1 glucuronide were not investigated. In 2008, an X-ray crystallography study showed
that montelukast binds to the active site cavity of CYP2C8, so that its benzyl ring is
positioned near the haem iron of CYP2C8 (Schoch et al., 2008). Because the montelukast
metabolites M3, M4, and M6 result from the oxidation of its benzyl ring, this finding together
with the fact that it is a competitive CYP2C8 inhibitor in vitro (Walsky et al., 2005a, Walsky
et al., 2005b), suggests that montelukast may actually be a substrate of CYP2C8.
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Table 9. Pharmacokinetic profile of montelukast.
B/P, blood-to-plasma ratio; CLiv, intravenous clearance; CYP, cytochrome P450; F, bioavailability; fu, P,
unbound fraction in plasma; t½, elimination half-life; tmax, time to peak concentration; Vd, ss, iv,
distribution volume at steady state following intravenous doses.
Montelukast has been suggested to be a substrate of the uptake transporter OATP2B1
(Mougey et  al., 2009, Mougey et al., 2011), but recent in vitro and in vivo studies have
challenged this finding (Chu et al., 2012, Kim et al., 2013a, Tapaninen et al., 2013,
Brännström et al., 2014).
Pharmacokinetic interactions of montelukast. Montelukast is a potent, competitive and
selective inhibitor of CYP2C8 in vitro (Table 10) (Walsky et al., 2005a, Walsky et al.,
2005b). However, it does not affect the pharmacokinetics of the CYP2C8 substrates
pioglitazone, repaglinide, and rosiglitazone in healthy subjects (Jaakkola et al., 2006b,
Kajosaari et  al., 2006, Kim et al., 2007). The lack of an in vivo inhibition suggests that the
montelukast concentrations in hepatocytes are much lower than its Ki for CYP2C8, consistent
with its very small unbound fraction in plasma.
Parameter Value References
F 0.58-0.67 (Cheng et al., 1996, Zhao et al., 1997, Singulair Clinical
Pharmacology and Biopharmaceutic Review(s), 1998)
tmax 2-4 h (Cheng et al., 1996, Zhao et al., 1997, Hegazy et al., 2012)
Vd, ss, iv 0.14-0.15 l/kg (Cheng et al., 1996, Zhao et al., 1997, Singulair Clinical
Pharmacology and Biopharmaceutic Review(s), 1998)
fu, P 0.004 (Singulair Clinical Pharmacology and Biopharmaceutic
Review(s), 1998)
B/P 0.65 (Singulair Clinical Pharmacology and Biopharmaceutic
Review(s), 1998)
Metabolising
enzymes
CYP2C9, CYP3A4 (Chiba et al., 1997)
Elimination Extensively
metabolised,
metabolites are
excreted into bile
and faeces (<1% of
the dose is
excreted renally)
(Balani et al., 1997)
CLiv 1.8-2.9 l/h (Cheng et al., 1996, Zhao et al., 1997)
Terminal t½ 4.4-7.1 h (Cheng et al., 1996, Zhao et al., 1997, Hegazy et al., 2012)
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Figure 10. Oxidative metabolism of montelukast according to previous studies (Balani et  al., 1997,
Chiba et al., 1997, Singulair Clinical Pharmacology and Biopharmaceutic Review(s), 1998). In a mass
balance study (Balani et al., 1997), M5 and M6 were found both in plasma and bile, while M1 (an acyl
glucuronide; not shown), M2, M3, and M4 were only detected in bile.
In general, montelukast has had only a small or no effect on other drugs. Doses of
montelukast 10 mg once daily had no or only a minor effect on the plasma exposure to
digoxin, terfenadine, theophylline, and warfarin (Malmstrom et al., 1998, Singulair Clinical
Pharmacology and Biopharmaceutic Review(s), 1998, Van Hecken et al., 1999). However, at
a very high dose of 600 mg once daily, montelukast reduced the AUC of theophylline by 66%
(Malmstrom et al., 1998), possibly due to induction of CYP1A2. Furthermore, high doses of
montelukast 200 mg once daily had no effect on prednisolone concentrations, but the AUC of
prednisone was reduced by 29% (Singulair Clinical Pharmacology and Biopharmaceutic
Review(s), 1998). Montelukast has been routinely administered together with other drugs
used in asthma treatment without increased observations of adverse drug reactions (Singulair
Label, 2013).
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Table 10. Inhibitory effects of montelukast on CYP enzymes in vitro. Its inhibition potency on CYPs
decreases with increasing protein concentration, due to non-specific binding to proteins (Walsky et al.,
2005b).
CYP, cytochrome P450; HLM, human liver microsomes; IC50, inhibitor concentration producing 50%
inhibition; Ki, reversible inhibition constant; n/a, not available.
With regard to the effect of other drugs on montelukast concentrations, the inducer
phenobarbital has decreased the plasma exposure to montelukast by 38% (Singulair Clinical
Pharmacology and Biopharmaceutic Review(s), 1998). Roflumilast and desloratadine had no
effect on the pharmacokinetics of montelukast (Bohmer et al., 2009, Cingi et  al., 2013).
Fluconazole at steady state decreased montelukast AUC by 39%, while clarithromycin at a
dose of 1000 mg daily for two days, increased montelukast AUC by 2.4-fold (Hegazy et al.,
2012). The suggested interaction mechanisms included an interaction of fluconazole with
transporters involved in the intestinal absorption of montelukast, mechanism-based inhibition
of CYP3A4 by clarithromycin or clarithromycin-induced changes in the transporter-mediated
uptake of montelukast into the liver.
Montelukast has been suggested to be a substrate of OATP2B1 in vitro and in vivo (Mougey
et al., 2009). The SCLO2B1 polymorphism c.935G>A has been associated with a ~30% lower
plasma concentration of montelukast and an impaired drug response in patients with the
c.935GA genotype, as compared to carriers of the c.935GG genotype (Mougey et al., 2009).
In another study, co-administration of grapefruit juice and orange juice did not affect the
Inhibited enzyme IC50 (µM) Ki (µM) Test system References
CYP1A2 16 - HLM (Walsky et al., 2005b)
90 - n/a (Korzekwa, 2014)
CYP2A6 11 - HLM (Walsky et al., 2005b)
CYP2B6 5.95 - Recombinant CYP (Walsky et al., 2006)
11 - HLM (Walsky et al., 2005b)
CYP2C8 0.02-2.0
0.0092
0.014-0.15
0.0092
HLM
Recombinant CYP
(Walsky et al., 2005a,
Walsky et al., 2005b)
0.02 0.05 Recombinant CYP (Floyd et al., 2012)
0.022 0.013 HLM (Perloff et al., 2009)
0.27 - n/a (Korzekwa, 2014)
CYP2C9 1.2 - HLM (Walsky et al., 2005b)
- 15 HLM (Chiba et al., 1997)
12 - n/a (Korzekwa, 2014)
CYP2C19 32 - HLM (Walsky et al., 2005b)
>100 - n/a (Korzekwa, 2014)
CYP2D6 11 - HLM (Walsky et al., 2005b)
81 - n/a (Korzekwa, 2014)
CYP2E1 180 - HLM (Walsky et al., 2005b)
CYP3A4 1.2-7.9 - HLM (Walsky et al., 2005b)
- 200 HLM (Chiba et al., 1997)
26 - n/a (Korzekwa, 2014)
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plasma exposure to montelukast, as compared to control. On the other hand, when stratified
by genotype, orange juice caused a significant reduced montelukast AUC in c.935GG, but not
in c.935GA genotypes (Mougey et al., 2011). However, in other studies, c.935G>A and two
other SCLO2B1 polymorphisms, c.1475C>T and c.601G>A, had no effect on montelukast
pharmacokinetics in healthy volunteers (Kim et al., 2013a, Tapaninen et al., 2013), thus
suggesting that OATP2B1 appears to be a minor determinant of montelukast
pharmacokinetics. These findings are supported by recent in vitro studies (Chu et al., 2012,
Brännström et al., 2014).
7.2. Imatinib
Imatinib (orig. Gleevec, Glivec, CGP57148B, STI-571; Novartis) is a tyrosine kinase
inhibitor used in the treatment of chronic myelogenous leukaemia (CML), gastrointestinal
tumours (GISTs), and acute lymphoblastic leukaemia (ALL). It is also indicated for the
treatment of certain other hematologic and oncologic malignancies, such as aggressive
systemic mastocytosis, hypereosinophilic syndrome, and chronic eosinophilic leukaemia
(Gleevec label, 2014). The recommended dosing of imatinib is typically 400 or 600 mg once
daily.
Imatinib was the first rationally designed protein kinase inhibitor at the time of its approval in
2001. With high response rates and safety, it is one of the first examples of a successful
targeted-therapy for cancer. The majority of adverse reactions related to imatinib treatment
has been classified as mild or moderate. In patients, the most frequently reported adverse
reactions include oedema, nausea, vomiting, muscle cramps, musculoskeletal pain, diarrhoea,
rash, fatigue, and abdominal pain (Gleevec label, 2014).
Pharmacological mechanism. The Philadelphia chromosome, found in almost all cases of
CML and in about 5-25% of cases of ALL (Clark et al., 1988, Cortes et al., 1995), is formed
by a reciprocal translocation between chromosomes 9 and 22. The translocation results in a
gene fusion of breakpoint cluster region (BCR) and ABL. Depending on the breakpoint in the
BCR-ABL hybrid gene, three different fusion proteins can be generated (Melo, 1996). As
compared to the native ABL protein, all three proteins exhibit deregulated tyrosine kinase
activity leading to a block of apoptosis, and are associated with CML, BCR-ABL-positive
ALL and/or BCR-ABL positive chronic neutrophilic leukaemia to various degrees (Melo,
1996, Pane et al., 1996). Imatinib inhibits the ABL and BCR-ABL tyrosine kinases. It is a
competitive antagonist of the ATP binding site; by occupying the binding site of the ABL
kinase domain, imatinib prevents a change in the conformation of the protein that would
otherwise convert the molecule to its active form (Druker et al., 1996). Binding of imatinib
thereby leads to apoptosis of the target cells. Imatinib also interacts with other targets; it
inhibits the platelet-derived growth factor receptors α and β (PDGFRα and PDGFRβ), colony
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stimulating factor 1 receptor, and c-KIT (Buchdunger et al., 2000, Heinrich et al., 2000,
Dewar et al., 2005), important in, e.g. chronic eosinophilic leukaemia and GISTs.
Figure 11. Metabolism of imatinib. Imatinib, its main metabolite N-desmethylimatinib, and two of its
minor metabolites, piperidine N-oxide imatinib (M6) and pyridine N-oxide imatinib (M8). Imatinib is
considered to primarily undergo metabolism by CYP3A4, but several other enzymes also participate in
its biotransformation (Gleevec Clinical Pharmacology and Biopharmaceutic Review(s), 2001, Rochat
et al., 2008, Nebot et al., 2010, Narjoz et al., 2014). CYP, cytochrome P450; FMO, flavin-containing
monooxygenase.
Imatinib pharmacokinetics. The molecular weight of imatinib is 493.60 g/mol, and its
logarithm of octanol/water partition coefficient is 1.99 (Peng et al., 2005). Following oral
administration, imatinib is rapidly and completely absorbed (Table 11). It is mainly
eliminated via metabolism and biliary-faecal excretion (Gschwind et al., 2005). Following a
single radiolabelled imatinib dose, approximately 80% of the dose was excreted within one
week in faeces (67% of the dose) and urine (13% of dose). Parent imatinib accounted for 28%
of the administered dose (23% faeces, 5% urine), while its main metabolite N-
desmethylimatinib (CGP74588) accounted for 13% (11% faeces, 2% urine) (Gschwind et al.,
2005). N-desmethylimatinib is pharmacologically active and shows comparable biologic
activity in vitro as imatinib (Gleevec Clinical Pharmacology and Biopharmaceutic Review(s),
2001). In addition to N-desmethylimatinib, imatinib has several minor metabolites, including
oxidative metabolites and their phase II conjugates (Gschwind et  al., 2005, Marull and
Rochat, 2006, Rochat et  al., 2008, Ma et al., 2009). The sum of the excreted fractions of
minor metabolites, including piperidine N-oxide imatinib and pyridine N-oxide imatinib
(Figure 11), was ~10% of the administered dose (Gschwind et al., 2005).
N
N
NH NH N
NO
NImatinib
NH
N
NH NH N
NO
N
N-desmethylimatinib
N+
N
NH NH N
NO
N
O-
N
N
NH NH N
NO
N+
O-
Piperidine N-oxide imatinib
Pyridine N-oxide imatinib
CYP3A4
CYP2C8
CYP1A1, CYP2J2, CYP4F2,
CYP3A5, CYP2D6
CYP3A4
CYP2J2
FMO3
CYP3A4
FMO3
60
Imatinib has been considered to principally undergo metabolism by CYP3A4 (Gleevec
Clinical Pharmacology and Biopharmaceutic Review(s), 2001, Rochat et al., 2008), but in
2010 an in vitro study suggested that CYP2C8 contributes to the formation of N-
desmethylimatinib (Figure 11) (Nebot et al., 2010). Other enzymes that have been suggested
to participate in its metabolism to a smaller degree include CYP1A2, CYP2C9, CYPC19,
CYP2D6, CYP3A5, CYP4F, FMO3, and the extrahepatic enzymes CYP1A1, CYP1B1, and
CYP2J2 (Gleevec Clinical Pharmacology and Biopharmaceutic Review(s), 2001, Rochat et
al., 2008, Narjoz et al., 2014). In vitro, imatinib is a substrate and inhibitor of several
transporters, but their in vivo significance in imatinib pharmacokinetics has not yet been
established, apart from the role of OCT1 in uptake of imatinib to leukocytes and leukaemic
cells (Burger et al., 2005, Eechoute et al., 2011b, Wang et al., 2012, Eadie et al., 2014).
Table 11. Pharmacokinetic profile of imatinib.
Parameter Value References
F 0.98 (Gleevec Clinical Pharmacology and
Biopharmaceutic Review(s), 2001, Peng et al.,
2004a, Gleevec label, 2014)
tmax 1-4 h (Bornhauser et al., 2004, le Coutre et al., 2004,
Peng et al., 2005, Gleevec label, 2014)
Vd, ss 1.9-5.7 l/kg (Gambacorti-Passerini et al., 2003, le Coutre
et al., 2004, Bornhauser et al., 2005, Al-Batran
et al., 2007, Treiber et al., 2008)
fu, P 0.04-0.05 (Kretz et al., 2004, Peng et al., 2005)
B/P 0.73 Estimated from Kretz et al. (2004)
Main
metabolising
enzymes
CYP2C8, CYP3A4, CYP3A5 (Gleevec Clinical Pharmacology and
Biopharmaceutic Review(s), 2001, Rochat et
al., 2008, Nebot et al., 2010)
Elimination Metabolism, excreted into
faeces (~85%) and urine (~15%)
as both unchanged drug and
metabolites.
(Gschwind et al., 2005)
CLiv 14 l/h (Peng et al., 2004a)
Terminal t½ 8-27 h (le Coutre et al., 2004, Nikolova et al., 2004,
Peng et al., 2005, Treiber et al., 2008)
B/P, blood-to-plasma ratio; CLiv, intravenous clearance; CYP, cytochrome P450; F, bioavailability; fu, P,
unbound fraction in plasma; t½, elimination half-life; tmax, time to peak concentration; Vd, ss, distribution
volume at steady state.
Despite its efficacy and favourable pharmacokinetic profile, there is a large inter-individual
variability in imatinib plasma concentrations, which may lead to treatment failure and disease
progression (Peng et al., 2004b, Schmidli et al., 2005, Picard et al., 2007). It has been
estimated that 30-35% of imatinib-treated patients will fail to respond or lose their response
(Eadie et al., 2014). Suggested resistance mechanisms include mutations or amplification of
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the drug target, epigenetic modification, activation of alternative signalling pathways, poor
treatment compliance, and alterations in cellular uptake and efflux of imatinib (Mahon et al.,
2003, Thomas et al., 2004, Apperley, 2007). In addition, variability in CYP3A4 expression
activity has been proposed to partly explain the observed variations in imatinib concentrations
(Peng et al., 2005, Apperley, 2007). Several studies indicate a correlation between imatinib
trough levels and efficacy, suggesting that imatinib trough concentrations above 1,000-1,100
ng/ml are associated with a better treatment outcome (Teng et al., 2012, de Wit et al., 2014).
Pharmacokinetic interactions of imatinib. Imatinib inhibits several CYPs competitively in
vitro (Table 12), such as CYP2D6 and CYP3A4 with Ki values of 7.5 and 8 µM, respectively
(Gleevec Clinical Pharmacology and Biopharmaceutic Review(s), 2001). Taking into account
that unbound imatinib concentrations in plasma are generally below 0.3 µM, its effects on
CYP3A4 in vivo seem to be of greater magnitude than what would be predicted based on its
in vitro inhibition. In healthy volunteers, imatinib has increased the plasma concentrations of
the CYP3A4 substrate simvastatin by 3.5-fold, with individual concentrations ranging up to
>ten-fold (O'Brien et al., 2003). In another studies, imatinib has reduced the hepatic CYP3A4
activity by 10-70% (Gurney et al., 2007, Connolly et al., 2011). Despite similar Ki values for
CYP2D6 and CYP3A4 inhibition, as compared to the interaction study with simvastatin,
imatinib had only a small effect on the CYP2D6 substrate metoprolol pharmacokinetics in
Chinese patients (AUC increase of 26%) (Wang et al., 2008). In addition, imatinib had no
effect on paracetamol pharmacokinetics in Korean patients (Kim et al., 2011).
Table 12. Inhibitory effects of imatinib and N-desmethylimatinib on CYP enzymes in HLM (Gleevec
Clinical Pharmacology and Biopharmaceutic Review(s), 2001).
Inhibited enzyme Imatinib N-desmethylimatinib
CYP1A2 IC50 = 410 µM n/a
CYP2A6 IC50 = 230 µM n/a
CYP2C8 IC50 = 99 µM n/a
CYP2C9 Ki = 34.7 µM Ki = 40.3 µM
CYP2C19 IC50 = 120 µM n/a
CYP2D6 Ki = 7.5 µM Ki = 13.5 µM
CYP3A4 Ki = 8 µM Ki = 13.7 µM
CYP, cytochrome P450; HLM, human liver microsomes; IC50, inhibitor concentration producing 50%
inhibition; Ki, reversible inhibition constant; n/a, not available.
Although CYP3A4 has been suggested to be the main enzyme involved in imatinib
metabolism, strong CYP3A4 inhibitors have only had a small or no effect on its
pharmacokinetics (Table 13). Following a single dose of the strong CYP3A4 inhibitor
ketoconazole, the AUC of imatinib increased by 1.4-fold in healthy volunteers (Dutreix et al.,
2004), while ritonavir, another potent CYP3A4 inhibitor, had no effect on imatinib steady
state pharmacokinetics in patients (van Erp et al., 2007). Furthermore, in patients, the
clearance of the CYP3A4 substrates erythromycin and midazolam correlated with imatinib
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clearance at the beginning of imatinib therapy, but no longer at steady state (Gurney et al.,
2007). An interaction study with Japanese patients was terminated early when the results
indicated no effect on grapefruit juice on imatinib pharmacokinetics (Kimura et al., 2011).
The lack of effect was explained by the fact that grapefruit juice primarily inhibits intestinal
CYP3A4, and because the bioavailability of imatinib is nearly 100%, no effect on the
concentrations of imatinib was observed. The effect of ketoconazole on imatinib
pharmacokinetics suggests that CYP3A4 contributes to about 30% of the total clearance of
imatinib, following a single imatinib dose.
In patients, CYP enzyme-inducing anti-epileptic drugs such as carbamazepine, phenytoin, and
oxcarbazepine reduced the trough plasma concentrations of imatinib by up to 70% as
compared to controls (Pursche et  al., 2008). In other studies, omeprazole, aluminium
hydroxide, magnesium, and tobacco smoking did not affect imatinib pharmacokinetics (van
Erp et al., 2008, Egorin et al., 2009, Sparano et al., 2009), thus suggesting that CYP1A1,
CYP1A2, and CYP2C19 do not contribute to the metabolism of imatinib in vivo, and that
elevation of gastric pH does not affect its absorption.
Table 13. Effects of other drugs on imatinib pharmacokinetics in vivo.
AUC, area under concentration-time curve; Cmax, peak concentration; n/d, not determined; od, once
daily; sd, single dose; t½, elimination half-life; td, thrice daily.
Parameter Ketoconazole  Rifampicin Ritonavir St John’s Wort
Perpetrator dose 400 mg, sd 600 mg, od for
eleven days
600 mg, od for
three days
300 mg, td for two
weeks
Imatinib dose 200 mg, sd 400 mg, sd 400 - 800 mg, od 400 mg, sd
Change in imatinib
Cmax # 1.3-fold $ 54% 1 $ 15-29%
AUC # 1.4-fold $ 74% 1 $ 30-32%
t½ 1 $ 47% n/d $ 21-30%
Change in N-desmethylimatinib
Cmax $ 23% # 1.9-fold 1 # 1.1-fold
AUC 1 $ 12% # 1.4-fold 1
t½ 1 $ 10% n/d n/d
References (Dutreix et al.,
2004)
(Bolton et al.,
2004)
(van Erp et al.,
2007)
(Frye et al., 2004,
Smith et al., 2004a,
Smith et al., 2004b)
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7.3. Gemfibrozil
Gemfibrozil (Lopid; Pfizer) is a lipid-regulating agent that shares many properties with fibric
acid derivates (Miller and Spence, 1998). It has been used in the treatment of hyperlipidaemia
and hypertriglyceridemia for more than 30 years.
Pharmacological mechanism. The pharmacological mechanism of action of gemfibrozil is
not fully understood (Miller and Spence, 1998). It is an activator of peroxisome proliferator-
activated receptor alpha (PPARα), a nuclear receptor involved in metabolism of carbohydrates
and fats, and adipose tissue differentiation. Activation of PPARα by gemfibrozil has several
effects, including increase in the synthesis of lipoprotein protease, increase in the clearance of
triglycerides, stimulation of mobilisation of cholesterol towards the cell membrane, and
stimulation of high-density lipoprotein (HDL) production (Miller and Spence, 1998, Roy and
Pahan, 2009).
Gemfibrozil is usually administered as 600 mg twice daily, while some patients will respond
to 900 mg daily (Todd and Ward, 1988). Gemfibrozil is in general well-tolerated (Todd and
Ward, 1988). However, it has a complex interaction profile, which makes it not suitable to use
concomitantly with certain drugs.
Gemfibrozil pharmacokinetics. Following oral administration, gemfibrozil is completely
and rapidly absorbed, reaching peak plasma concentrations at 1-2 h (Okerholm et al., 1976,
Miller and Spence, 1998). It is extensively bound to plasma proteins (>97%), and its
distribution volume is ~0.2 l/kg (Todd and Ward, 1988). Gemfibrozil is mainly metabolised
by UGT2B7 to gemfibrozil 1-O-β glucuronide (Figure 12) (Mano et al., 2007), but also
undergoes oxidation, resulting in hydroxymethyl and carboxymethyl metabolites (Miller and
Spence, 1998, Lopid Label, 2013). Approximately 70% of the dose is excreted renally, with
<2% as unchanged drug (Okerholm et al., 1976, Lopid Label, 2013). The plasma half-life of
gemfibrozil is ~1.5 h following multiple doses, but a value of 7.6 h has also been reported
(Okerholm et al., 1976, Todd and Ward, 1988, Miller and Spence, 1998, Lopid Label, 2013).
Pharmacokinetic interactions. Gemfibrozil and gemfibrozil 1-O-β glucuronide inhibit
several enzymes and transporters. Most importantly, gemfibrozil inhibits CYP2C9 and
CYP2C8 in vitro with Ki values of 5.8-18.6 µM and 55.4 µM, respectively (Wen et al., 2001,
Fujino et  al., 2003), while its glucuronide metabolite is a potent, irreversible mechanism-
based inhibitor of CYP2C8 with kinact and KI values of 0.21 1/min and 20-52 µM, respectively
(Ogilvie et al., 2006, Baer et al., 2009, Jenkins et al., 2011). Inhibition of CYP2C8 by
gemfibrozil 1-O-β glucuronide explains the strong effects of gemfibrozil on the plasma
exposure to many drugs in vivo (Table 14). While gemfibrozil markedly affects the
pharmacokinetics of CYP2C8 substrates in vivo, its effect on the CYP2C9 substrate warfarin
is weak (Lilja et al., 2005). The combination of gemfibrozil and itraconazole increased the
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AUC of the CYP2C9 and CYP3A4 substrate nateglinide by 47% (Niemi et al., 2005a). The
effect of gemfibrozil on pravastatin, rosuvastatin, and simvastatin (Table 14), which are not at
all, or only partly, metabolised by CYP2C8, is likely due to inhibition of OATP1B1.
Gemfibrozil inhibits this transporter competitively in vitro with IC50 and Ki values in the
range of 4-32 µM, and gemfibrozil 1-O-β glucuronide inhibits it with IC50 and Ki values of
16-23 µM (Schneck et al., 2004, Shitara et al., 2004, Yamazaki et al., 2005, Hirano et al.,
2006, Nakagomi-Hagihara et al., 2007b). In addition, gemfibrozil inhibits OAT3 (IC50 6.8
µM) and OAT2B1 (IC50 8 µM), and its glucuronide inhibits OAT3 with an IC50 of 20 µM (Ho
et al., 2006, Nakagomi-Hagihara et al., 2007a).
Furthermore, gemfibrozil has been reported to induce CYP2C8, CYP3A4, and UGT1A1 in
vitro (Prueksaritanont et  al., 2005), but the in vivo relevance of the induction is not known.
No effect of gemfibrozil on brivaracetam, fluvastatin, zafirlukast, and zopiclone has been
observed (Spence et al., 1995, Tornio et al., 2006, Karonen et al., 2011, Nicolas et al., 2012).
Figure 12. Chemical structures of gemfibrozil and gemfibrozil 1-O-β glucuronide.
Gemfibrozil
Gemfibrozil 1-O-β glucuronide
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Table 14. Effect of gemfibrozil on the pharmacokinetics of other drugs in healthy subjects.
Gemfibrozil 600 mg twice daily for three or more days was used as pretreatment in the studies.
* Unclear whether the study was performed in healthy volunteers. ** Multiple doses. *** Administered
as racemic drug. AUC, area under concentration-time curve; Cmax, peak concentration; n/a, not
available; n/d, not determined; od, once daily; sd, single dose; t½, elimination half-life; td, thrice daily.
Victim drug Dose Change in
Cmax AUC t½
References
Atorvastatin
acid
20 mg # 1.2-fold # 1.2-fold $ 16% (Backman et al., 2005)
Cerivastatin
acid
0.3 mg # 3.1-fold # 5.6-fold # 2.7-fold (Backman et al., 2002)
Dabrafenib* 75 mg** n/a # 1.5-fold n/a (Tafinlar label, 2014)
Enzalutamide 160 mg $ 18% # 4.3-fold n/a (Xtandi Clinical Pharmacology
and Biopharmaceutic
Review(s), 2012)
Ezetimibe* 10 mg** # 1.3-fold # 1.4-fold n/a (Zetia Clinical Pharmacology
and Biopharmaceutic
Review(s), 2001)
Glimepiride 0.5 mg ↔ # 1.2-fold # 1.1-fold (Niemi et al., 2001)
R-ibuprofen 400 mg*** ↔ # 1.3-fold # 1.5-fold (Tornio et al., 2007)
Loperamide 4 mg # 1.6-fold # 2.2-fold # 1.4-fold (Niemi et al., 2006)
Lovastatin
acid
40 mg # 2.8-fold # 2.8-fold n/d (Kyrklund et al., 2001)
Pioglitazone 15 mg
15 mg
↔
↔
# 4.3-fold
# 3.2-fold
# 3.1-fold
# 2.7-fold
(Aquilante et al., 2013a)
(Jaakkola et al., 2005)
30 mg ↔ # 3.4-fold # 2.2-fold (Deng et al., 2005)
Pitavastatin
(acid)
4 mg** # 1.3-fold # 1.5-fold n/a (Mathew et al., 2004)
Pravastatin 40 mg # 1.8-fold # 2.0-fold ↔ (Kyrklund et al., 2003)
Repaglinide 0.25 mg # 2.0-fold
# 2.7-fold
# 2.2-fold
# 2.4-fold
# 7.0-fold
# 7.6-fold
# 7.0-fold
# 8.1-fold
# 1.9-fold
# 2.0-fold
# 2.6-fold
# 2.9-fold
(Honkalammi et al., 2012)
(Backman et al., 2009)
(Tornio et al., 2008)
(Niemi et al., 2003b)
Rosiglitazone 4 mg # 1.2-fold # 2.3-fold # 2.1-fold (Niemi et al., 2003a)
Rosuvastatin 80 mg # 2.2-fold # 1.9-fold ↔ (Schneck et al., 2004)
Simvastatin
acid
40 mg # 2.1-fold # 2.9-fold # 1.5-fold (Backman et al., 2000)
Sitagliptin 100 mg # 1.2-fold # 1.6-fold # 1.3-fold (Arun et al., 2012)
R-warfarin 10 mg*** ↔ $ 6% ↔ (Lilja et al., 2005)
S-warfarin 10 mg*** ↔ $ 11% ↔ (Lilja et al., 2005)
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AIMS OF THE STUDY
The aim of this thesis was to determine the role of CYP2C8 in the in vitro and in vivo
metabolism of montelukast and imatinib.
The specific aims of the studies were:
I To establish the importance of CYP2C8 in the in vitro metabolism of
montelukast using human liver microsomes and recombinant CYP enzymes.
II To determine the effects of the CYP2C8 inhibitor gemfibrozil on the
pharmacokinetics of montelukast in healthy subjects. In addition, to investigate
the effects of gemfibrozil and gemfibrozil 1-O-β glucuronide on the in vitro
metabolism of montelukast in human liver microsomes.
III To determine the inhibitory effects of imatinib on CYP2C8 and CYP3A4
activities in human liver microsomes.
IV To establish the importance of CYP2C8 in the in vitro metabolism of imatinib
using human liver microsomes and recombinant CYP enzymes. In addition, to
construct a physiologically based pharmacokinetic model for imatinib in order
to translate in vitro findings to clinical relevance.
V To determine the effects of the CYP2C8 inhibitor gemfibrozil on the
pharmacokinetics of imatinib in healthy subjects. In addition, to apply the
physiologically based pharmacokinetic model to these data in order to predict
the contribution of CYP2C8 to imatinib metabolism during multiple-dose
administration.
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MATERIALS AND METHODS
The work consisted of in vitro, in silico, and in vivo studies according to Figure 13.
Figure 13. Overview of the content of studies I-V.
8. In vitro studies (Studies I-IV)
In vitro experiments were carried out in studies I-IV. The in vitro metabolism of montelukast
was investigated in study I. Study II included an in vitro assessment of the inhibitory effects
of gemfibrozil and gemfibrozil 1-O-β glucuronide on the main metabolic pathway of
montelukast. In study III, the inhibitory effects of imatinib and N-desmethylimatinib on
CYP2C8 and CYP3A4/5 activities were evaluated. Finally, in study IV, the in vitro
metabolism of imatinib was investigated. Detailed descriptions of chemicals, microsomes,
and experiments are presented in the respective publications. This section briefly summarises
the most important methods used in these studies.
8.1. Microsomes and chemicals
Pooled HLM and recombinant CYPs (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9,
CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5) were purchased from BD
Biosciences (BD Gentest; Woburn, MA, USA). The study drugs, their metabolites, inhibitors,
and other chemicals were obtained from commercial sources.
8.2. In vitro conditions and assays
Incubation conditions. All incubations contained sodium phosphate buffer (0.1 M, pH 7.4),
microsomes, and substrate. Addition of 1.0 mM NADPH initiated the reactions. Incubations
in studies I and II also contained 5.0 mM MgCl2. With the exception of some experiments,
I II III IV V
In vitro
In silico
In vivo
Montelukast Imatinib
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the incubations generally contained a protein concentration of 0.1, 0.05, 0.1, and 0.5 mg/ml in
studies I, II, III, and IV, respectively. The equal protein concentration in recombinant
enzyme incubations resulted in variable CYP isoform contents. Compounds were dissolved in
acetonitrile, ethanol, or methanol, and the final solvent concentration was 1% in all
incubations (including controls). As appropriate, the incubation time was optimised within the
linear range for metabolite formation depending on the turnover conditions of each specific
experiment. Incubations were carried out in Eppendorf tubes as duplicates or triplicates in a
shaking water bath (37ºC). Samples were taken at determined time points, added to a solvent
solution containing internal standard, and put on ice to stop the reactions.
Table 15. CYP-selective inhibitors used in inhibition experiments in studies I and IV.
* Mechanism-based inhibitors. Compared to direct inhibition experiments, where substrate and
inhibitor were simultaneously added to the incubation, mechanism-based inhibitors were first pre-
incubated for 15 min with HLM and NADPH before addition of substrate. In the case of gemfibrozil 1-
O-β glucuronide, the inhibitor was first pre-incubated for 30 min with a high HLM concentration (2 and
10 mg/ml in studies I and IV, respectively) and NADPH before a 20-fold dilution to another tube
containing substrate and NADPH. CYP, cytochrome P450.
Metabolism of montelukast. In study I, inhibition of the metabolism of montelukast was
investigated by incubating montelukast at concentrations of 0.02-0.4 µM and CYP-selective
inhibitors (Table 15) with HLM. Thereafter, the metabolism of montelukast at a high
concentration (1 µM) was first studied in a recombinant CYP screening containing each of the
ten CYPs individually. Based on the results, lower, clinically more relevant montelukast
concentrations (0.02-0.1 µM) were further incubated with CYP2A6, CYP2C8, CYP2C9,
CYP3A4, and CYP3A5. In addition, the enzyme kinetics of M6 formation from montelukast
(0.03-30 µM) by CYP2C8 and CYP2C9 was investigated. As CYP2A6 has previously been
reported to participate in montelukast metabolism, it was also tested with a high montelukast
Inhibitor Inhibited
CYP
Inhibitor
concentration
(µM)
References
Furafylline* CYP1A2 20 (Newton et al., 1995, Eagling et al., 1998)
8-methoxy-psoralen* CYP2A6 0.5 (Draper et al., 1997, Koenigs et al., 1997)
Clopidogrel* CYP2B6 1 (Richter et al., 2004)
Gemfibrozil 1-O-β
glucuronide*
CYP2C8 60 (Ogilvie et al., 2006)
Montelukast CYP2C8 5 (IV) (Walsky et al., 2005b)
Trimethoprim CYP2C8 100 (I) (Wen et al., 2002)
Sulfaphenazole CYP2C9 10 (Baldwin et al., 1995, Newton et al., 1995,
Eagling et al., 1998)
Omeprazole CYP2C19 10 (Ko et al., 1997)
Quinidine CYP2D6 10 (Newton et al., 1995, Bourrie et al., 1996)
Diethyldithio-
carbamate*
CYP2E1 100 (Guengerich et al., 1991, Newton et al.,
1995, Eagling et al., 1998)
Ketoconazole CYP3A4/5 1 (Baldwin et al., 1995, Eagling et al., 1998)
Troleandomycin* CYP3A4/5 50 (IV), 100 (I) (Newton et al., 1995)
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concentration of 10 µM. Finally, further metabolism of M6 (0.02-1 µM) was studied using
recombinant CYPs.
In study II, the effects of gemfibrozil (1-320 µM) and gemfibrozil 1-O-β glucuronide (0.2-
3240 µM) on the formation of M6 from montelukast (0.05 µM) and that of M4 from M6 (0.2
µM) in HLM were tested in an IC50 experiment. Gemfibrozil 1-O-β glucuronide was first pre-
incubated for 30 min with a high HLM concentration (2 mg/ml) and NADPH, before dilution
(40-fold) to another tube containing substrate and NADPH.
CYP2C8 and CYP3A4/5 inhibition by imatinib and N-desmethylimatinib. In study III,
amodiaquine N-deethylation and midazolam 1′-hydroxylation were used as marker reactions
for CYP2C8 and CYP3A4/5 activities, respectively. First, IC50-shift experiments in HLM
were carried out with imatinib (0.25-500 µM) and N-desmethylimatinib (0.25-500 µM), using
substrate concentrations of 2 µM. In addition, the effects of piperidine N-oxide imatinib and
pyridine N-oxide imatinib (0.1-10 µM) on CYP2C8 and CYP3A4/5 were studied. To evaluate
time-dependent inhibition of CYP3A4 by imatinib, imatinib (2-128 µM) was pre-incubated
with NADPH and HLM (0.5 mg/ml) for up to 30 min, before a 20-fold dilution to another
tube containing midazolam (8 µM) and NADPH. Follow-up experiments included an
experiment with ketoconazole (0.01-1 µM) and dialysis with sodium phosphate buffer, as well
as testing of mechanism-based inhibition potential of imatinib in recombinant CYP3A4 and
CYP3A5 incubations. Direct Ki experiments were also carried out for imatinib (5-30 µM) and
N-desmethylimatinib (5-30 µM) using substrate concentrations of 0.6-20 µM in HLM.
Metabolism of imatinib. In study IV, the depletion of imatinib (0.1 µM) and metabolite
formation from imatinib (1 µM) was first investigated using recombinant CYP screening.
Then, the kinetics of N-desmethylimatinib formation from imatinib (0.10-320 µM) in
CYP2C8, CYP3A4, and CYP3A5 incubations was determined. Next, inhibition of imatinib
metabolism (1 or 0.1 µM) by CYP-selective inhibitors was studied in HLM (Table 15).
Finally, the further metabolism of N-desmethylimatinib (0.05-1 µM) was studied using HLM
and recombinant CYPs.
8.3. Determination of drug concentrations
After sample preparation (protein precipitation or protein precipitation and solid phase
extraction), the concentrations of the study drugs and their metabolites were determined using
liquid chromatography-tandem mass spectrometry (LC-MS/MS) (MDS Sciex, Concord, ON,
Canada) (Table 16). No authentic reference compounds were available for montelukast
metabolites M3, M4, and M5a/b in studies I and II, nor for piperidine N-oxide imatinib,
pyridine N-oxide imatinib, and hydroxyl benzylic imatinib (M5) in study IV. Their
concentrations were therefore measured as arbitrary units based on the ratio of the peak height
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of each metabolite to that of the internal standard in the chromatogram. A signal/noise ratio of
10:1 was used as the limit of quantification of these metabolites.
Table 16. Quantification of analytes in in vitro studies.
Study Analytes quantified Lower limit of quantification Interday CV
I Montelukast 2 nM <14%
M6 2.5 nM <19%
II Montelukast 3.8 nM (2.2 ng/ml) <17%
M6 3.7 nM (2.2 ng/ml) <10%
III N-desethylamodiaquine 1 nM <18%
1’-hydroxymidazolam 2 nM <13%
IV Imatinib 5 nM <15%
N-desmethylimatinib 10 nM <15%
CV, coefficient of variation.
8.4. Data analysis
Mean values of duplicate or triplicate incubations were used in calculations.
Enzyme kinetics and substrate depletion. In studies I and IV, the enzyme kinetics of
montelukast 36-hydroxylation (M6 formation) and imatinib N-demethylation were analysed
using SigmaPlot version 9.01 (Systat Software Inc., San Jose, CA, USA). Selection of the best
model was based on the Akaike information criterion (AIC), on r2, and on the examination of
Michaelis-Menten plots. SigmaPlot was also used to calculate kdep values of the depletion of
montelukast, montelukast M6, imatinib, and N-desmethylimatinib concentrations. CLint, in vitro
values were calculated according to Equations 8 and 9.
Enzyme inhibition. In CYP-selective inhibition experiments in studies I and IV, per cent
inhibition of montelukast and imatinib depletion was calculated by comparing kdep values of
incubations containing inhibitor with those of control incubations. In studies II and III, IC50
values were determined by non-linear regression analysis with SigmaPlot. For determination
of direct inhibition Ki values in study III, selection of the best-fit enzyme inhibition model in
SigmaPlot was based on AIC and on r2 (primary criteria), and on the visual examination of
different inhibition plots (secondary criterion when AIC and r2 of different models were
similar or when these values were conflicting with each other). In study III, imatinib was
investigated for time-dependent inhibition of CYP3A4. For estimation of its metabolism-
dependent inactivation constants, pre-incubation time dependent loss of CYP3A4 activity in
the absence of imatinib was accounted for by adjusting the observed rate of metabolism with
reference to the respective control incubation at each pre-incubation time. kobs was determined
by linear regression analysis of the natural logarithm of the percentage of remaining activity
versus pre-incubation time. Initial estimates of KI and kinact were obtained from the Kitz-
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Wilson plot (Kitz and Wilson, 1962), while final KI and kinact values were estimated by non-
linear regression using Equation 7.
9. In vitro-in vivo predictions (Studies I and III-V)
9.1. Static models
Metabolism of montelukast. To estimate the relative contributions of different CYPs to the
metabolism of montelukast in study I, RAF values were calculated for CYP2C8, CYP2C9
and CYP3A4 using activity information provided by the manufacturer for the recombinant
CYP and HLM batches used. For comparison, the relative contributions of CYP2C8,
CYP2C9, CYP3A4, and CYP3A5 to montelukast metabolism were also estimated using the
RA approach. RAF and RA adjusted CLint, in vitro values and HLM CLint, in vitro were converted
to hepatic clearance using standard in vitro-in vivo scaling parameters and the well-stirred
model (Equation 11). Blood clearance (CLB) of montelukast was calculated according to
Equation 16:
ܥܮ஻ = ܥܮ௉ × 1ܥ஻ ܥ௉⁄ (Equation 16.)
where CLP is the in vivo plasma clearance of montelukast (0.578 ml/min) (Singulair
Pharmacology Review(s), 2002), and CB/CP is the blood/plasma concentration ratio of
montelukast (0.65) (Singulair Clinical Pharmacology and Biopharmaceutic Review(s), 1998).
The unbound fraction of montelukast in blood was assumed to correspond to that in plasma
(0.004) (Singulair Pharmacology Review(s), 2002),
CYP2C8 and CYP3A4/5 inhibition by imatinib. In study III, the potential clinical impact
of the inhibition of CYP2C8 and CYP3A4/5 by imatinib was predicted by use of static
models considering the fm and FG of the substrates. In the calculations, Ki and KI were
adjusted for non-specific binding to microsomes. Hepatic CYP3A4 half-lives of 36 and 72 h
were used in the predictions (Yang et al., 2008, Rowland Yeo et al., 2011), which were
carried out for clinically relevant unbound plasma concentrations of imatinib.
Metabolism of imatinib. In study IV, to estimate the relative contributions of different CYPs
to imatinib and N-desmethylimatinib metabolism, CLint, in vitro values, adjusted for non-specific
binding in microsomes, were multiplied with ISEFs of each CYP isoform and with average
CYP isoform abundance per microsomal protein. The obtained values were scaled to in vivo
CLH using standard scaling factors and the well-stirred model (Equation 11).
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9.2. Physiologically based pharmacokinetic simulations
In study IV, in vitro inhibition and metabolism data from studies III and IV were combined
with literature data to create the drug-dependent component of a PBPK model for imatinib
and N-desmethylimatinib. The model was created within the Simcyp Population-Based
Simulator (version 11.00; Simcyp Ltd., Sheffield, UK). PBPK simulations were carried out to
predict the importance of CYP2C8 and CYP3A4 in imatinib pharmacokinetics. After
completion of the clinical trial in study V, the models of imatinib and N-desmethylimatinib
were refined in Simcyp version 12.00 to better match the obtained clinical findings (Figure
14). Simulations were subsequently conducted to estimate the contribution of CYP2C8 to
imatinib metabolism during multiple-dose administration, and to provide a possible
explanation for the unexpected effect of gemfibrozil on imatinib absorption observed in vivo.
Detailed descriptions of the models and simulations are presented in the respective
publications. Here, an overview of these dynamic predictions is given.
Figure 14. Construction of the PBPK model for imatinib and N-desmethylimatinib. Data from two in
vitro studies (III and IV) was combined with literature data to create the drug-dependent component
of a PBPK model for imatinib and its metabolite. After the clinical study (V) in healthy volunteers, the
PBPK model was refined to better match the obtained clinical data. CLint, intrinsic clearance; fu,  p,
fraction unbound in plasma; ka, absorption rate constant; Ki, inhibition constant; KI, inactivation
constant; kinact, maximal inactivation rate; MW, molecular weight; PBPK, physiologically based
pharmacokinetic.
PBPK simulations in study IV. Initial PBPK models for imatinib and N-desmethylimatinib
comprised first-order oral absorption of imatinib from the intestine, intestinal metabolism, a
minimal physiologically based distribution model including a single adjusting compartment,
and elimination by hepatic CYP-mediated metabolism, and by renal excretion. Hepatic
elimination input parameters were obtained from the in vitro data of study IV. ISEF factors
for CYP2C8, CYP3A4, and CYP3A5 were experimentally determined, while ISEFs for
CYP1A2, CYP2B6, and CYP2D6 were provided by the software. ISEFs and other software-
generated parameters were then used to scale CLint, in vitro to CLH with the well-stirred model.
Hepatic and renal clearances were combined with additional systemic clearance to derive the
total clearance. When literature and experimental values had been entered into the drug-
dependent component, the model was refined by modifying the single adjusting compartment,
Imatinib in vitro
inhibition study
(III)
Imatinib in vitro
metabolism study
(IV)
CLint, in vitro
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Ki, KI, and kinact
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1. In silico
simulations (IV)
PBPK model
2. In vivo study
(V)
3. In silico
simulations (V)Literature
Improvement
of model
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so that published single-dose pharmacokinetic data could be described accurately (Nikolova
et al., 2004). Thereafter, the model was validated by comparing simulations to published
multiple-dose pharmacokinetic studies and interaction studies (Bolton et al., 2004, Dutreix et
al., 2004, van Erp et al., 2007). In addition, PBPK models for gemfibrozil and gemfibrozil 1-
O-β glucuronide were constructed to allow interaction simulations with a CYP2C8 inhibitor.
Final simulations were conducted aiming to estimate the roles of CYP2C8 and CYP3A4 in
the in vivo pharmacokinetics of imatinib (Table 17).
PBPK simulations in study V. Based upon the findings of the clinical study, the initial
models for imatinib and N-desmethylimatinib were slightly modified: imatinib additional
clearance was increased to better match the proportion excreted as unchanged imatinib in
faeces (~25%), the unbound fraction of imatinib in plasma was reduced, and an advanced
absorption and dissolution model was chosen to simulate imatinib absorption so that an apical
uptake transport mechanism could be included. In addition, the additional compartment of N-
desmethylimatinib was modified. The refined model was validated by comparing the
simulated time-concentration profile with that of the clinical study (V), and with previous
studies (Bolton et al., 2004, Dutreix et al., 2004, van Erp et al., 2007).
In Simcyp version 12.00, default PBPK models for gemfibrozil and gemfibrozil 1-O-β
glucuronide were included in the software. However, to better match the clinical data of study
V, they were slightly adjusted, and a transporter inhibition constant was included so that
inhibition of an apical transporter involved in imatinib absorption by gemfibrozil could be
tested. Simulations were conducted to estimate the role of CYP2C8 to imatinib metabolism
during multiple-dose administration, and to provide a potential explanation for the unexpected
effect of gemfibrozil on imatinib absorption observed in vivo (Table 17).
Table 17. Main PBPK simulations of studies IV and V.
Study Description
IV 1 Multiple dose simulation with imatinib 100 or 400 mg once daily or 400 mg twice daily.
2 Interaction simulations with gemfibrozil (600 mg twice daily), itraconazole (100 mg
twice daily), or their combination on imatinib pharmacokinetics after a single or multiple
doses of imatinib 400 mg.
3 Simulation of the effects of CYP2C8 polymorphisms on imatinib pharmacokinetics after
multiple doses of imatinib 400 mg.
V 1 Interaction simulation with gemfibrozil (600 mg twice daily) on the pharmacokinetics of
a single dose of imatinib 200 mg, when inhibition of an intestinal uptake transporter by
gemfibrozil was included in or excluded from the model.
2 Interaction simulation with gemfibrozil (600 mg twice daily) on imatinib
pharmacokinetics after multiple doses of imatinib 200 mg or 400 mg once daily.
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10. In vivo studies in humans (Studies II and V)
Two clinical drug-drug interaction studies (II and V) were carried out at the Department of
Clinical Pharmacology, University of Helsinki. The study protocols were approved by the
Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District, by the
Helsinki University Central Hospital (HUSLAB), and by the Finnish Medicines Agency
(Fimea).
10.1. Subjects
The subjects in the clinical studies were healthy volunteers. Before entering the studies, they
had been given both oral and written information, and they had given a written informed
consent. The number of subjects in the studies was estimated to be sufficient to detect a 30%
difference between the phases in the AUC0-∞ of montelukast and imatinib with a power of
>80% (α-level 5%). Ten subjects were chosen for the studies.
The subjects (Table 18) were ascertained to be healthy by medical history, physical
examination and routine laboratory tests. None of them used continuous medication such as
oral contraceptives and none was a tobacco smoker. Female subjects gave a negative
pregnancy test before entering the studies. Participation in other studies and blood donation
were prohibited two months before and during the studies. Use of alcohol, grapefruit, and any
medications was not allowed one week prior to each study day.
Table 18. Characteristics of the subjects in studies II and V.
Age, weight, and body mass index are presented as mean ± standard deviation. BMI, body mass
index; n/d, not determined.
10.2. Study design
Both studies had a randomised, placebo-controlled cross-over (all subjects completing both
phases) design (Table 19). The studies consisted of two phases, which included a pre-
II V
Subjects n (female/male) 10 (4/6) 10 (2/8)
Age (y) 23 ± 2 24 ± 3
Weight (kg) 69 ± 11 72 ± 13
BMI (kg/m2) 23 ± 3 22 ± 2
CYP2C8*1/*1 genotype 7/10 8/10
CYP2C8*1/*3 genotype 2/10 1/10
CYP2C8*1/*4 genotype 1/10 1/10
CYP3A5*1/*3 genotype 1/10 n/d
CYP3A5*3/*3 genotype 9/10 n/d
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treatment period with gemfibrozil or placebo, followed by ingestion of a single oral dose of
the study drug on the study day (day 3). Gemfibrozil, placebo, and the study drugs
(montelukast/imatinib) were supplied, packed, and labelled according to a randomisation list
for each subject by the Helsinki University Central Hospital Pharmacy.
Table 19. Designs of in vivo studies II and V.
After an overnight fast, the study drugs were administered orally with water at 09:00 on the
study day, one hour after the morning dose of gemfibrozil. The subjects received a
standardised warm meal three hours after the study drug intake. In study II, standardised light
meals were served seven and 11 hours after montelukast intake. In study V, light meals were
served six and nine hours after the intake of imatinib. The subjects were under medical
supervision for 12 hours after administration of the study drug.
10.3. Blood sampling and determination of drug concentrations in
plasma
Timed blood samples (5 or 10 ml in study II, 9 ml in study V), were drawn from a cannulated
forearm vein before administration of the study drug and at determined time points. Samples
were collected into ethylenediaminetetraacetic acid (EDTA) containing tubes. Plasma was
separated within 30 min and stored at -70°C until analysis.
Plasma samples were spiked with internal standards. Montelukast and M6 concentrations and
the metabolite-to-internal standard peak height ratios (M4, M5a, and M5b) were measured
using a SCIEX API 2000 LC-MS/MS system (MDS Sciex, Toronto, ON, Canada), after
protein precipitation (montelukast) or solid-phase extraction (metabolites). Imatinib plasma
samples were spiked with internal standards, extracted to methyl tert-butyl ether and
centrifuged at 2,500g for 10 min. The concentrations of imatinib and N-desmethylimatinib
were measured using an Agilent 1100 series LC system (Agilent Technologies, Waldbronn,
Germany) coupled to an API 3000 MS/MS system (MDS Sciex) (Table 20). The plasma
concentrations of gemfibrozil and gemfibrozil 1-O-β glucuronide in studies II and V were
determined using an API 2000 QTRAP LC-MS/MS system (MDS Sciex).
Study Pre-treatment Pre-treatment
(days)
Wash-out period
(weeks)
Study drug
II 1. Gemfibrozil 600 mg Í 2
2. Placebo Í2
3 4 Montelukast 10 mg, single
dose, on day 3 at 09:00
V 1. Gemfibrozil 600 mg Í 2
2. Placebo Í 2
6 2 Imatinib 200 mg, single
dose, on day 3 at 09:00
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Table 20. Quantification of analytes in the two clinical studies.
CV, coefficient of variation
10.4. Pharmacokinetic calculations
The pharmacokinetics of the study drugs, gemfibrozil, and metabolites were characterised by
Cmax,  tmax,  t½, and AUC. Cmax and tmax values were obtained directly from original data. The
terminal log-linear part of each plasma concentration-time curve was identified visually. The
elimination rate constant (ke) was determined by linear regression analysis of the log-linear
part of the plasma concentration-time curve. t½ was calculated according to t½ = ln(2)/ke. AUC
values were calculated using a combination of the linear and the log-linear trapezoidal rules,
with extrapolation to infinity, when appropriate, by dividing the last measured concentration
by ke. The pharmacokinetics was calculated by non-compartmental analysis using MK-Model,
version 5.0 (Biosoft, Cambridge, UK).
10.5. Statistical analysis
In study II, results were expressed as mean ± standard deviation. Due to updated journal
guidelines, in study V, results were expressed as geometric mean values and coefficients of
variation (or 95% confidence intervals; or 90% confidence intervals in figures). tmax was
expressed as median (range) in both studies. In study V, logarithmic transformation was
performed for pharmacokinetic variables (except for tmax) before statistical analysis. Statistical
comparisons between the phases were made with the paired t-test or, in the case of tmax, with
the Wilcoxon signed-rank test. Differences were considered statistically significant at P <
0.05. Statistical analyses were carried out using SPSS for Windows, version 17.0 (SPSS,
Chicago, IL, USA) and PASW for Windows, version 18.0 (SPSS), in studies II and V,
respectively.
Study Analytes quantified Lower limit of quantification Interday CV
II Montelukast
M6
Gemfibrozil
Gemfibrozil 1-O-β glucuronide
3.8 nM (2.2 ng/ml)
3.7 nM (2.2 ng/ml)
10 nM (0.0025 mg/l)
5.9 nM (0.0025 mg/l)
<17%
<10%
<4%
<8%
V Imatinib
N-desmethylimatinib
Gemfibrozil
Gemfibrozil 1-O-β glucuronide
6.1 nM (3 ng/ml)
6.3 nM (3 ng/ml)
1.0 µM (0.25 mg/l)
0.59 µM (0.25 mg/l)
<5%
<15%
<4%
<7%
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RESULTS
11. Montelukast studies (I and II)
11.1. In vitro metabolism of montelukast
In studies I and II, CYP2C8 was found to play a major role in the metabolism of montelukast.
Montelukast. Among the ten recombinant CYPs tested, CYP2C8, CYP2C9, and CYP3A4
metabolised montelukast most extensively. The relative importance of CYP2C8 in its in vitro
metabolism increased from about 14 to 68% as the concentration of montelukast was reduced
from 1 µM to a more clinically relevant concentration of 0.02 µM (Figure 15). At 0.02 µM,
CYP2C8 inhibitors and CYP3A4 inhibitors inhibited montelukast depletion in HLM by ~40-
60%, while the CYP2C9 inhibitor did not affect it at all. CYP2A6 did not metabolise
montelukast.
M6 and M4. In study I, M6 was formed by CYP2C8 (by ~75%) and CYP2C9 (by ~22%).
Recombinant CYP2C8 formed M6 at a six-fold higher intrinsic clearance (Vmax/Km) than
CYP2C9 (Figure 15). At montelukast 0.05 µM, M6 formation was inhibited by gemfibrozil 1-
O-β glucuronide by 78%, while the inhibition by sulfaphenazole was weak (7%).
Furthermore, while other CYPs did not form M4, CYP2C8 catalysed its formation. In study
II, gemfibrozil 1-O-β glucuronide was 36-fold more potent than gemfibrozil as an inhibitor of
M6 formation in HLM (Figure 15). Gemfibrozil 1-O-β glucuronide also inhibited the further
metabolism of M6 to M4 more potently than did gemfibrozil.
M3. In study I, several CYP isoforms formed M3 from montelukast, 1 µM, but at 0.1 µM
only CYP2C8 formed detectable M3 amounts. Among the CYP-selective inhibitors,
gemfibrozil 1-O-β glucuronide inhibited M3 formation most strongly (by 49%).
M5a/b and M2. In study I, M5a/b was formed in recombinant CYP3A4 (by ~90%) and
CYP3A5 (by ~10%) incubations, and the CYP3A4/5 inhibitors almost completely inhibited
(>90%) the formation of these metabolites in HLM. Similarly, initial experiments indicated
that CYP3A4 and CYP3A5 formed M2. However, the metabolite was not quantified because
montelukast sulfoxide (M2) was found as an impurity (~1%) in montelukast sodium. This
impurity inhibited CYP2C8 but not CYP2C9 at high montelukast concentrations, as evident
from HLM and CYP incubations of M2 with montelukast. Montelukast sulfoxide 0.1 µM
inhibited M6 formation by ~55 and 73% in HLM and CYP2C8 incubations, respectively. In
study II, M5b formation was unaffected by gemfibrozil and its glucuronide, while M5a was
not detectable at the montelukast concentration used.
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Figure 15. Main findings from montelukast experiments. A, the (RAF-adjusted) relative importance
of CYP2C8 in the in vitro metabolism of montelukast increased with decreasing montelukast
concentrations. B, the enzyme kinetics of M6 formation was best described by an uncompetitive
substrate inhibition model for both CYP2C8 and CYP2C9. Vmax,  Km,  and  Ki for M6 formation by
CYP2C8 were 0.18 pmol/min/pmol, 0.050 µM, and 11 µM, respectively, and by CYP2C9 0.11
pmol/min/pmol, 0.19 µM, and 7.4 µM, respectively. C, D, the inhibitory effect of gemfibrozil 1-O-β
glucuronide on M6 and M4 formation (from montelukast and M6, respectively) in HLM incubations
was greater than that of gemfibrozil. CYP, cytochrome P450; IC50, inhibitor concentration producing
50% inhibition.
Table 21. Intrinsic and predicted hepatic clearance values of montelukast, calculated based on the
depletion of montelukast in recombinant CYP2C8, CYP2C9, and CYP3A4 incubations.
* Total CLH (1.35 ml/min/kg) calculated as the sum of predicted CLH values. CLH, hepatic clearance;
CLint, RAF, RAF-adjusted intrinsic clearance; CYP, cytochrome P450.
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CYP2C9 0.48 0.040 0.16 12
CYP3A4 1.8 0.053 0.22 16
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11.2. Prediction of the role of CYP2C8 in montelukast pharmacokinetics
The CLint, in vitro based on montelukast depletion (0.02 µM) in HLM was 0.14 ml/min/mg. This
value yields a scaled montelukast in vivo CLH of 0.54 ml/min/kg, which is approximately
60% of the estimated CLB (0.89 ml/min/kg) in humans. Based on depletion of montelukast
0.02 µM in recombinant CYP incubations, the contribution of CYP2C8 to the total in vivo
metabolism of montelukast was estimated to average 72% using the RAF approach (Table
21). The RA approach resulted in a higher predicted role for CYP3A4 (60%) and a lower one
for CYP2C8 (27%), with 11 and 2.3% contributions for CYP2C9 and CYP3A5. Both
approaches slightly overestimated the in vivo CLB:  the  sum  of  CLH of CYP2C8, CYP2C9,
CYP3A4, and CYP3A5 was ~1.4 ml/min/kg (Table 21).
11.3. Effect of gemfibrozil on montelukast in vivo
In study II, gemfibrozil markedly affected the concentrations of montelukast and its
metabolites M6, M4 and M5a/b in humans.
Montelukast and its metabolites. Compared to placebo, gemfibrozil increased the mean
AUC0-∞ of montelukast 4.5-fold (P < 0.001) and mean Cmax 1.5-fold (P < 0.001) (Figure 16).
Montelukast t½ was prolonged three-fold to 13.5 h (P < 0.001). Compared to placebo, the
formation rate of M6 was reduced by gemfibrozil. M6 median tmax was prolonged three-fold
and its mean AUC0-7 was reduced to 60% of control (Figure 16), while its AUC0-24 was
increased by 86% (P = 0.005) by gemfibrozil. In addition, gemfibrozil markedly reduced the
plasma exposure to M4 to about 10% of control (P < 0.001). Furthermore, gemfibrozil
increased the Cmax of M5a and M5b five-fold and 2.5-fold (P ≤ 0.001), respectively, and their
AUC0-24 by 9.3-fold and 4.8-fold (P < 0.001), respectively. Based upon the effect of
gemfibrozil on the AUC0-∞ of montelukast, it can be estimated that total clearance of
montelukast was reduced by almost 80% by gemfibrozil.
Figure 16. Effects of gemfibrozil on the pharmacokinetics of montelukast (Monte) and its metabolites
M6, M4, M5a, and M5b. Bars represent ratios of mean values during the gemfibrozil phase to those
during the control (placebo) phase (n = 10). AUC, area under concentration-time curve; Cmax, peak
concentration; t½, elimination half-life.
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Effects of genotype. Two of 10 subjects had the CYP2C8*1/*3 genotype and one had the
CYP2C8*1/*4 genotype (Table 18). One of the subjects had the CYP3A5*1/*3 (CYP3A5
expressor) genotype, while the other subjects had the CYP3A5*3/*3 non-expressor genotype.
Pharmacokinetic variables of montelukast in CYP2C8*3, CYP2C8*4, and CYP3A5*1 carriers
were similar to those in non-carriers.
12. Imatinib studies (III-V)
12.1. Effect of imatinib on CYP2C8 and CYP3A4/5 activities in vitro
In study III, imatinib affected CYP3A4 by mechanism-based inhibition.
Time-dependent inhibition. Compared to no pre-incubation, a 30-min pre-incubation of
imatinib in the presence of NADPH increased its CYP3A4/5 inhibitory effect, leading to an
eight-fold reduction in its (unadjusted) IC50 value to 7.1 µM (Table 22). Pre-incubation of
imatinib with NADPH increased its inhibition of midazolam 1’-hydroxylation in recombinant
CYP3A4 incubations but not in CYP3A5 incubations, suggesting that imatinib inhibits only
CYP3A4 time-dependently. Its (unadjusted) KI and kinact in HLM were 14.3 µM and 0.072
1/min. Ketoconazole reduced the inactivation of CYP3A4 by imatinib in a concentration-
dependent manner, and dialysis did not abolish the inhibitory effect of imatinib on midazolam
1’-hydroxylation, suggesting that the imatinib-induced inactivation of CYP3A4 is irreversible
or quasi-irreversible. Imatinib did not affect amodiaquine N-deethylation (CYP2C8 activity)
by time-dependent inhibition. In addition, N-desmethylimatinib, piperidine N-oxide imatinib,
and pyridine N-oxide imatinib were not time-dependent inhibitors of CYP2C8 or CYP3A4/5.
Table 22. Inhibition of CYP2C8 and CYP3A4 by imatinib and N-desmethylimatinib in HLM. The
values have been corrected for non-specific binding to microsomal proteins.
CYP, cytochrome P450; IC50, inhibitor concentration producing 50% inhibition; Ki, reversible inhibition
constant; KI, inhibitor concentration supporting half of the maximal rate of inactivation; kinact, maximal
rate of inactivation; NADPH, nicotinamide adenine dinucleotide phosphate.
Direct inhibition. Direct inhibition of CYP2C8 activity by imatinib and N-desmethylimatinib
was best described by a mixed full inhibition model for both inhibitors. Direct inhibition of
Inhibitor Enzyme
inhibited
IC50 (µM), no
pre-incubation
IC50 (µM), pre-
incubation with
NADPH
Ki
(µM)
KI
(µM)
kinact
(1/min)
Imatinib CYP2C8 14 23 7.6 - -
CYP3A4/5 48 6.4 21 11 0.07
N-desmethyl-
imatinib
CYP2C8 28 40 12 - -
CYP3A4/5 32 26 16 - -
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midazolam 1′-hydroxylation by imatinib was also best described by the mixed full inhibition
model, while N-desmethylimatinib inhibited CYP3A4/5 activity in a competitive manner.
12.2. In vitro metabolism of imatinib
In study IV, CYP2C8 and CYP3A4 metabolised imatinib extensively, while other isoforms
had minor effect on imatinib concentrations.
Table 23. Intrinsic and predicted hepatic clearance values of imatinib, calculated based on the
depletion of imatinib and formation of N-desmethylimatinib in recombinant enzyme incubations. The
values have been corrected for non-specific binding to microsomal proteins.
* Total CLH (13.75 l/h) calculated as the sum of predicted CLH values from recombinant incubations.
CLint, intrinsic clearance; CLint, ISEF, ISEF-adjusted intrinsic clearance; CLH, hepatic clearance; CYP,
cytochrome P450; M, metabolites (intrinsic clearance calculated using the substrate depletion
approach); N-DMI, N-desmethylimatinib (intrinsic clearance calculated on the basis of N-
desmethylimatinib formation kinetics); OM, other metabolites (intrinsic clearance calculated as
substrate depletion CLint, in vitro - N-desmethylimatinib formation CLint, in vitro).
Imatinib. Recombinant CYP2C8 and CYP3A4 metabolised imatinib rapidly (<15% of the
parent drug remained at 30 min), while other CYPs had a minor effect on its concentrations
(>78% imatinib left). CYP2C8 inhibitors inhibited the depletion of imatinib (0.1 µM) by
~45%, while CYP3A4 inhibitors inhibited it by almost 80%.
N-desmethylimatinib. At imatinib 1 µM, the formation of N-desmethylimatinib was
mediated by CYP2C8, CYP3A4 and CYP3A5, but small amounts were formed also by
CYP2D6, CYP2C19, and CYP2C9. However, at imatinib 0.1 µM, only CYP2C8, CYP3A4,
and CYP3A5 formed detectable N-desmethylimatinib amounts. CYP2C8 inhibitors and
CYP3A4 inhibitors inhibited its formation by ≥50%. The further metabolism of N-
desmethylimatinib was mainly catalysed by CYP3A4, with a smaller contribution by
CYP2C8, and minor involvement by CYP1A2, CYP2D6 and CYP3A5. Comparison of CLint
values obtained from the depletion (total metabolism) of imatinib 0.1 µM with those
calculated based on the kinetics of N-desmethylimatinib formation indicated that N-
Enzyme Metabolic
pathway
CLint, in vitro
(µl/min/pmol)
CLint, ISEF
(µl/min/mg)
CLint, scaled
(l/h)
CLH
(l/h)
% total CLH*
CYP1A2 M 0.03 0.84 3.6 0.14 1.1
CYP2B6 M 0.07 0.66 2.9 0.11 0.83
CYP2C8 N-DMI
OM
1.06
0.14
29
3.9
127
17
4.8
0.66
40
CYP2D6 M 0.05 0.34 1.5 0.059 0.43
CYP3A4 N-DMI
OM
1.03
2.75
13
35
56
151
2.2
5.7
57
CYP3A5 N-DMI
OM
0.07
0.02
0.47
0.16
2.0
0.67
0.081
0.027
0.79
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desmethylation accounts for the majority (88%) of imatinib metabolism by CYP2C8, while
the metabolite accounts for 27 and 75% of imatinib metabolism by CYP3A4 and CYP3A5,
respectively (Table 23).
12.3. In vitro-in vivo predictions
In study III, the mechanism-based inhibition of CYP3A4 by imatinib was predicted to cause
clinically relevant interactions. In study IV, the static prediction and PBPK simulations
estimated a marked role for CYP2C8 in imatinib metabolism. In study V, PBPK simulations
estimated that the importance of CYP2C8 in imatinib pharmacokinetics increases with time
during multiple dosing, while that of CYP3A4 decreases.
Figure 17. Predicted effect of imatinib on the pharmacokinetics of CYP3A4 substrates in vivo,
assuming that the intestinal bioavailability is unaffected. The substrate AUC depends on several
factors: imatinib concentration, the fraction of the substrate metabolised by CYP3A4, and on CYP3A4
half-life. During treatment with imatinib 400 mg once daily, its average unbound trough concentration
(Ctrough) and Cmax in plasma approximates 0.1 and 0.25 µM, respectively, while the unbound imatinib
Cmax in the portal vein was estimated at 0.73 µM (indicated by the dashed lines). AUC, area under
concentration-time curve; t½, turnover half-life.
Prediction of in vivo drug interactions with imatinib as the inhibitor drug. In study III,
interaction predictions based on inhibition of hepatic CYP3A4 by imatinib using the obtained
mechanism-based inhibition values yielded a maximal AUC increase of 5.9-fold for a drug
completely metabolised by hepatic CYP3A4, when using unbound imatinib Cmax (0.25 µM)
during steady state administration of 400 mg imatinib daily and the CYP3A4 half-life of 36 h
(Figure 17) (Gleevec Clinical Pharmacology and Biopharmaceutic Review(s), 2001, le Coutre
et al., 2004, Peng et al., 2004b, Bornhauser et al., 2005). The interaction magnitude was even
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higher when inhibition of intestinal CYP3A4 was included in the prediction. The direct
inhibitory effects of CYP2C8 and CYP3A4 by imatinib and N-desmethylimatinib were
predicted to be clinically insignificant. For instance, the predicted increase in the plasma
exposure to simvastatin was 1.1-fold, when assuming direct inhibition only of hepatic
CYP3A4 by imatinib. When predicting the effect of mechanism-based inhibition of both
hepatic and intestinal CYP3A4 on simvastatin concentrations, the corresponding increase was
5.9-fold.
Imatinib metabolism using the ISEF approach. In study IV, with use of the ISEF
approach, CYP2C8 and CYP3A4 were estimated to be the most important enzymes in
imatinib metabolism in vivo (contributions of 40 and 57%, respectively, following a single
imatinib dose) (Table 23). The total CLH (13.8 l/h) calculated as the sum of predicted CLH
values of recombinant CYP incubations corresponded to 72% of the estimated in vivo CLB
(19.2 l/h). The calculated CLH based on imatinib depletion in HLM equalled 14.8 l/h.
Imatinib metabolism using PBPK simulations. In study IV, simulated concentration-time
curves, as well as mean pharmacokinetic parameters of imatinib and N-desmethylimatinib,
matched well with published data on imatinib single-dose and multiple dose pharmacokinetics
(Figure 18). Compared with when direct inhibition only of CYP3A4 by imatinib was
considered, a model which included mechanism-based autoinhibition of CYP3A4 matched
better with observed imatinib plasma concentrations during treatment with imatinib 400 mg
once daily. This model predicted a 2.1-2.3-fold accumulation of imatinib, imatinib trough
levels of 900-950 ng/ml, and peak concentrations of ~2,800 ng/ml following multiple dosing
with imatinib 400 mg once daily, in line with clinical data (Gleevec Clinical Pharmacology
and Biopharmaceutic Review(s), 2001, Peng et al., 2004b, van Erp et al., 2007, Larson et al.,
2008, Demetri et al., 2009).
Similarly, the simulations predicted well the effects of ketoconazole, rifampicin, and ritonavir
on the pharmacokinetics of imatinib. In drug-drug interaction simulations, gemfibrozil was
predicted to increase the AUC0-∞ of a single dose of imatinib 400 mg by 1.8-fold and reduce
that of N-desmethylimatinib by 59%. Following multiple doses of imatinib, gemfibrozil was
predicted to increase its AUC0-τ by 2.3-fold and reduce that of the metabolite by ~85%.
Furthermore, simulations of a low activity CYP2C8 genotype (50% reduction in its activity)
resulted in a reduced imatinib metabolism, leading to increased imatinib and decreased N-
desmethylimatinib concentrations. In contrast, a high CYP2C8 activity (two-fold increase in
activity) was predicted to cause markedly increased imatinib metabolism. The results of the
simulations with the refined PBPK model in study V are described in section 12.4.
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Figure 18. Pharmacokinetic simulations of the concentrations of imatinib following a single dose
(left) and multiple doses (right) of imatinib 400 mg in study IV. The circles refer to clinical data from
Nikolova et al. (2004). The grey area in the right figure depicts the range of reported peak
concentrations of imatinib following treatment with imatinib 400 mg once daily (Gleevec Clinical
Pharmacology and Biopharmaceutic Review(s), 2001, Peng et al., 2004b, van Erp et al., 2007,
Demetri et al., 2009). The dashed line defines the suggested target trough concentration for imatinib
treatment (1,000 ng/ml) (Teng et al., 2012). TDI, time-dependent inhibition.
12.4. Effect of gemfibrozil on imatinib in vivo
In study V, gemfibrozil unexpectedly reduced the peak concentration of imatinib. In line with
the simulations of study IV, however, gemfibrozil markedly reduced the CYP2C8-mediated
formation of N-desmethylimatinib from imatinib.
Imatinib. Compared to placebo, gemfibrozil 600 mg twice daily reduced the geometric mean
Cmax and AUC0–12 h of imatinib by 35 and 23% (P < 0.001), respectively (Figure 19, Figure
20). During the gemfibrozil phase, impaired absorption of imatinib was seen in all ten
subjects, and six subjects had a double peak of imatinib plasma concentrations. In the placebo
phase, only one subject had a double peak. The imatinib peak plasma concentration/plasma
concentration at 24 h (Cmax/C24 h) ratio was reduced by 44% during co-administration with
gemfibrozil (P < 0.001). Gemfibrozil prolonged imatinib t½ by 8% (P = 0.003), while its
AUC0–96 h and AUC0–∞ were unaffected by gemfibrozil (Figure 19). Gemfibrozil did not alter
imatinib fu, P measured in 2-h and 12-h samples.
N-desmethylimatinib. Gemfibrozil reduced N-desmethylimatinib Cmax and AUC0–∞ by 56
and 48% (P < 0.001), respectively, as compared with placebo. Thus, gemfibrozil markedly
reduced the N-desmethylimatinib/imatinib plasma concentration ratio in all subjects. On
average, the N-desmethylimatinib/imatinib AUC0–∞ ratio was reduced by 45% by gemfibrozil
(P < 0.001), but N-desmethylimatinib half-life was unaffected. Furthermore, gemfibrozil
reduced the Cmax/C24 h ratio of N-desmethylimatinib by 17% (P = 0.022). Moreover,
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gemfibrozil reduced the AUC0–∞ of the sum of imatinib and N-desmethylimatinib by 14%
only (P = 0.015). N-desmethylimatinib fu, P in 2-h samples was increased 1.3-fold (P = 0.017)
by gemfibrozil co-administration, but no change was observed in 12-h samples.
Figure 19. Effects of gemfibrozil on the pharmacokinetics of imatinib (Ima) and N-desmethylimatinib
(N-DMI) in the clinical study (V). Bars represent ratios of geometric mean values during the
gemfibrozil phase to those during the control (placebo) phase (n = 10). AUC, area under
concentration-time curve; C24, concentration at 24 h; Cmax, peak concentration; t½, elimination half-life.
Effect of genotype. One subject was heterozygous for the CYP2C8*3 allele, and one was
heterozygous for CYP2C8*4. The other eight subjects had the CYP2C8*1/*1 genotype (Table
18). The CYP2C8*3 carrier had the largest N-desmethylimatinib AUC0–∞ during both study
phases. Otherwise, the pharmacokinetic variables of imatinib and N-desmethylimatinib in
CYP2C8*3 and CYP2C8*4 carriers were similar to those in non-carriers.
PBPK simulations. In study V, the effect of gemfibrozil on imatinib pharmacokinetics could
be well simulated when the PBPK model considered inhibition of both CYP2C8-mediated
metabolism and active intestinal uptake transport by gemfibrozil (Figure 20). Gemfibrozil was
predicted to decrease the AUC0–12 of a single imatinib dose of 200 mg by 20% and to increase
its AUC0–∞ by 14%. The model over-predicted the effect of gemfibrozil on N-
desmethylimatinib pharmacokinetics, and steady state simulations of N-desmethylimatinib
concentrations were therefore not conducted. Interaction simulations with multiple imatinib
doses suggested that gemfibrozil can increase its dosing interval AUC 1.3-fold after imatinib
doses of 200 mg once daily and 1.5-fold after doses of 400 mg once daily. The simulations
also suggested that gemfibrozil can increase its trough concentrations more than two-fold.
During multiple dosing of imatinib 400 mg once daily, the contribution of CYP2C8 to
imatinib metabolism was predicted to increase from ~40 to 70%, and consequently,
gemfibrozil was predicted to increase imatinib trough concentrations to ~1,700 ng/ml (Figure
20). At steady state, the peak/trough fluctuation of the simulated imatinib concentrations was
smaller during co-administration with gemfibrozil (Cmax/C24 h ratio: ~2/1) than during the
placebo phase (Cmax/C24 h ratio: ~4/1–5/1). Compared to simulations including gemfibrozil-
mediated inhibition of an uptake transporter in the intestine, other alternatives such as enzyme
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induction and displacement of imatinib from plasma protein by gemfibrozil did not reflect the
observed interaction as accurately.
Figure 20. Simulations of the gemfibrozil-imatinib interaction with the refined PBPK model in study
V. Simulated effects of gemfibrozil (600 mg twice daily) on multiple dose pharmacokinetics of
imatinib, when imatinib treatment was started on day 3 of the gemfibrozil treatment. The full lines
represent the simulations, while circles refer to the clinical data of study V. The dashed lines in the
lower figures define the suggested target Ctrough for imatinib treatment (1,000 ng/ml) (Teng et al.,
2012).
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DISCUSSION
13. Methodological considerations
13.1. In vitro studies
Pooled HLM and recombinant CYPs were used in the in vitro studies as they are
recommended systems for in vitro phenotyping of CYP-mediated metabolism and inhibition
(FDA, 2012). To mimic physiological conditions, sodium phosphate buffer (0.1 M, pH 7.4)
was used as the incubation medium, and incubations were conducted at 37ºC. In studies I and
II, MgCl2 was added to the incubation mixtures to support binding of NADPH to POR
(Ogilvie et al., 2008). However, it was excluded from incubations in III and IV, following
preliminary experiments where exclusion of MgCl2 in the incubations did not alter the
metabolism of the tested drugs, as compared to when MgCl2 was included. Furthermore,
MgCl2 was not mentioned in the incubation condition recommendations of the manufacturer.
Because organic solvents affect the activities of CYPs, their concentrations were kept low in
the incubations (1%). In order to keep non-specific binding of drugs equal in the experiments,
and to enable precise comparisons of results with different CYP isoforms, an equal protein
concentration was used in parallel experiments.
In study I, the CYP-mediated metabolism of montelukast in vitro was re-evaluated. Low
montelukast concentrations were incubated with recombinant CYPs or HLM and CYP-
selective inhibitors. Following a single oral dose of montelukast 10 mg, its peak
concentrations in plasma approximate to 500 ng/ml (Zhao et al., 1997), which corresponds to
an unbound concentration of 0.003 µM. Using LC-MS/MS, a montelukast concentration of
0.02 µM could be incubated and accurately quantified. This concentration is reasonably close
to its unbound plasma concentration. Studies have suggested that the intracellular
concentrations of montelukast in hepatocytes might be higher than its unbound plasma
concentrations due to uptake transport by OATP2B1, however, recent findings indicate that
montelukast is not a OAT2B1 substrate (Chu et al., 2012, Kim et al., 2013a, Tapaninen et al.,
2013, Brännström et al., 2014, Korzekwa, 2014).
Because montelukast binds non-specifically to protein (Walsky et al., 2005b), low protein
concentrations were used. Unfortunately, similarly as in a previous study (Walsky et al.,
2005b), it was not possible to determine the unbound fraction of montelukast in the
microsomal incubations. Equilibrium dialysis and ultrafiltration were used in attempts to
determine its non-specific binding, while ultracentrifugation was not tested. This method has
been shown to accurately determine the unbound fraction of very lipophilic compounds
(MacKichan, 2006). Using the Simcyp in silico fumic prediction calculator
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(http://www.simcyp.com), the unbound fraction of montelukast in microsomal incubations
can retrospectively be predicted to have equalled 0.70 and 0.82 at protein concentrations of
0.1 and 0.05 mg/ml, respectively. The implications of adjusting the obtained enzyme kinetic
parameters for these values are discussed in section 13.2.
Another limitation of study I was the montelukast sulfoxide (M2) impurity (1%) found in
montelukast sodium from two commercial vendors. Montelukast sulfoxide inhibited CYP2C8
in vitro. However, the inhibition is likely to be negligible at the low montelukast
concentrations (≤1 µM) used in the study; although it could have affected the enzyme kinetics
of M6 formation by CYP2C8, where the highest montelukast concentration tested was 30 µM.
An additional limitation is the lack of reference compounds for M3, M4, and M5. In
particular, quantification of M4 would have been of interest, as it is the main metabolite in
bile (Balani et al., 1997).
In study III, the inhibitory effects of imatinib on CYP2C8 and CYP3A4 activities in HLM
were studied. In accordance with recommendations (FDA, 2011, EMA, 2013), amodiaquine
deethylation and midazolam 1-hydroxylation were used as marker reactions for CYP2C8 and
CYP3A4, respectively. The study could have been improved by use of a second marker
reaction for CYP3A4 (FDA, 2011, EMA, 2013). In addition, more extensive follow-up
experiments could have been conducted, including incubations with ferricyanide to
discriminate between quasi-irreversible and irreversible inhibition, or determination of the
partition ratio of imatinib to evaluate its inactivation potency (Grimm et al., 2009).
Furthermore, it would also have been of interest to identify and determine the structure of the
inactivating agent.
In study IV, the importance of CYP2C8 in the in vitro metabolism of imatinib was
investigated. Similarly as in study I, low drug concentrations were incubated with HLM or
with recombinant enzymes. The imatinib concentrations used corresponded to clinically
relevant unbound peak concentrations of imatinib in plasma during treatment with imatinib
400 mg once daily (generally around 0.2-0.3 µM) (Gleevec Clinical Pharmacology and
Biopharmaceutic Review(s), 2001, le Coutre et al., 2004, Peng et al., 2004b, Bornhauser et
al., 2005). In order to overcome mechanism-based inhibition of its own CYP3A4-mediated
metabolism, very short incubation times were used. No other metabolites than N-
desmethylimatinib were quantified, although M5, piperidine N-oxide imatinib, and pyridine
N-oxide imatinib were monitored.
13.2. In vitro-in vivo predictions
In study I, montelukast intrinsic clearance obtained from recombinant enzyme incubations
was scaled to in vivo hepatic clearance using the RA and RAF approaches. The estimated
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relative contributions of CYP2C8 and CYP3A4 to the hepatic clearance of montelukast varied
markedly depending on the method used. The RAF approach takes CYP activity into account
and has been considered more reliable than the RA method (Stringer et al., 2009). With the
RAF approach, the contribution of CYP2C8 was estimated to equal 72%, which is in good
agreement with the in vivo results of study II. However, activity data provided by the
manufacturer for the microsomal lots was used to calculate RAFs. Because the activities of
CYP3A4 and CYP3A5 had not been differentiated, it was not possible to determine the
contribution of CYP3A5 using RAFs. Theoretically, assuming that some of the donors of the
HLM pool used were CYP3A5 expressors, and that CYP3A5 thus contributed to the CYP3A
activity as measured by the manufacturer, it can be estimated that the role of CYP3A4 in
montelukast metabolism is in fact smaller than predicted. Thus, a possible contribution by
CYP3A5 alters the predicted role of CYP3A4 but affects those of CYP2C8 and CYP2C9 very
little. The contribution of CYP3A5 might have been possible to estimate by use of HLM from
single donors expressing CYP3A5.
One limitation of the in vitro-in vivo extrapolations was the fact that it was not possible to
correct the obtained enzyme kinetic values for non-specific binding at the time of the study.
However, as described in section 13.1., by use of an in silico predictor it is possible to
retrospectively adjust the intrinsic clearance values obtained from montelukast depletion in
recombinant enzymes (Table 21) and HLM. Using an unbound fraction of 0.70, the calculated
intrinsic clearance values of montelukast in different microsomal incubations will increase by
43%. The sum of the scaled hepatic clearance from recombinant enzyme experiments can
then be estimated to equal 1.89 ml/min/kg, which is ~two-fold of the calculated blood
clearance of montelukast. However, the estimated percentage contributions of the different
CYPs involved in the metabolism of montelukast are not altered by adjusting for non-specific
binding (Table 21). Furthermore, when adjusting for non-specific binding, the hepatic
clearance calculated based on the depletion of montelukast in HLM can then be estimated to
0.76 ml/min/kg, corresponding to 85% of the blood clearance of montelukast.
In study III, static models were used to predict the effects of imatinib and N-
desmethylimatinib on the plasma exposure to CYP2C8 and CYP3A4 substrate drugs. The
predictions were carried out using different inhibitor concentrations, since no consensus has
been reached on which inhibitor concentration to use (Yamano et al., 1999, Kanamitsu et al.,
2000, Ito et al., 2004, Bachmann, 2006). Because several values for the hepatic CYP3A4
turnover half-life have been reported in the literature (Yang et al., 2008), the predictions
based on mechanism-based inhibition by imatinib were carried out using 36 and 72 h, of
which 36 h has been considered to be more accurate (Rowland Yeo et al., 2011). Similarly, at
least two different FG values (0.14 and 0.66) of simvastatin have been reported (Obach et al.,
2006, Gertz et al., 2008). The FG value of 0.14 led to over-predictions of the effect of imatinib
on simvastatin concentrations, while that of 0.66 was predicted to cause a 5.9-fold increase in
simvastatin AUC, when using a steady-state unbound imatinib Cmax of 0.25 µM. This value is
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somewhat higher than that observed in vivo (average AUC increase of 3.5-fold), however, the
individual AUC ratios ranged from no change to >ten-fold increase (O'Brien et al., 2003). It
is, however, common that interaction predictions based on time-dependent inhibition of
CYP3A4 in HLM experiments leads to over-predictions, possibly due to inaccuracies in
prediction parameters, such as the turnover half-life of CYP3A4 (Chen et al., 2011).
In study III, one source of error in the predictions was that an imatinib dose of 335 mg was
used in the calculation of imatinib unbound Cmax, portal and inhibitor concentration in the
enterocytes. This dose would have corresponded to 400 mg of imatinib mesilate. However,
using an imatinib dose of 400 mg, the corrected values for these concentrations generate
interaction magnitudes that are <13% higher than those predicted based on the original values.
Thus, this miscalculation does not alter findings and conclusions reported in the study III
publication.
In study IV, ISEFs were used to adjust imatinib clearance. One potential source of error might
have been the fact that ISEFs were obtained from different sources. For CYP2C8, CYP3A4,
and CYP3A5 it was possible to experimentally determine the ISEFs, while those of CYP1A2,
CYP2B6, and CYP2D6 were obtained from Simcyp. However, because CYP2C8 and
CYP3A4 are the most important CYPs in imatinib metabolism, the ISEFs of the other
enzymes are not crucial to the predictions.
In studies IV and V, PBPK simulations with Simcyp were conducted. The PBPK models
make several assumptions and simplifications. In study IV, the model comprised first-order
oral absorption, assuming that the administered drug is in solution, and that the driving
concentration at the level of the intestine is that of the portal veinÍ fu, G. fu, G of imatinib was
chosen to correspond to that in plasma. Because the elimination of imatinib has not been fully
reported, it was assumed that <5% was eliminated renally and that ~10-15% was excreted as
unchanged imatinib. A single adjusting compartment, which represents a lump tissue, was
included to adjust the concentration-time profile of imatinib. The model seemed to predict
imatinib pharmacokinetics after a single dose and multiple doses, as well as the effects of
CYP3A4 inhibitors on imatinib and N-desmethylimatinib pharmacokinetics well. However,
as evident after completion of the clinical study in V, the model had over-predicted the effect
of gemfibrozil on imatinib pharmacokinetics. The model was therefore refined so that the
additional clearance was increased to correspond to ~25%, and the unbound fraction of
imatinib in plasma was reduced. In addition, an advanced absorption and dissolution model
was selected to simulate its absorption so that an intestinal uptake transporter could be
included in the model.
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13.3. In vivo studies
The two clinical studies II and V performed in healthy volunteers had a randomised, placebo-
controlled cross-over design. Thus, the subjects served as their own controls, limiting the
effects of inter-individual variability. In addition, it reduced the number of subjects needed to
find a possible clinically significant interaction. The wash-out periods were chosen to
minimise the risk of possible carry-over effects. The wash-out time intervals were chosen
according to the pharmacokinetic properties of the drugs studied, and taking into account the
time necessary for the synthesis of new CYP enzyme in the case of irreversible inhibition.
In both studies, the pre-treatment dose was administered one hour before the victim drug on
the study day. This was done to ensure adequate absorption of the pre-treatment drug by the
time the study drug was ingested. In order to decrease variability in drug absorption, the
subjects fasted overnight and received standardised meals during the study days. Gemfibrozil
was used as the inhibitor drug of CYP2C8. The subjects were given gemfibrozil 600 mg twice
daily for three days as pre-treatment since this dosing has been shown to cause an almost
complete inhibition of CYP2C8 in healthy volunteers (Backman et al., 2009). The
concentrations of gemfibrozil and its glucuronide were monitored during the study days and
ascertained to be at therapeutic levels. In study V, gemfibrozil was given to the end of the
sampling period, while in study II, gemfibrozil was administered to the end of the study day.
Because full recovery of CYP2C8 occurs first after four days (Backman et al., 2009), it can
be assumed that the inhibition of CYP2C8 lasted over the whole sampling period.
In study II, a montelukast dose of 10 mg was used, which corresponds to its normal,
therapeutic dose. The drug is relatively safe as doses up to 900 mg have been administered
without clinically relevant adverse effects (Singulair Label, 2013). In study V, a low dose of
imatinib (200 mg) was chosen for safety reasons.
14. Role of CYP2C8 in the metabolism of montelukast
(Studies I and II)
Before the initiation of study I, several studies indicated that montelukast interacts with
CYP2C8 (Walsky et al., 2005a, Walsky et al., 2005b, Schoch et al., 2008). However, the role
of CYP2C8 in the pharmacokinetics of montelukast had not been examined. Early in vitro
studies demonstrated that the oxidative metabolism of montelukast was exclusively mediated
by CYPs, in particular by CYP2C9 and CYP3A4 (Chiba et al., 1997). These experiments
were conducted using supra-therapeutic montelukast concentrations exceeding more than
20,000-fold its clinically relevant unbound concentrations in plasma. In addition, very high
protein concentrations were used, the enzymes forming M3 and M4 were not studied, and the
contributions by CYP2C8 and CYP3A5 were not examined. Thus, because of data suggesting
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an interaction between montelukast and CYP2C8, studies I and II were carried out aiming to
determine the importance of CYP2C8 in the metabolism of montelukast in vitro and in vivo.
Figure 21. Oxidative metabolism of montelukast according to studies I and II, and recent literature
(VandenBrink et al., 2011, Karonen et al., 2012).
In study I, CYP2C8-selective inhibitors inhibited the main metabolic pathway (formation of
M6) of montelukast more potently than did inhibitors of the other CYPs. Recombinant
CYP2C8 and CYP2C9 were the only CYP isoforms forming M6 at low montelukast
concentrations; however, CYP2C8 catalysed its formation at a six-fold higher intrinsic
clearance rate than did CYP2C9. Moreover, CYP2C8 mediated montelukast depletion and the
further metabolism of M6 more actively than did any of the other CYP forms. The findings of
study I further suggested that M3 is mainly formed by CYP2C8, whereas M4 formation from
M6 is mediated almost exclusively by CYP2C8 (Figure 21). It should be noted, however, that
the formation of M4 from M6 is a two-step reaction, where enzymes other than CYPs might
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participate. The RAF approach estimated a >70% contribution of CYP2C8 in the in vivo
metabolism of montelukast, and contributions of 12 and 16% for CYP2C9 and CYP3A4,
respectively.
In study II, in almost exact accordance with the estimation, the strong CYP2C8 inhibitor
gemfibrozil increased the plasma exposure to montelukast by 4.5-fold. Thus, the observed
effect on montelukast concentrations by gemfibrozil is smaller than that on cerivastatin and
repaglinide, but larger than the effect on other CYP2C8 substrates, such as pioglitazone and
rosiglitazone (Table 14). Furthermore, in study II, the formation of M6 was delayed by
gemfibrozil and the formation of the secondary metabolite M4 was reduced by over 90%. In
the in vitro study, gemfibrozil and gemfibrozil 1-O-β glucuronide inhibited the formation of
M4 and M6, but not of M5.
In addition to the mechanism-based inhibition of CYP2C8, gemfibrozil also inhibits several
membrane transporters, including OATP2B1 in vitro (Ho et al., 2006). This transporter has
been suggested to be involved in the pharmacokinetics of montelukast (Mougey et al., 2009,
Mougey et al., 2011). However, a possible inhibition of OATP2B1-mediated uptake of
montelukast in the intestine by gemfibrozil would have resulted in a decreased plasma
exposure to montelukast. In contrast, if hepatic OATP2B1 had been inhibited by gemfibrozil,
it could have contributed to the observed interaction, due to inhibited hepatic uptake and thus
decreased hepatic clearance of montelukast. However, a possible inhibitory effect of
OATP2B1 by gemfibrozil is likely to be weak and of short duration; gemfibrozil has a short
half-life and its inhibition of OATP2B1 was only as strong as that of CYP2C9 in vitro (Wen
et al., 2001, Ho et al., 2006). In addition, recent in vitro and in vivo findings suggest that the
role of OATP2B1 in montelukast disposition is not important (Chu et al., 2012, Kim et al.,
2013a, Tapaninen et al., 2013, Brännström et al., 2014).
Altogether, the findings of studies I and II strongly suggest that CYP2C8 plays a major role
(~80%) in the metabolism of montelukast. After the publication of studies I and II, this
conclusion has been confirmed by other reports. In an in vitro study using a low montelukast
concentration of 0.01 µM, M6 was mainly formed by CYP2C8 (by almost 75%) and CYP2C9
(~20%), M2 was formed by CYP3A4 (~70%), and M5 by CYP3A4 (almost 80%)
(VandenBrink et al., 2011). The Vmax and Km of M6 formation by recombinant CYP2C8 at an
enzyme concentration of 0.05 µM corresponded to ~23 pmol/min/pmol and 0.014 µM,
respectively, which is in good agreement with the enzyme kinetic results of study I. In
addition, paclitaxel 6α-hydroxylation (CYP2C8 marker reaction) was highly correlated
(r2=0.89) with M6 formation. In a clinical study, the CYP3A4 inhibitor itraconazole had no
effect on the total elimination of montelukast (Karonen et al., 2012), nor did it affect the
concentrations of M6 and M4. However, itraconazole markedly reduced those of M5a and
M5b, thus confirming in vitro findings indicating that CYP3A4 forms M5. In addition, this
study also investigated the effects of gemfibrozil on montelukast exposure, and similar results
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as in study II were obtained; gemfibrozil increased montelukast AUC0-∞ by 4.3-fold and
prolonged its elimination t½ by 2.1-fold (Karonen et al., 2012).
Given the findings of studies I and II and literature data, the high fm, CYP2C8 of montelukast
(0.8), and its beneficial safety profile, montelukast is a good candidate for use as a CYP2C8
probe in both in vitro and in humans. The suitability of montelukast as a marker substrate is
further discussed in section 16.
15. Roles of CYP2C8 and CYP3A4 in the metabolism of
imatinib (Studies III-V)
At the time of study III, a discrepancy between in vitro and in vivo data on CYP3A4/5
inhibition by imatinib was evident. In clinical studies, imatinib was a relatively strong
inhibitor of CYP3A4/5; imatinib at steady state increased the plasma exposure to the
CYP3A4/5 substrate simvastatin by 3.5-fold (O'Brien et al., 2003), and reduced hepatic
CYP3A4/5 activity by up to 70% (Gurney et al., 2007, Connolly et al., 2011). However, the
unbound concentrations of imatinib and its main metabolite N-desmethylimatinib in plasma
(<1 and <0.1 µM, respectively) were much lower than their reported direct Ki values for
CYP3A4/5 inhibition in HLM (8 and 14 µM, respectively) (Gleevec Clinical Pharmacology
and Biopharmaceutic Review(s), 2001, Gleevec label, 2014). Because of these
inconsistencies, and because CYP2C8 was reported to be involved in the metabolism of
imatinib (Nebot et al., 2010), study III aiming to elucidate the inhibitory effects of imatinib
on CYP2C8 and CYP3A4 in HLM was carried out.
In study III, both imatinib and N-desmethylimatinib were found to be moderately potent
direct inhibitors of CYP2C8 and CYP3A4/5. In addition, inhibition of CYP3A4 (but not of
CYP3A5) by imatinib was concentration-, NADPH-, and time-dependent; the presence of a
competitive CYP3A4 inhibitor decreased the inhibition; and dialysis was unable to restore
CYP3A4 activity. Thus, these findings suggested that imatinib affects CYP3A4 by
mechanism-based inhibition in vitro.  Its KI and kinact values were 11 µM (after adjusting for
non-specific binding) and 0.072 1/min, respectively. The direct inhibitory effects of imatinib
on CYP2C8 and CYP3A4/5 were predicted to be of negligible clinical relevance, while
mechanism-based inhibition by imatinib was estimated to cause several-fold increases in the
plasma concentrations of CYP3A4 substrates.
CYP3A4 has been described to be the main enzyme in imatinib metabolism (Marull and
Rochat, 2006, Rochat et al., 2008, Gleevec label, 2014). However, imatinib-mediated
mechanism-based inhibition of this enzyme suggests that imatinib could time- and
concentration-dependently inhibit its own metabolism, leading to a decreasing importance of
CYP3A4 in its pharmacokinetics with time. This hypothesis could explain why strong
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CYP3A4 inhibitors have had only a small or no effect on imatinib concentrations in vivo
(Dutreix et al., 2004, Widmer et al., 2006, van Erp et  al., 2007), and why the clearances of
CYP3A4 substrates correlated with imatinib clearance in the beginning of imatinib treatment
but no longer at steady state (Gurney et al., 2007). Based on this theory and the fact that
CYP2C8 was suggested to play a key role in imatinib metabolism (Nebot et al., 2010), studies
IV and V were undertaken to investigate the importance of CYP2C8 in the pharmacokinetics
of imatinib by use of an integrated in vitro, in silico, and in vivo approach.
In study IV, both CYP2C8 and CYP3A4 inhibitors inhibited the depletion of imatinib by
>40%, and the main metabolic pathway of imatinib by >50%. Likewise, recombinant
CYP2C8 and CYP3A4 metabolised imatinib extensively, while other CYP isoforms had
minor effect on its concentrations. Using the ISEF approach, the fractions of the hepatic
clearance of imatinib mediated by CYP2C8 and CYP3A4 were predicted to approximate 40
and 60%, respectively. PBPK simulations predicted that the autoinhibition of CYP3A4 by
imatinib could increase the role of CYP2C8 in imatinib pharmacokinetics time-dependently,
and that a strong CYP2C8 inhibitor like gemfibrozil could increase its plasma exposure by
1.8-fold following a single imatinib dose of 400 mg.
Figure 22. Simulated importance of
CYP2C8 and CYP3A4 in imatinib
metabolism during treatment with imatinib
200 or 400 mg once daily (V). Curves for
CYP1A2, CYP2B6, CYP2D6, and CYP3A5
were omitted for clarity because their roles
were negligible (<5% of total hepatic
clearance) (Filppula et al. (2013),
unpublished results).
In study V, gemfibrozil unexpectedly reduced the absorption of imatinib; its Cmax decreased
by 35%, while its total AUC was unaffected by gemfibrozil coadministration. Gemfibrozil
also reduced the Cmax and total AUC of N-desmethylimatinib by 56 and 48%, respectively,
and the Cmax/C24 ratios of imatinib and N-desmethylimatinib by 44 and 17%, respectively.
Simulations with the refined PBPK model predicted well the effect of gemfibrozil on imatinib
pharmacokinetics, when inhibition of both CYP2C8-mediated metabolism and active
intestinal uptake transport were included in the model. Based upon these simulations, the
contribution of CYP2C8 to imatinib metabolism was predicted to increase from ~40 to 70%
during multiple dosing with imatinib 400 mg once daily because of time-dependent
autoinhibition of CYP3A4 by imatinib (Figure 22). Interaction simulations with gemfibrozil
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600 mg twice daily and imatinib 200 or 400 mg once daily suggested that the interaction
magnitude increases with higher imatinib doses and during multiple dosing.
The effect of gemfibrozil on the absorption of imatinib had not been anticipated. Initially, the
absorption rate of imatinib appeared to follow that observed in the placebo phase, but it
successively declined, resulting in reduced peak concentrations and double peaks in the
gemfibrozil phase. Due to the similar absorption profiles of imatinib in the beginning of the
placebo and gemfibrozil phases, its altered absorption is unlikely due to gemfibrozil-induced
changes in the emptying rate of the stomach or dissolution of imatinib. Previously, markedly
reduced itraconazole concentrations and a reduced Cmax of enzalutamide have been observed
during gemfibrozil coadministration (Niemi et al., 2003b, Jaakkola et al., 2005, Niemi et al.,
2006, Xtandi Clinical Pharmacology and Biopharmaceutic Review(s), 2012). One of the
proposed explanations for the finding with itraconazole is displacement of it from plasma
proteins by gemfibrozil, leading to an increased clearance or volume of distribution. In a
previous study, displacement of imatinib from α1-acid glycoprotein has been suggested to
explain why clindamycin reduced the plasma exposure to imatinib by 70% (Gambacorti-
Passerini et al., 2003). However, in study V, gemfibrozil had no effect on the unbound
fraction of imatinib in 2 and 12-h plasma, making displacement of imatinib from plasma
proteins an unlikely cause of interaction.
Induction of CYPs or other enzymes involved in imatinib pharmacokinetics could possibly
explain the observed effect on imatinib absorption by gemfibrozil. Previously, the CYP2C8
and CYP3A4 inducers rifampicin and St John’s Wort have reduced imatinib Cmax and AUC
by 15-54% and 30-74%, respectively, and increased N-desmethylimatinib Cmax by 13-89%,
but had little or no effect on its AUC (Bolton et al., 2004, Frye et al., 2004, Smith et al.,
2004a, Smith et al., 2004b). Gemfibrozil is a mild inducer of CYP2C8 and CYP3A4 in vitro
(Prueksaritanont et al., 2005), but there is no evidence for such an effect in vivo. In vitro,
imatinib is also a substrate of other CYPs, FMO3, and the extrahepatic enzymes CYP1A1,
CYP1B1, and CYP2J2 (Rochat et al., 2008, Narjoz et  al., 2014). In theory, gemfibrozil-
mediated induction of other enzymes than CYP2C8 and CYP3A4 could also be one putative
explanation, but no such effect has been described in the literature. Regardless, strong
mechanism-based inhibition of CYP2C8 is most likely the dominating mechanism in the
metabolism-mediated interaction. Furthermore, induction of imatinib-transporting efflux
proteins is also unlikely; no such mechanism has been demonstrated for gemfibrozil. Because
of the high absolute availability of imatinib (98%), the role of uptake proteins is probably
more important than that of efflux transporters.
Based on early in vitro transport studies, imatinib was initially classified as a low
permeability drug (Gleevec Clinical Pharmacology and Biopharmaceutic Review(s), 2001).
However, following a clinical study showing that its bioavailability is very high (Peng et al.,
2004a), imatinib was classified as a high permeability drug, thus suggesting that it might be a
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substrate of uptake transporters. Gemfibrozil inhibits OATP1B1 both in vitro and in vivo
(Kyrklund et al., 2003, Schneck et al., 2004). As the AUC of imatinib did not increase
following gemfibrozil co-administration, it is unlikely that OATP1B1 inhibition by
gemfibrozil contributed to the interaction. The transporters OATP1A2 and OCTN have been
suggested to participate in the intestinal absorption of imatinib (Hu et al., 2008, Eechoute et
al., 2011a, Eechoute et al., 2011b); however, it is not known whether gemfibrozil or its
metabolites can affect these proteins. In vitro studies are therefore needed to identify the
transporter possibly affected by gemfibrozil.
Thus, the findings of study III suggest that imatinib is a mechanism-based inhibitor of
CYP3A4, while those of studies IV and V indicate that CYP2C8 forms N-desmethylimatinib
from imatinib. Simultaneously with the publication of study III, another study also proposed
that imatinib is a mechanism-based inhibitor of CYP3A4 (Kenny et  al., 2012). Here, its KI
and kinact values were determined to 4.4 µM and 0.028 1/min, respectively. In addition, a
recent publication studied the reactive intermediates of imatinib, and found that they could be
imine and imine-carbonyl conjugate structures on the piperazine ring, and imine-methide on
the p-toluidine partial structure of imatinib (Li et al., 2014). Altogether, the findings of studies
III, IV, and V, and recent literature propose that it is likely that imatinib inhibits its own
CYP3A4-mediated pharmacokinetics, and this may lead to an increasing role for CYP2C8 in
its clinical use.
16. General discussion and clinical implications
Montelukast was developed before CYP2C8 was recognised as a major drug-metabolising
enzyme. Therefore it was not included in the early in vitro screening studies. However, had
CYP2C8 been included, it would likely have been saturated due to the high montelukast
concentrations tested. In addition, high protein concentrations were used in the incubations in
the previous study. Because montelukast is highly lipophilic, and binds non-specifically to
microsomal proteins, low HLM concentrations were used in studies I and II. In addition, very
low montelukast concentrations were tested, corresponding to its unbound peak
concentrations in plasma. Results obtained using low montelukast and HLM concentrations
together with carefully validated in vitro conditions, indicated that CYP2C8 is the main
enzyme in the metabolism of montelukast.
The in vitro finding was confirmed in the clinical interaction study with gemfibrozil.
Together, the findings of studies I and II propose that CYP2C8 contributes to about 80% of
the elimination of montelukast. Because no differences in montelukast pharmacokinetics
between healthy volunteers and asthma patients have been reported (Singulair Clinical
Pharmacology and Biopharmaceutic Review(s), 1998, Singulair Label, 2013), it is likely that
the gemfibrozil-mediated increase in montelukast AUC in healthy subjects could also occur in
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patients. Because montelukast has a very wide safety margin, however, the increase in
montelukast exposure is probably not clinically significant in most cases. On the other hand,
an increased risk for concentration-dependent adverse effects cannot be excluded, in
particular for patients with impaired hepatic function. Therefore, a dose reduction of 50-80%
could be considered for montelukast when given in combination with CYP2C8 inhibitors.
As compared to other CYP2C8 substrate drugs (Table 14), only the effects of gemfibrozil on
the pharmacokinetics of repaglinide and cerivastatin have been larger than that observed on
montelukast. Cerivastatin was early withdrawn from the market, partly due to harmful
interactions with gemfibrozil (Backman et al., 2002, Huang et al., 2008), while repaglinide is
commonly used as a CYP2C8 probe in clinical interaction studies. Although sensitive to
CYP2C8 inhibition in vivo (Niemi et al., 2003b, Tornio et al., 2008, Backman et al., 2009,
Honkalammi et al., 2012), repaglinide is, like cerivastatin, also a substrate of OATP1B1
(Niemi et al., 2005b), which confounds the interpretation of interaction data. Furthermore,
repaglinide, an antidiabetic drug, easily causes hypoglycaemia in healthy volunteers, whereby
monitoring of blood glucose levels is necessary in interaction studies. Another CYP2C8 probe
is the antimalarial agent amodiaquine (EMA, 2013). However, although available in Africa, it
is not on the market in the European Union and United States. Therefore, given its
availability, beneficial safety profile, high fm, CYP2C8 (0.8), linear pharmacokinetics, and the
fact that it does not seem to be a substrate of clinically relevant drug transporters, montelukast
could be used as sensitive CYP2C8 probe in clinical interaction studies. In addition, because
CYP2C8 forms the main metabolite of montelukast, M6, almost exclusively in vitro,
montelukast 36-hydroyxylation (M6 formation) could also serve as a CYP2C8 marker
reaction in vitro.
The results obtained for imatinib in study III indicate that it is a mechanism-based CYP3A4
inhibitor, which suggest that concomitant use of imatinib with CYP3A4 substrates may
increase the risk of concentration-dependent adverse drug reactions. Its estimated R value for
mechanism based inhibition of CYP3A4 (section 5.2), calculated based on its steady state
unbound Cmax, equals ~6, suggesting a >two-fold change in AUC of CYP3A4 substrates
(Fujioka et al., 2012). Hence, its R value is smaller than those observed for other mechanism-
based inhibitors of CYP3A4, such as erythromycin (12), nelfinavir (77), and verapamil (21)
(Fujioka et al., 2012), which have increase the AUC of simvastatin by 4.6-6.2-fold (Kantola
et al., 1998, Hsyu et al., 2001). The finding that imatinib affects CYP3A4 by mechanism-
based inhibition explains its interaction with simvastatin, but also the previously mentioned
inconsistencies related to its own pharmacokinetics. Therefore, in order to reliably determine
the role of CYP2C8 in its metabolism, it was necessary to first characterise the inhibitory
effect of imatinib on CYP3A4 (III), and then conduct the in vitro metabolism studies (IV).
Furthermore, use of static models to predict the in vivo contribution of CYP2C8 was not
sufficient as the mechanism-based autoinhibition of its metabolism proceeds with increasing
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time and concentrations. Consequently, dynamic PBPK simulations were carried out to model
the contributions by CYP2C8 and CYP3A4 with time.
In the clinical study (V), gemfibrozil reduced the CYP2C8-mediated formation of N-
desmethylimatinib from imatinib, in line with the in vitro findings of study IV. However, the
CYP2C8 inhibitory effect of gemfibrozil was possibly counteracted by a simultaneous
inhibition of the absorption of imatinib. The impaired absorption may be a result of inhibition
of a transporter involved in imatinib uptake. Further studies are needed to elucidate the exact
mechanism by which gemfibrozil affects imatinib absorption. It is thus likely that at least
three different processes participated in the findings; mechanism-based inhibition of CYP2C8
by gemfibrozil, impairment of imatinib absorption by gemfibrozil, and mechanism-based
inhibition of CYP3A4 by imatinib. However, the effect of imatinib on CYP3A4 was probably
small following the single imatinib dose administrated. With use of a PBPK model, it was
possible to simulate this complex interaction following repeated dosing of both gemfibrozil
and imatinib. According to the simulations, the interaction magnitude increases as imatinib
approaches steady state. Due to a cumulating effect of the CYP3A4-mediated autoinhibition
by imatinib, the role of CYP3A4 in its metabolism becomes less important with time, while
that of CYP2C8 increases. According to the final simulations, the elimination of imatinib
relies more on CYP2C8 than on CYP3A4 during long-term treatment. Clinical studies with
multiple doses of imatinib are needed to further evaluate the roles of CYP3A4 and CYP2C8
in imatinib pharmacokinetics during steady state. Given that the efficacy and adverse effects
of imatinib are concentration-dependent, care is warranted when CYP2C8 inhibitors are given
in combination with imatinib.
In this work, the role of CYP2C8 in the metabolism of two structurally unrelated drugs from
two different therapeutic classes was investigated. The finding that CYP2C8 was able to
metabolise both drugs is in line with its capability to accommodate molecules of diverse sizes
and structures. Together, these studies strengthen the role of CYP2C8 as an important drug-
metabolising enzyme, and suggest that the number of drugs metabolised by CYP2C8 might
actually be higher than previously thought. In addition, they highlight the importance of
carefully validated in vitro experiments, and demonstrate the advantages of PBPK simulations
to explain complex drug-drug interactions.
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CONCLUSIONS
The following conclusions can be made based on the studies in this thesis:
1. In contrast to previous information, CYP2C8 is the principal enzyme involved
in the metabolism of montelukast. CYP2C8 catalyses the main metabolic
pathway of montelukast; the formation of M6 and its further metabolism to M4.
2. Montelukast could serve as a safe and sensitive CYP2C8 marker substrate in
drug-drug interaction studies during drug development.
3. Imatinib is a mechanism-based inhibitor of CYP3A4 in vitro, which explains its
previously observed interaction with simvastatin. Imatinib may also increase the
plasma exposure to other CYP3A4 substrate drugs. Autoinhibition of CYP3A4
by imatinib provides an explanation to previously documented inconsistencies
regarding the role of CYP3A4 in its pharmacokinetics.
4. The formation of the active metabolite of imatinib, N-desmethylimatinib, is
catalysed by CYP2C8 and CYP3A4. During multiple dosing, the elimination of
imatinib is likely to rely more on CYP2C8 than on CYP3A4, due to the
concentration- and time-dependent CYP3A4 autoinhibition by imatinib.
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